THE HUMAN C3b/C4b RECEPTOR (CR1)

Abstract: The present invention relates to the C3b/C4b receptor (CR1) gene, its encoded protein, and CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various embodiments of the present invention include the cloning, nucleotide sequence and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof. The expression of the CR1 protein and fragments thereof is also described as is the expression of a secreted CR1 molecule lacking a transmembrane region which is useful in reducing damage caused by inflammation and in reducing myocardial infarct size and preventing reperfusion injury.

Description: THE HUMAN C3b/C4b RECEPTOR (CRl) 1. INTRODUCTION The present invention relates to the C3b/C4b receptor (CRl) gene and its encoded protein. The invention also relates to CRl nucleic acid sequences and fragments thereof comprising 70 nucleotides, and their encoded peptides or proteins comprising 24 amino acids. The invention also provides for the expression of the CRl protein and fragments thereof. The CRl nucleic acids and proteins have use in the diagnosis or therapy of disorders involving complement activity, and various inflammatory and immune disorders. BACKGROUND OF THE INVENTION 2.1. THE COMPLEMENT SYSTEM The complement system is a group of proteins that constitutes about 10 percent of the globulins in the normal serum of humans (Hood, L.E., et al., 1984, Immunology, 2d Ed., The Benjamin/Cummings Publishing Co., Menlo Park, California, p. 339) . Complement (C) plays an important role in the mediation of immune and allergic reactions (Rapp, H.J. and Borsos, T, 1970, Molecular Basis of Complement Action, Appleton-Century-Crofts (Meredith) , New York) . The activation of complement components leads to the generation of a group of factors, including chemotactic peptides that mediate the inflammation associated with complement- dependent diseases. The sequential activation of the complement cascade may occur via the classical pathway involving antigen-antibody complexes, or by an alternative pathway which involves the recognition of certain cell wall polysaccharides. The activities mediated by activated complement proteins include lysis of target cells, chemotaxis, opsonization, stimulation of vascular and other smooth muscle cells, and functional aberrations such as degranulation of mast cells, increased permeability of small blood vessels, directed migration of leukocytes, and activation of B lymphocytes and macrophages (Eisen, H.N. , 1974, Immunology, Harper & Row Publishers, Inc. Hagerstown, Maryland, p. 512) . During proteolytic cascade steps, biologically active peptide fragments, the anaphylatoxins C3a, C4a, and C5a (See WHO Scientific Group, 1977, WHO Tech. Rep. Ser. 606:5 and references cited therein), are released from the 0 third (C3) , fourth (C4) , and fifth (C5) native complement components (Hugli, T.E., 1981, CRC Crit. Rev. Immunol. 1:321; Bult, H. and Herman, A.G., 1983, Agents Actions 13:405) . 15 2.2. THE C3b/C4b COMPLEMENT RECEPTOR (CRl) The human C3b/C4b receptor, termed CRl, is present on erythrocytes, monocytes/macrophages, granulocytes, B cells, some T cells, splenic follicular dendritic cells, and glomerular podocytes (Fearon, D.T., 20 1980, J. Exp. Med. 152:20, Wilson, J.G. , et al., 1983, J. Immunol. 131:684; Reynes, M. , et al., 1985, J. Immunol. 135:2687; Gelfand, M.C., et al., 1976, N. Engl. J. Med. 295:10; Kazatchkine, M.D., et al., 1982, Clin. Immunol. - 5 Immunopathol. 27:170). CRl specifically binds C3b, C4b, and iC3b. A soluble form of the receptor has been found in plasma that has ligand binding activity and the same molecular weight as membrane-associated CRl (Yoon, S.H. and Fearon, D.T., 1985, J. Immunol. 134:3332). CRl binds C3b 30 and C4b that have covalently attached to immune complexes and other complement activators, and the consequences of these interactions depend upon the cell type bearing the receptor (Fearon, D.T. and Wong, W.W. , 1983, Ann. Rev. Immunol. 1:243). Erythrocyte CRl binds immune complexes for 35 transport to the liver (Cornacoff, J.B., et al., 1983, J. Clin. Invest. 71:236; Medof, M.E. , et al., 1982, J. Exp. Med. 156:1739) CRl on neutrophils and monocytes internalize bound complexes, either by adsorptive endocytosis through coated pits (Fearon, D.T., et al., 1981, J. Exp. Med. 153:1615; Abraha son, D.R. and Fearon, D.T. , 1983, Lab. Invest. 48:162) or by phagocytosis after activation of the receptor by phorbol esters, chemotactic peptides, or proteins that are present in the extracellular matrix, such as fibronectin and laminin (Newman, S.L. , et al., 1980, J. Immunol. 125:2236; Wright, S.D. and Silverstein, S.C., 1982, J. Exp. Med. 156:1149; Wright, S.D., et al., 1983, J. Exp. Med. 158:1338). Phosphorylation of CRl may have a role in the acquisition of phagocytic activity (Changelian, P.S. and Fearon, D.T., 1986, J. Exp. Med. 163:101). The function of CRl on B lymphocytes is less defined, although treatment of these cells with antibody to CRl enhanced their response to suboptimal doses of pokeweed mitogen (Daha, M.R. , et al., 1983, Immunobiol. 164:227 (Abstr.)). CRl on follicular dendritic cells may subserve an antigen presentation role (Klaus, G.G.B., et al., 1980, Immunol. Rev. 53:3). CRl can also inhibit the classical and alternative pathway C3/C5 convertases and act as a cofactor for the cleavage of C3b and C4b by factor I, indicating that CRl also has complement regulatory functions in addition to serving as a receptor (Fearon, D.T., 1979, Proc. Natl. Acad. Sci. U.S.A. 76:5867; Iida, K. and Nussenzweig, V., 1981, J. Exp. Med. 153:1138). In the alternative pathway of complement activation, the bimolecular complex C3b,Bb is a C3 activating enzyme (convertase) . CRl (and factor H, at higher concentrations) can bind to C3b and can also promote the dissociation of C3b,Bb. Furthermore, formation of C3b,CRl (and C3b,H) renders C3b susceptible to irreversible proteolytic inactivation by factor I, resulting in the formation of inactivated C3b (iC3b) . In the classical pathway of complement activation, the complex C4b,2a is the C3 convertase. CRl (and C4 binding protein, C4bp, at higher concentrations) can bind to C4b, and can also promote the dissociation of C4b,2a. The binding renders C4b susceptible to irreversible proteolytic inactivation by factor I through cleavage to C4c and C4d (inactivated complement proteins.) CRl is a glycoprotein composed of a single polypeptide chain. Four allotypic forms of CRl have been found, differing by increments of -40,000-50,000 daltons molecular weight. The two most common forms, the F and S allotypes, also termed the A and B allotypes, have molecular weights of 250,000 and 290,000 daltons (Dykman, T.R. , et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:1698; Wong, W.W. , et al., 1983, J. Clin. Invest. 72:685), respectively, and two rarer forms have molecular weights of 210,000 and >290,000 daltons (Dykman, T.R. , et al., 1984, J. Exp. Med. 159:691; Dykman, T.R., et al., 1985, J. Immunol. 134:1787). These differences apparently represent variations in the polypeptide chain of CRl, rather than glycosylation state, because they were not abolished by treatment of purified receptor protein with endoglycosidase F (Wong, W.W. , et al., 1983, J. Clin. Invest. 72:685), and they were observed when receptor allotypes were biosynthesized in the presence of tunicamycin (Lublin, D.M. , et al., 1986, J. Biol. Chem. 261:5736). All four CRl allotypes have C3b-binding activity (Dykman, T.R. , et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:1698; Wong, W.W. , et al., 1983, J. Clin. Invest. 72:685; Dykman, T.R. , et al., 1984, J. Exp. Med. 159:691; Dykman T.R., et al., 1985, J. Immunol. 134:1787). Two nonoverlapping restriction fragments of a CRl cDNA were shown to crosshybridize under conditions of high stringency (Wong, W.W. , et al., 1985, Proc. Natl. Acad. Sci. U.S.A. 82:7711). Both cDNA probes also hybridized to multiple restriction fragments of genomic DNA, most of which were common to both probes (id.) . The existence of repetitive coding sequences within CRl was confirmed by sequence comparisons (Klickstein, L.B., et al., 1985, Complement 2:44 (Abstr.)). In addition, the CRl gene has been shown to have repetitive intervening sequences by the demonstration of crosshybridization of a genomic probe lacking coding sequences to several genomic restriction fragments (Wong, W.W. , et al., 1986, J. Exp. Med. 164:1531 Further, DNA from an individual having the larger S alloty had an additional restriction fragment hybridizing to this genomic probe when compared with DNA from an individual having the F allotype, suggesting that duplication of genomic sequences occurred in association with the higher molecular weight CRl allele (id.) . CRl has been shown to have homology to compleme receptor type 2 (CR2) (Weis, J.J., et al., 1986, Proc. Nat Acad. Sci. U.S.A. 83:5639-5643). 2.3. ABNORMALITIES OF CRl IN HUMAN DISEASE Diminished expression of CRl on erythrocytes of patients with systemic lupus erythematosus (SLE) has been reported by investigators from several geographic regions, including Japan (Miyakawa et al., 1981, Lancet 2:493-497; Minota et al., 1984, Arthr. Rheum. 27:1329-1335), the Unit States (Iida et al., 1982, J. Exp. Med. 155:1427-1438; Wilson et al., 1982, N. Engl. J. Med. 307:981-986) and Europe (Walport et al., 1985, Clin. Exp. Immunol. 59:547; Jouvin et al., 1986, Complement 3:88-96; Holme et al., 198 Clin. Exp. Immunol. 63:41-48). Taken as a group, patients have an average number of receptors per cell that is 50-60 that of normal populations. An early report noted that CR number on erythrocytes varied inversely with disease activity, ' with lowest numbers occurring during periods of most severe manifestations of SLE, and higher numbers bein observed during periods of remission in the same patient (Iida et al., 1982, J. Exp. Med. 155:1427-1438). CRl numb has also been found to correlate inversely with serum level of immune complexes, with serum levels of C3d, and with the amounts of erythrocyte-bound C3dg,- perhaps reflecting uptake of complement-activating immune complexes and deposition on the erythrocyte as an "innocent bystander" (Ross et al. , 1985, J. Immunol. 135:2005-2014; Holme et al., 1986, Clin. Exp. Immunol. 63:41-48; Walport et al., 1985, Clin. Exp. Immunol. 59:547). A patient with SLE lacking CRl on erythrocytes was found to have an auto-antibody to CRl (Wilson et al., 1985, J. Clin. Invest. 76:182-190). Decreased titers of the anti-CRl antibody coincided with improvement of the patient's clinical condition and with partial reversal of the receptor abnormality. Anti-CRl antibody has been detected in two other SLE patients (Cook et al., 1986, Clin. Immunol. Immunopathol. 38:135-138). Recently, acquired loss of erythrocyte CRl in the setting of active SLE and hemolytic anemia was demonstrated by observing the rapid loss of the receptor from transfused erythrocytes (Walport et al., 1987, Clin. Exp. Immunol. 69:501-507) . The relative loss of CRl from erythrocytes has also been observed in patients with Human Immunodeficiency Virus (HIV) infections (Tausk, F.A. , et al., 1986, J. Clin. Invest. 78:977-982) and with lepromatus leprosy (Tausk, F.A., et al., 1985, J. Invest. Dermat. 85:58s-61s). Abnormalities of complement receptor expression in SLE are not limited to erythrocyte CRl. Relative deficiencies of total cellular CRl of neutrophils and plasm membrane CRl of B lymphocytes of the SLE patients have been shown to occur (Wilson et al., 1986, Arthr. Rheum. 29:739- 747) - In patients with Type IV SLE nephritis, all detectable CRl antigen is lost from podocytes, whereas in less severe forms of SLE nephritis and in non-SLE types of proliferative nephritis, including membranoproliferative glomerulonephritis Types I and II, CRl expression on glo erular podocytes does not differ from normal (Kazatchkine et al., 1982, J. Clin. Invest. 69:900-912; Emancipator et al., 1983, Clin. Immunol. Immunopathol..27: 170-175) . However, patients having Type IV SLE nephritis d not have fewer numbers of erythrocyte CRl than do SLE patients having other types of renal lupus or no nephritis (Jouvin et al., 1986, Complement 3:88-96). In vivo complement activation up-regulates CRl expression at the plasma membrane of neutrophils (Lee, J. , et al., 1984, Clin. Exp. Immunol. 56:205-214; Moore, F.D., Jr., et al., 1986, N. Engl. J. Med. 314:948-953). Complement activation has also been associated with disease states involving inflammation. The intestinal inflammation of Crohn's disease is characterized by the lymphoid infiltration of mononuclear and polyaorphonuclear leukocytes. It was found recently (Ahrenstedt et al. , 1990 New Engl. J. Med. 322:1345-9) that the complement C4 concentration in the jejunal fluid of Crohn's disease patients increased compared to normal controls. Other disease states implicating the complement system in inflammation include thermal injury (burns, frostbite) (Gelfand et al. , 1982, J. Clin. Invest. 70:1170; Demling et al., 1989, Surgery 106:52-9), hemodialysis (Deppisch et al. 1990, Kidney Inst. 37:696-706; Kojima et al., 1989, Nippon Jenzo Gakkai Shi 31:91-7) , and post pump syndrome in cardiopulmonary bypass (Chenoweth et al., 1981, Complement Inflamm. 3:152-165; Chenoweth et al. , 1986, Complement 3:152-165; Sala a et al. , 1988, N. Engl. J. Med. 318:408- 14) . Both complement and leukocytes are reported to be implicated in the pathogenesis of adult respiratory distres syndrome (Zilow et al. , 1990, Clin. Exp. Immunol. 79:151-57; Langlois et al., 1989, Heart Lung 18:71-84). Activation of the complement system is suggested to be involved in the development of fatal complication in sepsis (Hack et al . , 1989, Am. J. Med. 86:20-26) and causes tissue injury in ani al models of autoimmune diseases such as immune- complex-induced vasculitis (Cochrane, 1984, Springer Seminar Immunopathol. 7:263), glomerulonephritis (Couser et al., 1985, Kidney Inst. 29:879), hemolytic anemia (Schreiber & Frank, 1972, J. Clin. Invest. 51:575), myasthemis gravis (Lennon et al., 1978, J. Exp. Med. 147:973; Biesecker & Gomez, 1989, J. Immunol. 142:2654), type II collagen-induced arthritis (Watson & Townes, 1985, J. Exp. Med. 162:1878), and experimental allergic neuritis (Feasby et al., 1987, Brain Res. 419:97). The complement system is also involved in hyperacute allograft and hyperacute xenograft rejection (Knechtle et al., 1985, J. Heart Transplant 4(5):541; Guttman, 1974, Transplantation 17:383; Adachi et al., 1987, Trans. Proc. 19(1):1145). Complement activation during immunotherapy with recombinant IL-2 appears to cause the severe toxicity and side effects observed from IL-2 treatment (Thijs et al., 1990, J. Immunol. 144:2419). Complement may also play a role in diseases involving immune complexes. Immune complexes are found in many pathological states including but not limited to autoimmune diseases such as rheumatoid arthritis or SLE, hematologic malignancies such as AIDS (Tayler et al., 1983, Arthritis Rheum. 26:736-44; Inada et al., 1986, AIDS Research 2:235-247) and disorders involving autoantibodies and/or complement activation (Ross et al., 1985, J. Immunol. 135:2005-14) . Inada et al. reported that erythrocyte CRl has a functional role in the removal of circulating immune complexes in autoimmune patients and may thereby inhibit the disposition of immune complexes within body tissue (Inada et al., 1989, Ann. Rheum. Dis 4:287). A decrease in CRl activity has been associated with clinical disease state in ARC and AIDS patients (Inada et al., 1986, AIDS Res. 2:235). 3. SUMMARY OF THE INVENTION The present invention relates to the C3b/C4b receptor (CRl) gene and its encoded protein. The invention also relates to CRl nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptide or proteins comprising 24 amino acids. The invention further provides for the expression of the CRl protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CRl cDNA and fragments thereof are described. The expression of the CRl protein and fragments t ereof is also described. Expression of the CRl protein and its fragments which contain binding sites for C3b and/or C4b, and which exhibit factor I cofactor activity, is obtained. Also described in the examples infra are the production and purification of soluble CRl molecules, which molecules are shown to be therapeutically useful for the treatment of inflammatory reactions and in the reduction of myocardial infarct size and prevention of reperfusion injury. 3.1. DEFINITIONS Ad2 MLP = adenovirus 2 major late promoter C = complement C3(ma) = methylamine-treated C3 C4bp = C4 binding protein CMV = cytomegalovirus CRl = complement receptor type 1, the C3b/C4b receptor CR2 = complement receptor, type 2 DCFDA = dichlorofluorescin diacetate HPLC = high performance liquid chromatography iC3b = inactivated C3b LHR = long homologous repeat mAb = monoclonal antibody PAGE = polyacrylamide gel electrophoresis RPAR = reverse passive Arthrus reaction SCR = short consensus repeat sCRl = soluble CRl molecule 4. DESCRIPTION OF THE FIGURES Figure 1. Nucleotide and amino acid sequence of the entire CRl coding region. The sequence begins with the first nucleotide following the octamer EcoRI linker in clone AT109.1. Nucleotide number 1531 of this sequence is the first nucleotide 5' of nucleotide number 1 of the sequence depicted in Figure 3. The strand corresponding to the mRNA is shown, with the deduced amino acid sequence presented below. The putative signal sequence encoded by nucleotide numbers 28-147 is bracketed. Figure 2. Restriction map of 5.5 kb of human CRl cDNA. The black bar indicates the cDNA, restriction sites are H, Hindlll; B, BamHI; R, EcoRI; P, Pstl; A, Apal; S, Sacl; G, Bglll; K, Kpnl. The cDNA clones from which the sequence was derived are shown below the map. The arrows indicate the direction and extent of sequence analysis by the dideoxynucleotide chain termination method. cDNA clones were oriented on the basis of restriction maps and overlapping sequence identity. Figure 3. Nucleotide sequence of 5.5 kb of human CRl cDNA. The strand corresponding to the mRNA is shown and base number 1 (corresponding to base number 1532 of Fig. 1) is the first base after t.÷e EcoRI linker in the most 5' clone. The stop codon is underlined. The 110-bp sequence in the box was found between nucleotides 147 and 148 (arro and is believed to represent a portion of an intervening sequence. Figure 4. Dot matrix analysis of the nucleotid sequence of 5.5 kb of human CRl cDNA. A dot was plotted i there was at least a 40 bp of 90 bp match. The dark line bisecting the square diagonally indicates the identity of the sequence with itself. The two additional parallel dar lines 1.35 and 2.7 kb from the line of identity represent two tandem, direct long homologous repeats (LHRs) of 1.35 each. The six lighter, dashed lines between two LHRs correspond to short consensus repeats of -0.2 kb. The sho consensus repeats (SCRs) extend 0.4 kb beyond the long homologous repeats. Figure 5. Deduced amino acid sequence of human CRl. Each residue is shown in the one letter code (Lehninger, A.L., 1975, Biochemistry, 2d Ed., Worth Publishers, Inc., New York, p. 72). The residues in the long homologous repeats have been aligned to illustrate their homology. All the residues in LHR-B are shown, and a residue is given for LHR-C and LHR-D only where it is different from that in LHR-B. A hydropathy profile is aligned under the COOH-terminus of the protein to illustrat the presumptive transmembrane region. A stretch of four positively charged residues immediately after the hydrophobic sequence is overlined. The six amino acid sequence with 67% homology to the site of protein kinase C phosphorylation in the epidermal growth factor receptor is underlined. A schematic diagram of the CRl protein is show above the sequence. (TM) transmembrane region, (Cyt) cytoplasmic region, (3'UT) 3' untranslated sequence. Figure 6. (A) Alignment of the SCRs of CRl. Th repeats are numbered 1-23 from NH -terminal to COOH-termnal Spaces have been introduced to maximize the alignment. residue is deemed conserved if it, or a conservative substitution, is present in at least half of the SCRs. The horizontal arrow indicates an SCR that was also sequenced from CRl genomic clone 2.38 and is encoded by a single exon. (B) Restriction map, sequencing strategy, and partial sequence of genomic clone λ2.38. The restriction sites are: (B) BamHI, (S) Sad, (E) EcoRV, (K) Kpnl, (P) Pstl. The horizontal arrow indicates direction :uιά extent of sequencing and the vertical arrows indicate the exon-intron boundaries. Figure 7. Alignment of the consensus sequence of the SCRs of proteins known to have this structure. Spaces were introduced to maximize the alignment. A residue is deemed conserved as in Figure 5, except for those proteins having only one or two SCRs, in which a residue is conserved if it is present in at least half of the other proteins. The dashes correspond to nonconserved positions. The underlined portions of CR2 and C2b indicate that no sequence information has been published in this region for these proteins. The boxes indicate the invariant half-cystines. The number to the right of the sequence represents the number of SCRs used to generate the consensus sequence. The protein abbreviations and references for the sequence data used to determine the consensus sequences are: (CRl) complement receptor type 1, (H) factor H (Kristensen, T. , et al., 1986, J. Immunol. 136:3407), (C4bp) C4 binding protein (Chung, L.P., et al. , 1985, Biochem. J. 230:133), (CR2) complement receptor type 2 (Weis, J.J., et al., 1986, Proc. Natl. Acad. Sci. U.S.A. 83:5639), (Ba) proteolytic fragment of factor B (Morley, B.J. and Campbell, R.D., 1984, EMBO J. 3:153), (C2b) proteolytic fragment of C2 (Gagnon, J. , 1984, Philos. Trans. R. Soc. Lond. B Biol. Sci. 306:301) , (Clr) r subunit of Cl (Leytus, S.P., et al., 1986, Biochemistry 25:4855), (Xlllb) b subunit of factor XIII (Ichinose, A., et al., 1986, Biochemistry 25:4633), (02GP1) β2 glycoprotein I (Lozier, J., et al. , 1984, Proc. Natl., Acad. Sci. U.S.A. 81:3640), (Hap) haptoglobin (Kurosky, A., et al., 1980, Proc. Natl. Acad. Sci. U.S.A. 77:3388), (IL-2-R) the interleukin-2 receptor (Leonard, W.J. , et al., 1985, Science 230:633). Asterisk indicates that incomplete sequence is available. Figure 8. Schematic diagram of the proposed structure of human CRl. The COOH-terminal cytoplasmic region is on the right side of the lipid bilayer. 30 SCRs are arrayed linearly on the extracellular side of the plasma membrane. The brackets indicate the LHRs. The inset is an enlargement of a single SCR to illustrate the triple loop structure. Figure 9. Restriction map of the insert of the plasmid, pBSABCD, encoding human CRl. Indicated within the box delineating the region containing the coding sequence are the nine fragments of eight cDNA clones that were ligated to form the CRl construct. The brackets designate the positions of LHR-A, -B, -C, and -D, respectively. The lines below the box represent the positions of the newly isolated 5' cDNA clones. The restriction sites are: A, Apal, B, BamHI; G, Bglll; H, Hindlll; K, Kpnl; M, BspMII; P, Pstl; R, EcoRI; and S, Sad. Figure 10. The deduced amino acidSequence of the 5' cDNA clones encoding the seven SCRs of LHR-A, and alignment of this sequence with the corresponding SCRs of LHR-B, -C, and -D. The four cysteines that are conserved in each SCR are underlined. A residue is shown for LHR-B, -C and -D only where it is different from that in LHR-A. Figure 11. Restriction maps of the expression plasmids, ' piABCD and pMTABCD. P^ 1 **™ and P CMV represent the murine metallothionein and cytomegalovirus immediate early promoters, respectively. Figure 12. Analysis by phase contrast (panels a and c) and immunofluorescent (panels b and d) microscopy of COS cells transfected with piABCD (panels a and b) and CDM8 vector alone (panels c and d) , respectively, and indirectly stained with YZ1 monoclonal anti-CRl antibody and fluorescein-labelled goat anti-mouse F(ab')_. Figure 13. Analysis of C3b- and C4b-binding by COS cells expressing recombinant CRl. COS cells transfected with piABCD (panels a and c) or with the CDM8 vector alone (panels b and d) were incubated with EAC4b(lim) ,3b (panels a and b) or with EAC4b (panels c and d) and examined for formation of rosettes by phase contrast microscopy. Figure 14. Analysis of recombinant CRl expressed by transfected COS cells by SDS-PAGE. COS cells transfected with the CDM8 vector alone (lanes 1 and 4) and with piABCD (lanes 2 and 5) , respectively, and erythrocytes from an individual having the F and S allotypes of CRl (lanes 3 and 6) were surface labelled with 125I. Detergent lysates of the cells were sequentially immunoadsorbed with Sepharose- UPClO (lanes 1-3) and Sepharose-YZl (lanes 4-6) and the eluates analyzed by SDS-PAGE under non-reducing conditions and autoradiography. Figure 15. Cleavage of 125I-C3(ma) by factor I in the presence of immunoimmobilized recombinant CRl. Replicate samples of 125I-C3(ma) were treated with factor I in the presence of factor H (lane 1) , Sepharose-UPClO preincubated with the lysate of COS cells transfected with the CDM8 vector alone (lane 2) , Sepharose-UPClO preincubated with the lysate of piABCD-transfected COS cells (lane 3) , Sepharose-YZl preincubated with the lysate of CDM8- transfected COS cells (lane 4) , and 6 μl (lane 5) , 12 μl (lane 6) and 25 μl (lane 7) of Sepharose-YZl that had been preincubated with the lysate of piABCD-transfected COS cells. Samples of 125I-labelled C3(ma) were also treated in the absence of factor I with 25 μl of Sepharose-YZl that had been preincubated with the lysate of piABCD-transfected COS cells (lane 8). After reduction, the 125I-C3(ma) was analyzed by SDS-PAGE and autoradiography. Figure 16. The cDNA constructs encoding the CRl deletion mutants. The positions of the cDNA segments encoding the four LHRs are indicated by the brackets above the full length piABCD construct on which are shown the restriction sites used for preparation of the deletion mutants. The cDNA restriction fragments remaining in each of the mutants are indicated by the solid lines. The restriction sites are: A, Apal; B> Bsml; E, BstEII; and P, Pstl. Figure 17. Comparison of recombinant deletion mutants of CRl with the wild type F and S allotypes of CRl. Detergent lysates of 125I-surface labelled erythrocytes (lanes 1 and 7) and COS cells transfected with CDM8 vector alone (lanes 2 and 8) , piABCD (lanes 3 and 9) , piBCD (lanes 4 and 10) , piCD (lanes 5 and 11) and piD (lanes 6 and 12) , respectively, were immunoprecipitated with Sepharose-UPClO anti-levan antibody (lanes 1-6) , Sepharose-YZ-l anti-CRl monoclonal antibody (lanes 7-11) and rabbit anti-CRl antibody and Sepharose-protein A (lane 12) , respectively. The eluates were subjected to SDS-PAGE under reducing conditions and autoradiography. Figure 18. Cleavage of 125I-C3(ma) by factor I in the presence of COS cells expressing full length and deletion mutants of CRl. Replicate samples of 125I-C3(ma) were incubated with COS cells transfected with the CDM8 vector alone (lanes 1 and 7) , piABCD (lanes 2 and 8) , piAD (lanes 3 and 9) , piBD (lanes 4 and 10) , piCD (lanes 5 and 11) , and piD (lanes 6 and 12) , respectively, in the absence (lanes 1-6) or presence (lanes 7-12) of factor I. Samples of 125I-C3(ma) also were incubated with factor H and factor I (lane 13) and with factor I alone (lane 14) , respectively. After reduction, the 125I-C3(ma) was analyzed by SDS-PAGE and autoradiography. Figure 19. Schematic model depicting the types of SCRs comprising each LHR of CRl, and the predicted sites determining the specificities of the receptor for C3b and C4b. The secondary binding specificities of these are indicated by the parentheses. Figure 20. A schematic diagram illustrating the DNA regions remaining in the soluble CRl DNA constructs. The regions of the full length CRl cDNA are indicated by the boxes along the top of the figure. Figure 21. A schematic diagram illustrating the major elements in the pTCS series of expression vectors. Figure 22. A diagram of the expression vector pTCSgpt. The polyadenylation site is from the murine Ig kappa sequences (NBRF Nucleic database accession #Kcms, bp 1306-1714) ; the Ad2 MLP and tripartite regions are from the Ad2 sequence (NBRF Nucleic database accession #Gdad2, bp 5791-6069) ; the SV40 early promoter is from the SV40 genome (NBRF Nucleic Database accession #GSV40W) . The gpt gene, ampicillin gene and bacterial origin of replication are from the vector pSV2gpt (ATCC Accession No. 37145) . Figure 23. 4-20% SDS-PAGE of antibody affinity purified sCRl. Non-reducing (lanes 1, 2, 3) and reducing (lanes 4, 5, 6) conditions. Lanes 1, 3: molecular weight markers; lanes 3, 5: cell culture supernatant starting material; lanes 4, 6: sCRl purified by antibody affinity chromatography. Figure 24. Cation exchange HPLC elution profile. Eluted protein was monitored by absorbance at 280 nm (y- axis) . The absorbance of both the flow-through (0-100 minutes) and the eluted sCRl (150-165 minutes) were both offscale. The x-axis represents the elution time in minutes. Figure 25. 4-20% gradient SDS-PAGE of cation an anion exchange HPLC purified sCRl. SDS-polyacryamide gels were run under non-reducing conditions. Lane 1, an aliquot of bioreactor supernatant; lane 2, an aliquot of bioreactor supernatant dialyzed against cation HPLC starting buffer; lane 3, an aliquot of the eluted sCRl peak from a cation exchange HPLC column; lane 4, an aliquot of the sCRl peak from the cation exchange HPLC column dialyzed into starting buffer for anion HPLC; lanes 5 and 6, aliquots of two different fractions of eluted sCRl from anion HPLC. Figure 26. C5a induction of an oxygen burst in human neutrophils. Following a C5a induced oxygen burst, DCFDA became oxidized and brightly fluoresced. Fluorescent intensity, as determined by flow cytometry, is measured on the x-axis and number of cells on the y-axis. Panel a, profile and gate for the cells; panel b, 0 minutes after C5a addition; panel c, 1 minute; panel d, 2 minutes; panel e, 3 minutes; panel f, 4 minutes; panel g, 20 minutes. This DCFDA assay gives a sensitive indication of C5a. Figure 27. Activation of human complement in the presence of sCRl shows reduced C5a activity in the DCFDA assay. Panel a, unstimulated cells; panel b, control without sCRl showing a high degree of fluorescende; panel c, DCFDA assay in the presence of sCRl showing a reduction of 75% in fluorescent intensity, y-axis is number of cells and x-axis is fluorescent intensity. Figure 28. Inhibition of classical pathway C5a and C3a production in human serum by sCRl. Similar profiles were observed for either antibody affinity purified or HPLC purified sCRl. Figure 29. Inhibition of complement-mediated hemolysis by recombinant sCRl. Similar profiles were observed for antibody affinity purified or HPLC purified sCRl. Figure 30. Gross morphology of RPAR in sCRl- treated (left) and untreated (right) rats. (a) Both rats received an intravenous injection of ovalbumin, followed by an intradermal injection of a mixture of either sCRl (left rat) or PBS (right rat) with anti-ovalbumin, neat (left site) ; anti-ovalbumin, 1/2 dilution (middle site) or rabbit IgG (right site) . The injections were performed in duplicate; top and bottom rows gave identical results. The rat which received sCRl had barely visible changes, while the untreated rat developed full symptoms of RPAR. (b) The dermal surface of the skin biopsies from (a) . The biopsy from the untreated rat (right) developed clearly visible lesion, while the biopsy from the sCRl-treated rat (left) showed normal morphology. Figure 31. Light microscopy of skin biopsies from sCRl-treated (a) and untreated (b) rats, (a) Perivascular accumulation of polymorphonuclear and mononuclear cells was observed, however, no extensive infiltration of neutrophils or extravasation of erythrocytes was seen. (b) Extensive infiltration of polymorphonuclear cells and extravasation of erythrocytes was identified. Figure 32. The clearance of injected sCRl from the blood of rats and monkeys showing biphasic, α and β, clearance phases. Figure 33. Autoradiographs of the Southern blot in which the CRl cDNA and intron probes were hybridized to the EcoRV digests of the DNA from individuals who expressed the F or the F' allotypes. The positions of the Hind III fragments of λDNA are designated in kilobases on the left. The position of the F'-specific fragment is designated by a single arrow. Figure 34. EcoRV restriction map of the F allel of CRl. The white boxes represent the positions of the exons and the stippled boxes represent the sites of hybridizations of the intron probes. The brackets over the LHR-B and -C indicate two possible regions of deletion. V represents an EcoRV site. Figure 35. The cDNA inserts for the different forms of recombinant rCRl. The restriction sites shown are: A, ApaL I; B, BamH I; C, Sac I; H, Hind III; L, Bgl I; P, Pst I; R, EcoR I; and S, Sma I. The diagram at the top represents the CRl protein, and the SCR with identical sequences are filled in by the same patterns. Figure 36. Coomassie Blue-stained SDS-PAGE unde 10 nonreducing conditions of recombinant sCRl purified by absorption on YZ-1-Sepharose. Each lane contains 10 μg of recombinant sCRl purified from the culture supernatants of COS cells that have been transfected with pasecABBCD (lane 1) , pasecABCD (lane 2) , or pasecACD (lane 3) . The position 15 of the M markers are indicated on the right in kD. Figure 37. Cofactor activity of recombinant sCRl. Cleavage of the a' chain of C3b was measured in the presence of increasing amounts of recombinant sCRl derived from COS cells transfected with pasecABBCD, pasecABCD, or 20 pasecACD. Figure 38. Inhi .bi.ti.on of 125I-C3b dimer uptake on erythrocytes by recombinant sCRl. Erythrocyte-bound ligand was measured in the presence of increasing - concentrations of C3b dimer, C3b monomer, and recombinant sCRl derived from COS cells transfected with pasecABBCD, pasecABCD, or pasecACD. Figure 39. Inhibition of the alternative (A) and classical (B) C3 convertases by recombinant sCRl purified 30 from COS cells transfected with the different plasmids encoding the CRl variants. Figure 40. Inhibition of the alternative (A) and classical (B) C5 convertases by recombinant sCRl purified from COS cells transfected with the different plasmids 35 encoding the CRl variants. 5. DETAILED DESCRIPTION OF THE INVENTION The present invention is directed to the C3b/C4b receptor (CRl) gene and its encoded protein. The invention is also directed to CRl nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CRl protein and fragments thereof. Such CRl sequences and proteins have value in diagnosis and therapy of inflammatory or immune system disorders, and disorders involving complement activity. In a specific embodiment, the invention relates to soluble CRl molecules and the expression, purification, and uses thereof. As used herein, the term "soluble CRl molecules" shall mean portions of the CRl protein which, in contrast to the native CRl proteins, are not expressed on the cell surface as membrane proteins. In particular, CRl molecules which substantially lack a transmembrane region are soluble CRl molecules. In a preferred embodiment, the soluble CRl molecules are secreted by a cell in which they are expressed. In specific embodiments of the present invention detailed in the examples sections infra, the cloning and complete nucleotide and deduced amino acid sequence of the full-length CRl cDNA, and of fragments thereof, and the expression of the encoded CRl products, are described. The expression of CRl and fragments thereof, with binding sites for C3b and/or C4b, and which inhibit factor I cofactor activity, is also described. The invention is further illustrated by the production and purification of soluble, truncated CRl molecules. In specific examples, such molecules are demonstrated to be therapeutically useful in reducing inflammation, and in reducing myocardial infarct size and preventing reperfusion injury. 5.1. ISOLATION OF THE CRl GENE The complete coding sequence of the CRl gene and its deduced amino acid sequence is ' presented in Figure 1. Any human cell can potentially serve as the nucleic acid source for the molecular cloning of the CRl gene. Isolation of the CRl gene involves the isolation of those DNA sequences which encode a protein displaying CR1- associated structure or properties, e.g. , binding of C3b or C4b or immune complexes, modulating phagocytosis, immune stimulation or proliferation, and regulation of complement. The DNA may be obtained by standard procedures known in the art from cloned DNA (e.g. , a DNA "library") , by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired human cell. (See, for example, Maniatis et al., 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K., Vol. I, II.) Cells which can serve as sources of nucleic acid for cDNA cloning of the CRl gene include but are not limited to monocytes/macrophages, granulocytes, B cells, T cells, splenic follicular dendritic cell , and glomerular podocytes. Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the CRl gene should be molecularly cloned into a suitable vector for propagation of the gene. In the molecular cloning of the gene from genomic DNA, DNA fragments are generated, some of which will encode the desired CRl gene. The DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNAse in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarOse and polyacrylamide gel electrophoresis and column chromatography. Once the DNA fragments are generated, identification of the specific DNA fragment containing the CRl gene may be accomplished in a number of ways. For example, if an amount of a CRl gene or its specific RNA, or a fragment thereof, is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton, W. and Davis, R. , 1977, Science 196:180; Grunstein, M. and Hogness, D. , 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961). Those DNA fragments with substantial homology to the probe will hybridize. If a purified CRl-specific probe is unavailable, nucleic acid fractions enriched in CRl may be used as a probe, as an initial selection procedure. As an example, the probe representing B cell cDNA from which messages expressed by fibroblasts have been subtracted can be used. It is also possible to identify the appropriate fragment by restriction enzyme digestion(s) and comparison of fragment sizes with those expected according to a known restriction map if such is available. Further selection on the basis of the properties of the gene, or the physical, chemical, or immunological properties of its expressed product, as described infra, can be employed after the initial selection. The CRl gene can also be identified by mRNA selection by nucleic acid hybridization followed by in vitro translation. In this procedure, fragments are used to isolate complementary mRNAs by hybridization. Such DNA fragments may represent available, purified CRl DNA, or DNA that has been enriched for CRl sequences. Immunoprecipitation analysis or functional assays (e.g. , for C3b or C4b binding, or promotion of phagocytosis or immune stimulation, or complement regulation, etc.) of the in vitro translation products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments that contain the CRl sequences. In addition, specific mRNAs may be selected by adsorption of polysomes isolated from cells to immobilized antibodies specifically directed against CRl. A radiolabeled CRl cDNA can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template. The radiolabeled mRNA or cDNA may theh be used as a probe t identify the CRl DNA fragments from among other genomic DNA fragments. Alternatives to isolating the CRl genomic DNA include, but are not limited to, chemically synthesizing the gene sequence itself from a known sequence or making cDNA to the mRNA which encodes the CRl gene. For example, as described supra, RNA for cDNA cloning of the CRl gene can be isolated from cells including but not limited to monocytes/macrophages, granulocytes, B cells, T cells, dendritic cells, and podocytes. In a preferred embodiment, tonsilar cells can serve as the source of mRNA for cDNA cloning (See Section 6.1.2, infra). Other methods are possible and within the scope of the invention. The identified and isolated gene can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid or CDM8 plasmid (Seed, B. , 1987, Nature 329:840-842) or derivatives. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc. In an alternative method, the CRl gene may be identified and isolated after insertion into a suitable cloning vector, in a "shot gun" approach. Enrichment for the CRl gene, for example, by size fractionation, can be done before insertion into the cloning vector. The CRl gene is inserted into a cloning vector which can be used to transform, transfeet, or infect appropriate host cells so that many copies of the gene sequences are generated. In a specific embodiment, the cloning vector can be the CDM8 vector, which can be used to achieve expression in a mammalian host cell. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and CRl gene may be modified by homopolymeric tailing. Identification of the cloned CRl gene can be accomplished in a number of ways based on the properties of the DNA itself, or alternatively, on the physical, immunological, or functional properties of its encoded protein. For example, the DNA itself may be detected by plaque or colony nucleic acid hybridization to labeled probes (Benton, W. and Davis, R. , 1977, Science 196:180; Grunstein, M. and Hogness, D. , 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961). Alternatively, the presence of the CRl gene may be detected by assays based on properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that, e.g. , has similar or identical electrophoretic migration, isoelectric focusing behavior, proteolytic digestion maps, C3b and/or C4b and/or immune complex binding activity, complement regulatory activity, effects on phagocytosis or immune stimulation, or antigenic properties as known for CRl. Using an antibody to CRl, the CRl protein may be identified by binding of labeled antibody to the putatively CRl-synthesizing clones, in an ELISA (enzyme-linked immunosorbent assay)-type procedure. In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated CRl gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA. In a particular embodiment, CRl cDNA clones in a CDM8 vector can be transfected into COS (monkey kidney) cells for large-scale expression under the control of the cytomegalovirus promoter (see Section 8, infra) . If the ultimate goal is to insert .-the gene into virus expression vectors such as vaccinia virus or adenovirus, the recombinant DNA molecule that incorporates the CRl gene can be modified so that the gene is flanked by virus sequences that allow for genetic recombination in cells infected with the virus so that the gene can be inserted into the viral genome. After the CRl DNA-containing clone has been identified, grown, and harvested, its DNA insert may be characterized as described in Section 5.4.1, infra. When the genetic structure of the CRl gene is known, it is possible to manipulate the structure for optimal use in the present invention. For example, promoter DNA may be ligated 5' of the CRl-coding sequence, in addition to or replacement of the native promoter to provide for increased expression of the protein. Expression vectors which express CRl deletion mutants can also be made, to provide for expression of defined fragments of the CRl sequence (see the example sections, infra) . In a particular embodiment, deletion mutants can be constructed which encode fragments of the CRl protein that exhibit the desired C3b and/or C4b binding activity (see Section 9, infra), e.g. , LHR-A for binding of C4b, or LHR-C for binding of C3b. In a preferred embodiment, an expression vector which encodes a CRl molecule with a deletion of the transmembrane region ca be used to produce a soluble CRl molecule (see the examples sections 11-14, infra) . Many manipulations are possible, and within the scope of the present invention. 5.2. EXPRESSION OF THE CLONED CRl GENE The nucleotide sequence coding for the CRl protein (Fig. 1) or a portion thereof, can be inserted into an appropriate expression vector, i.e. , a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translation signals can also be supplied by the native CRl gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but . are not limited to mammalian cell systems infected with virus (e.g. , vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g. , baculovirus) ; microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA or cosmid DNA. The expression elements of these vectors vary in their strength and specifi ties. Depending on the host-vector system utilized, any one of a number of suitabl transcription and translation elements may be used. For instance, when cloning in mammalian cell systems, promoters isolated from the genome of mammalian cells or from viruses that grow in these cells (e.g. , adenovirus, simian virus 40, cytomegalovirus) may be used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the inserted sequences. Specific initiation signals are also required fo efficient translation of inserted protein coding sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where the entire CRl gene including its own initiation codon and adjacent sequences are inserted into the appropriate expression vectors, no additional translational control signals may be needed. However, in cases where only a portion of the CRl coding sequence is inserted, exogenous translational control signals, including the ATG initiation codon, must be provided. The initiation codon must furthermore be in phase with the reading frame of the protein coding sequences to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include jLn vitro recombinant DNA and synthetic techniques and _in vivo recombinations (genetic recombination) . In a specific embodiment, a soluble CRl molecule can be expressed. Such a soluble molecule can bό produced by use of recombinant DNA techniques to delete the DNA sequences encoding the CRl transmembrane region (see Sections 11-14, infra) . As demonstrated infra, the ability to express a soluble CRl molecule is not limited to any one genetic modification of the CRl nucleic acid sequence; as long as the nucleic acid sequence encoding a substantial portion of the CRl transmembrane region is deleted, soluble CRl constructs can be obtained. Expression vectors containing CRl gene inserts can be identified by three general approaches: (a) DNA-DNA hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a foreign gene inserted in an expression vector can be detected by DNA-DNA hybridization using probes comprising sequences that are homologous to the inserted CRl gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g. , thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes into the vector. For example, if the CRl gene is inserted within the marker gene sequence of the vector, recombinants containing the CR insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the foreign gene product expressed by the recombinant. Such assays can be based on the physical, immunological, or functional properties of the gene product. Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. In a particular embodiment detailed in the examples of the present invention, CDM8 vectors with an CRl cDNA insert can be transfected into COS cells, in which the CR1 cDNA insert is expressed to produce the CRl protein. I other particular embodiments detailed in the examples sections infra, CDM8 vectors with a CRl cDNA insert corresponding to a portion of the CRl coding region can be transfected into COS cells, where the CRl or fragment is expressed. Per yet another example, infra, truncated, soluble CRl molecules can be expressed in mammalian cells b use of expression vectors such as the pTCS vectors describe in Section 11.3.1. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g. , lambda) , and plasmid and cosmid DNA vectors, to name but a few. In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the chimeric gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered CRl protein may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the expressed heterologous protein. For example, in one embodiment, expression in a bacterial system can be used to produce an unglycosylated CRl protein with the deduced amino acid sequence of Figure 1. Expression in yeast will produce a glycosylated product. In another embodiment, mammalian COS cells can be used to ensure "native" glycosylation of the heterologous CRl protein. Furthermore, different vector/host expression systems may effect processing reactions such as proteolytic cleavages to different extents. Many such variously processed CRl proteins can be produced and are within the scope of the present invention. In a preferred embodiment of the invention, large scale production of soluble CRl molecules may be carried out as described infra in Section 12.1 et seq. 5.3. IDENTIFICATION AND PURIFICATION OF THE EXPRESSED GENE PRODUCT Once a recombinant which expresses the CRl gene !0 is identified, the gene product should be analyzed. This can be achieved by assays based on the physical, immunological, or functional properties of the product. The CRl proteins may be isolated and purified by standard methods including chromatography (e.g. , ion 15 exchange, affinity, and sizing column chromatography, high pressure liquid chromatography) , centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In a preferred aspect of the invention detailed 20 in the examples infra, large quantities of soluble CRl can be purified by procedures involving HPLC (see Section 12.2 et seq.) . As described infra, large-scale production of purified CRl can be achieved by using an expression system which produces soluble CRl as starting material, thus 25 eliminating the requirement of solubilizing membrane-bound CRl with detergents. The reduction of fetal calf serum concentrations in the bioreactor cultures and/or the use of alternative culture medias in these cultures eliminates the need to remove high concentrations of extraneous proteins 30 from the soluble CRl-containing starting material during subsequent purification. Either cation HPLC or a combination of cation HPLC followed by anion exchange HPLC 35 can be used for purification in this preferred aspect. Substantially pure soluble CRl in high yield can thus be achieved in only one or two steps. Alternatively, once a CRl protein produced by a recombinant is identified, the amino acid sequence of the protein can be deduced from the nucleotide sequence of the chimeric gene contained in the recombinant. As a result, the protein can be synthesized by standard chemical methods known in the art (e.g. , see Hunkapiller, M. , et al., 1984, Nature 310:105-111). In particular embodiments of the present invention, such CRl proteins, whether produced by recombinant DNA techniques or by chemical synthetic methods include but are not limited to those containing, as a primary amino acid sequence, all or part of the amino acid sequence substantially as depicted in Figure 1, including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silen alteration. Nonconservative substitutions can also result in functionally equivalent proteins. In one embodiment, substitutes for an amino acid within the CRl sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Also included within the scope of the invention are CRl proteins which are differentially modified during or after translation, e.g. , by glycosylation, proteolytic cleavage, etc. In an example of the invention detailed infra, cloned recombinant CRl expressed by transfected cells was shown to be indistinguishable from the F allotype of erythrocytes by SDS-PAGE (Fig. 14) , capable of mediating the binding of sheep erythrocytes bearing either C4b or C3b, and able to reproduce the ligand specificity of CRl (Fig. 13) , and exhibit factor I co-factor activity for cleavage of the alpha polypeptide of C3(ma) (Fig. 15). 5.4. STRUCTURE OF THE CRl GENE AND PROTEIN The structure of the CRl gene and protein can be analyzed by various methods known in the art, including but not limited to those described infra. 5.4.1. GENETIC ANALYSIS The cloned DNA or cDNA corresponding to the CRl gene can be analyzed by methods including but not limited to Southern hybridization (Southern, E.M., 1975, J. Mol. Biol. 98:503-517), Northern hybridization (see e.g. , Freeman et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:4094-4098), restriction endonuclease mapping (Maniatis, T. , 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) , and DNA sequence analysis. The stringency of the hybridization conditions for both Southern and Northern hybridization can be manipulated to ensure detection of nucleic acids with the desired degree of relatedness to the specific CRl probe used. For example, hybridization under low stringency conditions with a probe containing CRl gene sequences encoding LHR-B and LHR-C, can be used to detect CR2 nucleic acid sequences. Restriction endonuclease mapping can be used to roughly determine the genetic structure of the CRl gene. In a particular embodiment, cleavage with restriction enzymes can be used to derive the restriction map shown in Figure 2, infra. Restriction maps derived by restriction endonuclease cleavage can be confirmed by DNA sequence analysis. DNA sequence analysis can be performed by any techniques known in the art, including but not limited to the method of Maxam and Gilbert (1980, Meth. Enzymol. 65:499-560), the Sanger dideoxy method (Sanger, F. , et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463), or use of an automated DNA sequenator (e.g. , Applied Biosystems, Foster City, CA.). The cDNA sequence of the CRl gene comprises the sequence substantially as depicted in Figure 1, and described in Sections 6 and 7, infra. 5.4.2. PROTEIN ANALYSIS The amino acid sequence of the CRl protein can be derived by deduction from the DNA sequence, or alternatively, by direct sequencing of the protein, e.g. , with an automated amino acid sequencer. The amino acid sequence of a representative CRl protein comprises the sequence substantially as depicted in Figure 1, and detailed in Section 6, infra. As described infra, all of the coding sequence of the F allotype CRl has been cloned and, after cleavage of the signal peptide of 41 amino acids, the mature receptor contained 1998 amino acids including an extracellular domain of 1930 residues that forms 30 SCRs, 28 of which are organized into LHRs-A, -B, -C and -D, (Fig. 10) , a single membrane spanning domain of 25 amino acids and a relatively short cytoplasmic domain of 43 amino acids. Among the C3/C4 binding proteins that contain multiple SCRs, CRl is unique in having groups of SCRs organized into LHRs. Comparison of the four LHRs of CRl reveals that each is a composite of four types of SCRs: types a, b, c and d (Fig. 19) . For example, the sequences of SCR-1 and -2 of LHR-A are only 62%, 62% and 57% identical to the first two SCRs of LHR-B, -C and -D, respectively. However, SCR-3 through SCR-7 differ from the corresponding SCRs of LHR-B at only a single position, and SCR-3 and -4 differ from those of LHR-C at only three positions (Fig. 10) . Thus, some of the type "a" SCRs of LHR-A are also present in LHR-B and -C. The first two SCRs of LHR-B, which differ from those of LHR-A, are 99% identical with the corresponding SCRs of LHR-C, so that LHR-B and -C share the type "b" SCR at these positions. The fifth, sixth and seventh SCR of LHR-C are only 77% identical to the type "a" SCRs in LHR-A and -B at these positions, and are considered as type "c" SCRs. The first through fourth SCRs of LHR-D are relatively unique and are type "d", while the fifth through seventh SCRs are approximately 93% identical to the "c" type found in LHR-C. The CRl protein sequence can be further characterized by a hydrophilicity analysis (Hopp, T. and Woods, K. , 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824). A hydrophilicity profile can be used to identify the hydrophobic and hydrophilic regions of the CRl protein and the corresponding regions of the gene sequence which encode such regions. A hydrophilicity profile of the COOH-terminus of the CRl protein is depicted in Figure 5. Secondary structural analysis (Chou, P. and Fasman, G. , 1974, Biochemistry 13:222) can also be done, to predict regions of CRl that assume specific secondary structures. Other methods of structural analysis can also be employed. These include but are not limited to X-ray crystallography (Engstom, A., 1974, Biochem. Exp. Biol. 11:7-13) and computer modeling (Fletterick, R. and Zoller, M. (eds.), 1986, Computer Graphics and Molecular Modeling, in Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) . 5.5. CR1-RELATED DERIVATIVES, ANALOGUES, AND PEPTIDES The production and use of derivatives, analogues, and peptides related to CRl are also envisioned, and within the scope of the present invention. Such derivatives, analogues, or peptides which have the desired immunogenicity or antigenicity can be used, for example, in immunoassays, for immunization, therapeutically, etc. Such molecules which retain, or alternatively inhibit, a desired CRl property, e.g. , binding of C3b or C4b, regulation of complement activity, or promotion of immune stimulation or phagocytosis, etc., can be used as inducers, or inhibitors, respectively, of such property. The CRl-related derivatives, analogues, and peptides of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned CRl gene can be modified by any of numerous strategies known in the art (Maniatis, T. , 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) . The CRl sequence can be cleaved at appropriate sites with restriction endonuclease(s) , followed by further enzymatic modification if desired, isolated, and ligated jLn vitro (see Section 8, infra) . In the production of the gene encoding a derivative, analogue, or peptide related to CRl, care should be taken to ensure that the modified gene remains within the same translational reading frame as CRl, uninterrupted by translational stop signals, in the gene region where the desired CRl-specific activity is encoded. In a particular embodiment, nucleic acid sequences encoding a fusion protein, consisting of a molecule comprising a portion of the CRl sequence plus a non-CRl sequence, can be produced. Additionally, the CRl gene can be mutated in vitro or in vivo, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification. Any technique for mutagenesis known in the art can be used, including but not limited to, _in vitro site-directed mutagenesis (Hutchinson, C, et al., 1978, J. Biol. Chem. 253:6551), use of TAB ® linkers (Pharmacia) , etc. Manipulations of the CRl sequence may also be made at the protein level. Any of numerous chemical modifications may be carried out by known techniques, including but not limited to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH.; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc. In addition, analogues and peptides related to CRl can be chemically synthesized. For example, a peptide corresponding to a portion of CRl which mediates the desired activity (e.g. , C3b and/or C4b binding, immune stimulation, complement regulation, etc.) can be synthesized by use of a. peptide synthesizer. Specific modifications of the nucleotide sequence of CRl can be made by recombinant DNA procedures that result in sequences encoding a protein having multiple LHR-B sequences. Such valency modifications alter the extent of C3b binding. 5 . 6. USES OF CRl 5.6.1. ASSAYS AND DIAGNOSIS CRl proteins, analogues, derivatives, and subsequences thereof, and anti-CRl antibodies, have uses in assays and in diagnostics. The molecules of the invention which demonstrate the desired CRl property or function can be used to assay such property or function. For example, CRl proteins or fragments thereof, which exhibit binding of C3b and/or C4b, in free and/or in complex forms, can be use 10 in assays to measure the amount of such substances in a sample, e.g. , a body fluid of a patient. In a specific embodiment, full-length CRl or a CRl deletion mutant expressed on the cell surface (e.g. , those described in Section 8, infra) having the ability to bind C3b (e.g. , see Table II, Section 9, infra), iC3b or C4 (e.g. , see Table II) can be used in assays to measure the levels of C3b, iC3b, or C4b, respectively, in a sample. In another embodiment, a CRl protein or fragment thereof which is constructed by recombinant DNA technology to lack a 20 transmembrane sequence, and is thus secreted, can be used. In a particular embodiment, such a measurement of C3b and/or C4b can be relied on as an indication of complement activity, and can be useful in the diagnosis of 2 __b inflammatory and immune system disorders. Such disorders include but are not limited to tissue damage due to burn- or myocardial infarct-induced trauma, adult respiratory distress syndrome (shock lung) , autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, and 2 Q other diseases or disorders involving undesirable or inappropriate complement activity (see, e.g. , Miescher, P.A. and Muller-Eberhard, H.J., eds., 1976, Text Book of Immunopathology, 2d Ed., Vols. I and II, Grune and Stratton, New York; Sandberg, A.L. , 1981, .in Cellular Functions in 35 Immunity and Inflammation, Oppenheim, J.J. et al., eds., Elsevier/North Holland, New York, p. 373; Conrow, R.B. et al., 1980, J. Med. Chem. 23:242; Regal, J.F. and Pickering, R.H. , 1983, Int. J. Immunopharmacol. 5:71; Jacobs, H.S., 1980, Arch. Pathol. Lab. Med. 104:617). The CRl protein and fragments thereof containing an epitope have uses in assays including but not limited to immunoassays. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay) , "sandwich" immunoassays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, and immunoelectrophoresis assays, to name but a few. CRl genes and related nucleic acid sequences and subsequences, can be used in hybridization assays. Such hybridization assays can be used to monitor inflammatory or immune responses associated with CRl expression, to diagnose certain disease states associated with changes in CRl expression, to determine the CRl allotype of a patient, and to detect the presence and/or expression of the CRl gene and related genes (e.g. , CR2) . Kits for practicing the assays for use in the present invention are also provided. 5.6.2. THERAPY The CRl protein and fragments, derivatives, and analogues thereof can be therapeutically useful in the modulation of functions mediated by CRl. Such functions include but are not limited to binding of C3b and/or C4b, i free or in complex forms, promotion of phagocytosis, complement regulation, immune stimulation, etc. Effective doses of the CRl proteins and related molecules of the invention have therapeutic value for many of the diseases o disorders associated with such functions, such as immune or inflammatory disorders (e.g. , those described supra in Section 5.6.1). For example, full-length CRl or fragments thereof and related molecules which exhibit the desired activity can have therapeutic uses in the inhibition of complement by their ability to act as a factor I cofactor, promoting the irreversible inactivation of complement components C3b or C4b (Fearon, D.T., 1979, Proc. Natl. Acad. Sci. U.S.A. 76:5867; Iida, K. and Nussenzweig, V., 1981, J. Exp. Med. 153:1138), and/or by the ability to inhibit the alternative or classical C3 or C5 convertases. In a specific embodiment of the invention, an expression vector can be constructed to encode a CRl molecule which lacks the transmembrane region (e.g. , by deletion carboxy-terminal to the arginine encoded by the most C-terminal SCR) , resulting in the production of a soluble CRl fragment. In one embodiment, such a fragment can retain the ability to bind C3b and/or C4b, in free or in complex forms. In a particular embodiment, such a soluble CRl protein may no longer exhibit factor I cofactor activity. The soluble CRl product can be administered in vivo to a patient, so that the soluble CRl can effectively compete out binding of the C3b and/or C4b to the native cell-surface CRl, thus blocking cell-surface CRl factor I cofactor activity, and increasing complement activity. After C3b has covalently attached to particles and soluble immune complexes, the inactivation of C3b by proteolytic processing into iC3b and C3dg has two biologic consequences: preventing excessive activation of the complement system via the amplification pathway, and formation of ligands that can engage receptors other than CRl. The iC3b fragment cannot bind factor B so that conversion to this state blocks additional complement activation via the alternative pathway amplification loop. However, iC3b can be bound by CRl and CR3, the two complement receptors that mediate phagocytosis by myelomonocytic cells. Therefore, the primary biologic consequence of C3b to iC3b conversion is cessation of complement activation without interference with CRl- and CR3-mediated clearance of the C3-coated complex. In contrast, the additional conversion of iC3b to C3dg creates a fragment that interacts only with CR2 and not with CRl and CR3. This circumstance limits complement-dependent binding of the C3dg-bearing complex to cell types expressing CR2, which include B lymphocytes, follicular dendritic cells and perhaps epithelial cells of the dermis, and diminishes or excludes interaction with phagocytic cell types. The biologic consequence of this altered pattern of cellular association would be targeting of the C3dg-bearing complexes to cells involved in the afferent phase of the immune response rather than to cells involved in clearance and degradation of particles and complexes. Therefore, CRl molecules may be used therapeutically not only to affect the clearance process, but also in the targeting of complexes to the CR2-bearing cell types that participate in antigen presentation and antibody production. In an alternative embodiment, a CRl protein or fragment thereof which can bind C3b or C4b, and/or retains the ability to inhibit the alternative or classical C3 or C5 convertases, or retains factor I cofactor activity, can be used to promote complement inactivation. In such an embodiment, the CRl protein or fragment can be valuable in the treatment of disorders which involve undesirable or inappropriate complement activity (e.g. , shock lung, tissue damage due to burn or ischemic heart conditions, autoimmune disorders, inflammatory conditions, etc.). In a specific embodiment detailed in the examples Sections 11-14 infra, a soluble CRl molecule can be expressed which retains a desired functional activity, as demonstrated, e.g., by the ability to inhibit classical complement-mediated hemolysis, classical C5a production, classical C3a production, or neutrophil oxidative burst in vitro. In a particular embodiment, such a soluble CRl molecule can be used to reduce inflammation and its detrimental effects, or to reduce myocardial infarct size or prevent reperfusion injury, etc. Such CRl molecules useful for in vivo therapy may be tested in various model systems known in the art, including but not limited to the reversed passive Arthrus reaction (see Section 14.1) and a rat myocardial infarct model (see Section 14.3). 0 In another embodiment of the invention, a fragment of CRl, or an analogue or derivative thereof, which is shown to inhibit a desired CRl property or function, can be used to prevent or treat diseases or disorders associated with that function. 5 Various delivery systems are known and can be used for delivery of CRl and related molecules, e.g. , encapsulation in liposomes, microparticles, or microcapsules, expression by hematopoietic stem cell progeny in gene therapy, etc. Other methods of introduction include 0 but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, and oral routes. The present invention also provides S pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a CRl protein, or an analogue, derivative, or fragment thereof, and a pharmaceutically acceptable carrier. Such a carrier includes but is not limited to saline, buffered saline, 0 dextrose, and water. 5.6.3. COMBINATION THERAPY In a further aspect there is provided a method of treating thrombotic conditions, especially acute myocardial 5 infarction, in humans and animals, which method comprises administering to a human or animal in need thereof an effective amount of a soluble CRl 1 protein according to the invention and an effective amount of a thrombolytic agent. The invention also provides the use of a soluble CRl protein and a thrombolytic agent in the manufacture of a medicament for the treatment of thrombotic conditions in humans and animals. In the above method, the compounds may be administered by any convenient route, for example by infusion or bolus injection, and may be administered sequentially or together. When the soluble CRl protein according to the invention and the thrombolytic agent are administered sequentially, the soluble CRl protein may be administered either before or after the thrombolytic agent. When the soluble CRl protein and the thrombolytic agent are administered together they are preferably given in the form of a pharmaceutical composition comprising both agents. Thus, in a further aspect of the invention there is provided a pharmaceutical composition comprising a soluble CRl protein and a thrombolytic agent together with a pharmaceutically acceptable carrier. In a preferred embodiment, the composition may be formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anaesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients will be supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilised powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent in activity units. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade 'Water for Injection' or saline. Where the composition is to be administered by injection, an ampoule of sterile water for injection or saline may be provided so that the ingredients may be mixed prior to administration. A pharmaceutical pack comprising one or more containers filled with one or more of the ingredients of the pharmaceutical composition is also within the scope of the invention. The quantity of material administered, and the ratio of thrombolytic agent to CRl protein, will depend upon the seriousness of the thromboembolic condition and position and size of the clot. The precise dose to be employed and mode of administration must per force in view of the nature of the complaint be decided according to the circumstances by the physician supervising treatment. However, in general, a patient being treated for a thrombus will generally receive a dose of from 0.5 to 50 mg of complement inhibitor (soluble CRl component) per standard dose of thrombolytic agent. Particular thrombolytic agents for use in combination therapy as described above are fibrinolytic enzymes, including plasminogen activators. The term plasminogen activator includes but is not limited to streptokinase, human tissue plasminogen activator (t-PA) and urokinase (u-PA) (both single and two- chain forms) . Such enzymes are obtained from natural sources or tissues or by recombinant DNA methods where heterologous host organisms such as bacteria, yeasts, fungi or mammalian cells express genes specifyng the enzymes. The term also includes: (a) proteins disclosed in EP(European Patent Publication) -A-0155387 and EP-A-0297882 which disclose a fibrinolytically active hybrid protein which comprises one chain of a 2-chain protease linked to a chain of a different 2-chain protease, at least one of the chains in the hybrid protein being derived from a fibrinolytically active protease, such that the hybrid protein has a ctalytic site essential for fibrinolytic activity which is optionally blocked by a removable blocking group; (b) protein conjugates disclosed in EP-A- 0152736, such as urokinase linked to reversibly blocked plasmin; (c) derivatives of fibrinolytic enzymes disclosed in EP-A-0155388 in which the catalytic site on the enzyme which is responsible for fibrinolytic activity is blocked by a human protein attached thereto by way of a reversible linking group, for example urokinase reversibly linked to the active centre of human plasmin; (d) conjugates comprising a fibrinolytic enzyme linked to a water-soluble polymer by means of a reversible linking group as disclosed in EP-A-0183503; and (e) genetically engineered derivatives including muteins of naturally occurring plasminogen activators such as those disclosed in EP-A-0201153, EP-A-0207589, WO(PCT Publication)-8604351, EP-0041766, EP-0213794, EP-0199574, EP-A-0240334, EP-A-0241208, EP-A-0241209, EP-A-0241210, EP-A-0233013, EP-A-290118, EP-A-292326, EP-A-0213794, EP-A-0231883, WO 8704722, EP-A-0242836, EP-A-0234051, EP-A-0253582, EP-A-0253241, WO-8604351, EP-A-0236040, EP-A-0200451, EP-A-0238304, EP-A-0225286, DE(West German Publication)-3537176, EP-A-0236289, WO-8601538, EP-0227462, AU(Australian Publication) -8661804, WO-8703906 and EP-0199574, such as des(cys 5 -asp )t-PA. In a particular aspect of the invention, the plasminogen activator is a hybrid molecule as described in EP-A-0297882 which comprises the five kringle domains of plasminogen linked to the B-chain of t-PA or u-PA via an amino acid sequence comprising, respectively, the t-PA cleavage site between residues 275 and 276 and the cysteine residue 264 of t-PA or the u-PA cleavage site between residues 158 and 159 and the cysteine residue 148 of u-PA. Examples of such hybrids include plasminogen 1-544/t-PA 262-527 including one and two chain variants, lys_ /o_ and glu1. variants, and mixtures thereof; plasminogen 1-544/t-PA 262-527 (arg - gin) including one and two chain variants, lys 78 and glu. variants, and mixtures thereof; plasminogen 1-541/t-PA 262-527 including one and two chain variants, lys 78 and glu variants, and mixtures thereof; t-PA 1-50/t-PA 88-91/pro-gly-ser/plasminogen 84-544/t-PA 262-527 including one and two chain variants, gly , ser. and val. variants, and mixtures thereof; t-PA 1-91/pro-gly-ser/plasminogen 84-544/t-PA 262-527 including one and two chain variants, gly_-, ser. and val. variants, and mixtures thereof; or plasminogen 1-546/u-PA 137-411 including one and two chain variants, lys_ 8 and glu. variants, and mixtures thereof. In a preferred embodiment, the thrombolytic agent for use in combination therapy is a reversibly blocked in vivo fibrinolytic enzyme having the meaning given by Smith in U.S. Patent No. 4,285,932, i.e. , an in vivo fibrinolytic enzyme wherein the catalytic site essential for fibrinolytic activity is blocked by a group which is removable by hydrolysis at a rate such that the pseudo-first order rate —6 —1 — * constant for hydrolysis is in the range 10 sec to 10 sec " in isotonic aqueous media at pH 7.4 at 37°C. Where the fibrinolytic -.nsyme is a plasminogen activator comprising a serine protease domain of t-PA or urokinase, an example of a removable blocking group is a 2-aminobenzoyl group substituted in the 3- or 4-position with a halogen atom and optionally further substituted with one or more weakly electron-withdrawing or electon-donating groups, wherein the pseudo first order rate constant for hydrolysis of the derivative is in the range of 6.0 x 10 -5 to 4.0 x 10 -4 sec-1 when measured in a buffer system consisting of 0.05 M sodium phosphate, 0.1 M sodium chloride, 0.01% v/v detergent comprising polyoxyethylene- sorbitan monoleate having a molecular weight of approximately 1300, at pH 7.4 at 37°C. Preferably, the reversibly blocked _in vivo fibrinolytic enzyme is a binary complex between streptokinase and plasminogen, most preferably a p-anisoyl streptokinase/plasminogen complex without internal bond cleavage as described in U.S. Patent No. 4,808,405, marketed by Beecham Group pic under the Trademark EMINASE (generic name anistreplase, hereinafter referred to as APSAC, i.e. anisoylated human plasminogen-streptokinase-activator complex; see for example J. P. Monk and R. C. Heel, 1987, Drugs 34:25-49) . In a preferred aspect, the soluble CRl component used in combination therapy is encoded by a nucleic acid vector selected from the group consisting of pBSCRlc, pBSCRls, pBM-CRlc, pBSCRlc/pTCSgpt and pBSCRls/PTCSgpt and is especially that prepared from pBSCRlc/pTCSgpt as described above (see Section 12) . Particular thrombolytics for use in combination therapy (with examples of dose and method of administration) are as follows: Streptokinase 1.0-3.0 megaunits over 30 minutes to 3 hours APSAC 30 units 2-5 minute injection t-PA (wild-type) 50-150 mg Infusion up to 6 hours Two-chain 40-100 mg Infusion up to 6 hours urokinase (3-12 megaunits) Single-chain 30-100 mg Infusion up to 5 hours urokinase Hybrid plasminogen 20-100 mg Injection or infusion activators and acyl derivatives (as in e.g. EP-A-0155387) Muteins of 10-100 mg Injection or i nfusio plasminogen activators (as in e.g. EP-A-0207589) 6. EXAMPLE: THE CLONING AND SEQUENCING OF THE HUMAN C3b/C4b RECEPTOR (CRl) In the examples detailed herein, we describe the cloning and nucleotide sequence of 5.5 kilobase pairs (kb) of the CRl coding region (Klickstein, L.B., et al., 1987, J. Exp. Med. 165:1095-1112). Ten overlapping CRl cDNA clones that span 5.5 kb were isolated from a tonsillar library and sequenced in whole or in part. A single long open reading frame beginning at the 5' end of the clones and extending 4.7 kb downstream to a stop codon was identified. This sequence represents -80% of the estimated 6 kb of coding sequence for the F allotype of CRl. Three tandem, direct, long homologous repeats (LHRs) of 450 amino acids were identified. Analysis of the sequences of tryptic peptides provided evidence for a fourth LHR in the F allotype of CRl. Amino acid identity between the LHRs ranged from 70% between the first and third repeats to 99% between the NH_-terminal 250 amino acids of the first and second repeats. Each LHR comprises seven short consensus repeats (SCRs) of 60-70 amino acids that resemble the SCRs of other C3/C4 binding proteins, such as complement receptor type 2, factors B and H, C4 binding protein, and C2. Two additional SCRs join the LHRs to a single membrane-spanning domain of 25 amino acids: thus, the F allotype of CRl probably contains at least 30 SCRs, 23 of which have been sequenced. Each SCR is predicted to form a triple loop structure in which the four conserved half-cystines form disulfide linkages. The linear alignment of 30 SCRs as a semi-rigid structure would extend 1,140 Angstroms from the plasma membrane and might facilitate the interaction of CRl with C3b and C4b located within the interstices of immune complexes and microbial cell walls. The COOH-terminal cytoplasmic domain of 43 residues contains a six amino acid sequence that is homologous to the sequence in the epidermal growth factor receptor that is phosphorylated by protein kinase C. 6.1. MATERIALS AND METHODS 6.1.1. ISOLATION AND SEQUENCE OF CRl TRYPTIC PEPTIDES CRl was purified from washed human erythrocyte membranes by sequential Matrex Red A and YZ-1 monoclonal antibody affinity chromatography (Wong, W.W. , et al. , 1985, J. Immunol. Methods 82:303). Tryptic peptides were prepared and isolated by sequential gradient and isocratic reverse- phase HPLC (high performance liquid chromatography) as described (Wong, W.W. , et al., 1985, Proc. Natl. Acad. Sci. U.S.A. 82:7711). Tryptic peptide analysis was performed with a 470A Protein Sequencer (Applied Biosystems, Inc., Foster City, CA) , and analysis of each degradative cycle was achieved using a 120 PTH-amino acid analyzer (Applied Biosystems, Inc.) . 6.1.2. ISOLATION OF cDNA CLONES AND GENOMIC CLONES A cDNA library was constructed in λgtll from human tonsilar poly(A) RNA as described (Wong, W.W. , et al., 1985, Proc. Natl. Acad. Sci. U.S.A. 82:7711). By RNA blot hybridization, the tonsil donor was homozygous for the t 5 F allele of CRl (id.) . The cDNA was selected on an agarose gel to include fractions between 2 and 7 kb before the cloning steps. The initial complexity of the library was 4.5 x 10 recombinants per 100 ng cDNA and the library was amplified in Escherichia coli strain Y1088. The library wa 10 screened (Maniatis, T., et al., 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) with CRl probes, CRl-1 (ATCC accession nos. 57330 (E. coli containing CRl-1 plasmid) , 57331 (purified CRl-1 DNA)) and CR1-2 (Wong, W.W. , et al., 15 1985, Proc. Natl. Acad. Sci. U.S.A. 82:7711), that had been Q radiolabeled to a specific activity of 2-8 x 10 cpm/μg by nick translation. Hybridization was performed in 50% formamide, 5x SSC (lx SSC: 15 mM sodium citrate, 150 mM sodium chloride) at 43°C and filters were washed at 60°C in 20 0.2x SSC, conditions that do not allow the detection of CR2 cDNA clones (Weis, J.J., et al., 1986, Proc. Natl. Acad. Sci. U.S.A. 83:5639). Positive clones were plaque-purified twice before restriction mapping and DNA sequence analysis. A genomic library was constructed in EMBL-3 with 25 15-20 kb fragments produced by partial digestion of human leukocyte DNA with Sau3AI. The initial complexity was 1.2 10 , and the library was amplified in E. coli strain P2392. The library was also screened with the cDNA probes CRl-1 an 30 CR1-2 (Wong, W.W., et al., 1985, Proc. Natl. Acad. Sci. U.S.A. 82:7711). r 35 6.1.3. DNA SEQUENCE ANALYSIS Restriction fragments of the cDNA clones were subcloned in M13mpl8 or M13mpl9 and sequenced by the dideoxynucleotide chain termination method (Sanger, F. , et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463). Some clones were sequenced in whole or in part by first creating ordered deletion mutants using exonuclease III (Henikoff, S., 1984, Gene 28:351). Each region was sequenced on both strands and in most cases each region was sequenced on M13 subclones constructed from two independently isolated cDNA clones (Fig. 2) . Sequence data were analyzed with the University of Wisconsin Genetics Computer Group package (Madison, WI) . 6.2. RESULTS 6.2.1. NUCLEOTIDE SEQUENCE OF THE CRl GENE A size-selected tonsillar cDNA library was screened with the CRl-1 and CR1-2 probes obtained from the CRl cDNA clone, AT8.3 (Wong, W.W. , et al., 1985, Proc. Natl. Acad. Sci. U.S.A. 82:7711). Fifteen positive phage were identified out of 1.5 x 10 recombinants and 13 of these represented distinct clones. Ten were restriction mapped and sequenced in whole or in part by the dideoxynucleotide chain termination method. The cDNA clones were aligned on the basis of overlapping sequence identity (Fig. 2) and were found to span 5.5 kb (Fig. 3). A single long open reading frame was identified beginning at the 5' end of the cDNA clones and extending 4.7 kb downstream to a stop codon. The coding sequence for CRl in this library is expected to be 6 kb, based on an estimated 220,000 dalton molecular weight for the nonglycosylated receptor (Wong, W.W. , et al., 1983, J. lin. Invest. 72:685). Thus, these clones span -80% of the estimated coding sequence. Clones T49.1 and T55.1 contain coding sequence a their 5' ends, indicating that additional 5' coding and noncoding sequences remain to be identified. In the 3' region, the overlapping clones, T8.2, T43.1 and T87.1, contain the transmembrane and cytoplasmic regions encoded b an identical sequence in each clone. The clone extending most 3', T8.2, contains 807 bp of untranslated sequence without a poly(A) sequence. Clone T8.3 contains a 91-bp deletion of nucleotides 1,406-1,497 and clone T40.1 contain a 9-bp deletion of nucleotides 1,498-1,507 relative to the 10 sequences found in clones T6.1 and T55.1. These deletions occurred in regions having sequences homologous to 5' splic sites and may represent splicing errors in the mRNA. Clones T49.1 and T55.1 contain a 110 bp insertion between nucleotides 147 and 148 of the open reading frame (Fig. 3) . 15 This sequence is judged to be a portion of an intron because it did not hybridize to blots of tonsillar poly(A) RNA, it contains a 5' splice site (Breathnach, R. , et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:4853) (Fig. 3), it is flanked by cDNA sequences in CRl genomic clones, and it 20 shifts the reading frame. Clone T9.4 contains 0.88 kb of intervening sequence at the 3' end that does not hybridize to blots of tonsillar poly(A) RNA. 25 6.2.2. ANALYSIS OF THE NUCLEOTIDE AND AMINO ACID SEQUENCE OF CRl Dot matrix analysis of the nucleotide sequence of CRl (Fig. 3) revealed two types of internal homologies (Fig. 4) . The first type of internal homology is represented by the bold, uninterrupted lines that indicate the presence of 30 three tandem, direct, highly homologous repeats of 1.35 kb. These nucleotide sequences encode the long homologous • T repeats (LHRs) of CRl. The second type of repeat is * represented by the dashed parallel lines that indicate 35 regions of lesser homology. These sequences occur every 190-210 nucleotides and encode the short consensus repeats (SCRs) of CRl. The amino acid sequence deduced from the cDNA sequence is presented in Figure 5 and the three LHRs, designated LHR-B, LHR-C and LHR-D, are aligned to demonstrate their homology. LHR-B extends from residue 1 through residue 438, LHR-C corresponds to residues 439-891, and LHR-D extends from residue 892 through 1,341. Residues 451-694 of LHR-C are 99% identical to residues 1-244 of LHR-B, but only 61% identical to the corresponding residues of LHR-D. In contrast, residues 695-891 of LHR-C are 91% identical to residues 1,148-1,341 of LHR-D but only 76% identical to the corresponding region of LHR-B. Thus, LHR-C appears to be a hybrid that comprises sequences most homologous to the first half of LHR-B and the second half of LHR-D. The LHRs are followed by two SCRs that are not repeated, a 25 residue hydrophobic segment and a 43 amino acid COOH-terminal region with no sequence homology to the SCRs (Fig. 5). The 5' 1.3 kb of the CRl coding sequence represents a fourth LHR, LHR-A (see Fig. 1, supra, and Section 7, infra) . This conclusion was supported by analysis of tryptic peptides of erythrocyte CRl. Ten tryptic peptides have sequences identical to the amino acid sequences derived from the cDNA clones (Table I) . TABLE I CRl TRYPTIC PEPTIDES FOUND IN THE DERIVED AMINO ACID SEQUENCE* Peptide Amino acid sequence Residue Numbers in Number the Derived Sequence 10 66 VDFVCDEGFQLKGS-A 330-345 28 GAASL QG-WSPEAP 732-749, 1,185- 1,202 49 IFC-NP-AIL 805-826, 1,258- 1,279 15 35 CQALNKWEPELPSCSR 228-243, 678-693 41c DKDNFSPGQEVFYSCEPGYDLR 260-281 34b AV-YTCDPHPDRGTSFDLIGESTIR 393-417 20 44d VCQPPPEILHG 694-704, 1,147- 1,157 54d VFELVGEPSIYCTSNDDQVGIWSGPAPQ 152-179, 602-629 57b YECRPEYYGRPFS 19-31, 469-481 39b LIGHSSAECILSGNAA 85-100 25 *Tryptic peptides from human erythrocyte CRl found in the derived amino acid sequence. The number ranges in the right-hand column indicate the location of the peptide in the derived amino acid sequence. Each dash in peptides 66, 30 28 and 49 indicates multiple residues were identified at that cycle. The dash in peptide 34b indicates no residue r was identified at that cycle. * 35 Each LHR comprises seven 60-70 amino acid SCRs that characterize the family of C3 and C4 binding proteins (C4bp) (Fig. 6A) . Maximal homology between the 23 SCRs of CRl was observed by introducing spaces in the alignment of the sequences (Fig. 6A) . Altogether, 29 of the average 65 residues in each repeat are conserved. There are six residues that are present in all SCRs: the four half- cystines that are in similar relative positions suggesting that each may be involved in a critical disulfide linkage, and the tryptophan and the second glycine after the second half-cystine (Fig. 6A) . Secondary structure analysis of the sequences between the invariant half-cystines using the algorithm of Chou and Fasman (Chou, P.Y. and Fasman, G.D., 1974, Biochemistry 13:222) predicted high probability / 9-turn formation and low probability α-helix formation. Sequence analysis of two CRl genomic clones, 2.38 (Fig. 6B) and 2.46, indicates that SCR-14 (Fig. 6A) is encoded by a single exon and that the COOH-terminus of SCR-23 corresponds to the end of an exon. Thus, the SCRs of CRl may be encoded by separate exons as has been shown for the SCRs of factor B (Campbell, R.D. and Bentley, D.R. , 1985, Immunol. Rev. 87:19) and of the IL-2-R (Leonard, W.J. , et al., 1985, Science 230:633). The consensus sequence of the CRl SCRs is compared with the SCRs of the other members of the superfamily having this characteristic structure (Fig. 7) . These members include not only proteins having C3/C4 binding function, CR2 (Weis, J.J., et al., 1986, Proc. Natl. Acad. Sci. U.S.A. 83:5639), C4bp (Chung, L.P., et al., 1985, Biochem. J. 230:133), factor H (Kristensen, T. , et al., 1986, J. Immunol. 136:3407), factor B (Morley, B.J. and Campbell, R.D., 1984, EMBO J. 3:153; Mole, J.E., et al., 1984, J. Biol. Chem. 259:3407), and C2 (Bentley, D.R. and Porter, R.R. , 1984, Proc. Natl. Acad. Sci. U.S.A. 81:1212; Gagnon, J. , 1984, Philos. Trans. R. Soc. Lond. B. Biol. Sci. 306:301), but also the proteins not known to have this function, such as the interleukin-2 receptor (Leonard, W.J., et al., 1985, Science 230:633), β -glycoprotein I (Lozier, J., et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:3640), 5 Clr (Leytus, S.P., et al., 1986, Biochemistry 25:4855), i. r haptoglobin a chain (Kurosky, A., et al., 1980, Proc. Natl. Acad. Sci. U.S.A. 77:3388), and factor Xlllb (Ichinose, A., et al., 1986, Biochemistry 25:4633). The half-cystine residues are invariant in the SCRs of all proteins, except 10 haptoglobin which lacks the third half-cystine. The tryptophan is also invariant with the exception of the fifth SCR in β -glycoprotein I and two of the repeats in factor Xlllb. Other residues that are conserved but not present in each SCR tend to cluster about the half-cystines. There is 15 only one free thiol group in factor B and C2 (Christie, D.L. and Gagnon, J., 1982, Biochem. J. 201:555; Parkes, C. , et al., 1983, Biochem. J. 213:201), and in the SCRs of β - glycoprotein I, the first half-cystine is disulfide-linked to the third and the second to the fourth (Lozier, J. , et 20 al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:3640). In the derived amino acid sequence of CRl, there are 17 potential sites for N-linked oligosaccharides and all of them are in the extracellular region (Fig. 6A) . 25 Molecular weight differences between CRl synthesized in the presence and absence of tunicamycin (Lublin, D.M. , et al., 1986, J. Biol. Chem. 261:5736) and analysis of glucosamine content (Sim, R.B., 1985, Biochem. J. 232:883) suggest the presence of only 6-8 N-linked complex oligosaccharides, 30 indicating that all potential sites are not used. For example, the asparagine at residue 263 of the derived amino T acid sequence (Fig. 5) was identified in peptide 41c (Table * I) , indicating absence of glycosylation at this site. In 35 contrast, the unidentified amino acid in peptide 34b probably corresponds to a glycosylated asparagine at residue 395. The only nonrepetitive CRl sequences identified in the 5.5 kb of cDNA are located in the COOH-terminal region. A secondary structure analysis of this region identifies a single 25-residue putative membrane-spanning segment having strong hydrophobic character and high potential for α-helix formation (Fig. 5) . This sequence is immediately followed by four positively charged residues, a characteristic of many membrane proteins. The presumed cytoplasmic region of CRl comprises 43 residues and contains a six amino acid sequence, VHPRTL, which is homologous to the sequence VRKRTL, a site of protein kinase C phosphorylation in the epidermal growth factor (EGF) receptor and the erbB oncogene product (Hunter, T., et al., 1984, Nature 311:480; Davis, R.J. and Czech, M.P., 1985, Proc. Natl. Acad. Sci. U.S.A. 82:1974). There are no tyrosine residues in the cytoplasmic region of tonsillar CRl. 6.3. DISCUSSION Approximately 80% of the primary structure of the F allotype of CRl has been obtained by sequencing overlapping cDNA clones. The most unusual structural feature of CRl observed in this analysis is the presence of tandem, direct LHRs of 450 amino acids, four of which are predicted to occur in the F allotype of CRl that has an estimated polypeptide chain length of 2,000 residues (Wong, W.W., et al., 1983, J. Clin. Invest. 72:685; Sim, R.B., 1985, Biochem. J. 232:883). Three of the LHRs have been cloned and sequenced while evidence for the existence of the fourth was provided by the analysis of tryptic peptides. Each LHR is comprised of seven SCRs which are the basic structural elements of other C3/C4 binding proteins. The conservation of the four half-cystines per SCR, the probabl involvement of the first and third and the second and fourt half-cystines in disulfide linkages (Lozier, J., et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:3640) and the presence of conserved amino acids such as proline, glycine 5 and asparagine which are frequently found in -turns (Rose, tt r G.D., et al., 1985, Adv. Protein Chem. 37:1) lead to the proposal that an SCR forms a triple loop structure maintained by disulfide linkages (Fig. 8) . This role for the half-cystine residues is supported by the finding that 10 mildly trypsin-treated CRl (Sim, R.B., 1985, Biochem. J. 232:883) and factor H (Sim, R.B. and DiScipio, R.G. , 1982, Biochem. J. 205:285) migrate as intact molecules when analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) under non-reducing conditions and as multiple tryptic 15 fragments after reduction. This series of tandemly repeated SCRs is predicted to form an elongated structure (Fig. 8) as has been proposed for factor H and for each subunit of human C4bp (Sim, R.B. and DiScipio, R.G., 1982, Biochem. J. 20 205:285; Whaley, K. and Ruddy, S., 1976, J. Exp. Med. 144:1147; Dahlback, B. , et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:3461). Electron microscopic studies of the subunits of C4bp have indicated dimensions of 300 x 30 25 Angstroms (Dahlback, B. , et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:3461). As each subunit is composed of eight SCRs (Chung, L.P., et al., 1985, Biochem. J. 230:133), an individual SCR is calculated to be 38 x 30 Angstroms. Assuming that the SCRs of CRl have similar dimensions and 30 that the F allotype has 30 SCRs, the receptor could extend as much as 1,140 Angstroms from the cell membrane. Consistent with this prediction of CRl structure is the earlier finding that ferritin-labeled antibody bound to CRl on neutrophils was frequently 500 Angstroms from the outer 35 leaflet of the plasma membrane (Abrahamson, D.R. and Fearon, D.T., 1983, Lab. Invest. 48:162). Such an elongated structure of CRl would facilitate the interaction of receptor-bearing cells with C3b that has covalently bound to relatively inaccessible sites within immune complexes and microbial cell surfaces. The finding that the SCR is the major, and perhaps only, extracytoplasmic element of CRl provides structural evidence for a close relationship between the receptor and factor H and C4bp, two plasma proteins that are exclusively or predominantly composed of SCRs (Chung, L.P., et al., 1985, Biochem. J. 230:133; Kristensen, T. , et al., 1986, J. Immunol. 136:3407). CRl was initially isolated as an erythrocyte membrane protein having factor H-like activity after detergent solubilization (Fearon, D.T., 1979, Proc. Natl. Acad. Sci. U.S.A. 76:5867), and it was found subsequently to have ^he regulatory functions of factor H and C4bp when residing on the plasma membrane (Iida, K. and Nussenzweig, V., 1981, J. Exp. Med. 153:1138). By analysis of the inheritance of structural polymorphisms of CRl, factor H, and C4bp, the genes encoding these three proteins were shown to be linked (de Cordoba, R. , et al., 1985, J. Exp. Med. 161:1189), and the locus for this linkage group and for the structurally related receptor, CR2, have been shown recently by in situ hybridization and by the analysis of somatic cell hybrids to be on the long arm of chromosome 1, band q32 (Weis, J.H., et al., 1987, J. Immunol. 138:312). Before the present study, the only evidence for a structural relationship between these proteins was a significant similarity in their amino acid compositions (Wong, W.W. , et al., 1985, J. Immunol. Methods 82:303). Therefore, the present finding of at least 23 SCRs in CRl constitutes the direct and formal demonstration of a structural relationship of the receptor with factor H and C4bp (Chung, L.P., et al., 1985, Biochem. J. 230:133; Kristensen, T. , et al., 1986, J. Immunol. 136:3407), proteins with similar functions, and with the Ba and C2b fragments of factor B and C2 (Morley, B.J. and Campbell, R.D., 1984, EMBO J. 3:153; Mole, J.E., et al., 1984, J. Biol. Chem. 259:3407; Bentley, D.R. and Porter, R.R., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:1212; Gagnon, J., 1984, Philos. Trans. R. Soc. Lond. B Biol. Sci. 5 306:301), components that form enzymatic complexes with C3b and C4b, respectively. However, the SCR is also found in several noncomplement proteins (Campbell, R.D., and Bentley, D.R., 1985, Immunol. Rev. 87:19; Lozier, J., et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:3640; Leytus, S.P., et al., 0 1986, Biochemistry 25:4855; Kurosky, A., et al., 1980, Proc. Natl. Acad. Sci. U.S.A. 77:3388; Ichinose, A., et al., 1986, Biochemistry 25:4633) (Fig. 7), indicating that it does not necessarily represent a C3/C4 binding structure. Among the proteins having SCRs, CRl is unique in 5 having organized this basic structure and genetic unit into the higher order structural unit of the LHR. Analysis of a 14.5 kb BamHI fragment of genomic DNA that is associated with expression of the S allotype has suggested that at least one repeating genomic unit in CRl is an extended 0 segment of DNA containing the exons encoding at least five SCRs and their flanking introns (Wong, W.W. , et al., 1986, J. Exp. Med. 164:1531). These studies have also suggested that the S allele contains an additional copy of this c genomic unit compared with the number present in the F b allele. This observation, combined with a tryptic peptide mapping study (Nickells, M.W. , et al., 1986, Mol. Immunol. 23:661) and the present finding that an LHR represents a peptide of -40-50 kD allows us to predict the presence in 0 the S allotype (290 kD) of an additional LHR relative to the estimate of four LHRs in the F allotype (250,000 daltons molecular weight) . In addition to providing evidence for duplication events, the sequences of the LHRs also suggest that 5 conversion events have occurred within the CRl gene. LHR-B and -D are 67% identical to each other throughout their length, whereas LHR-C is 99% identical to LHR-B in the NH_- terminal four SCRs and 91% identical to LHR-D in the COOH- terminal three SCRs. This organization could not have occurred by a single recombinational event between identical parental alleles in the origin of this hybrid LHR. Rather, the hybrid LHR may have arisen by gene conversion (Atchison, M. and Adesnik, M. , 1986, Proc. Natl. Acad. Sci. U.S.A. 83:2300) in which sequences in an LHR-C precursor were replaced by sequences present in LHR-B or LHR-D. The near complete identity and precise alignment of homologous sequences in these LHRs (Fig. 5) also may have been maintained by a mechanism involving gene conversion. Analysis of the extent of homology between intervening sequences of those segments of the CRl gene encoding the LHRs should determine whether gene conversion or selection based on functional constraints have strictly limited sequence divergence. Although a previous study suggested that CRl is monovalent (Wilson, J.G., et al., 1982, N. Engl. J. Med. 307:981), each LHR might represent a single C3b/C4b binding domain, which would make the receptor multivalent and adapted for the binding of complexes bearing multiple molecules of C3b and C4b. Alternatively, distinct LHRs might be responsible for binding C3b and C4b, respectively (see Section 9, infra), providing a structural basis for the combination of factor H and C4bp activities in CRl. Finally the LHRs of CRl may represent structural domains that serve to extend CRl from the plasma membrane, as suggested by the proposed structural model (Fig. 8) , and SCRs at the NH_- terminal region bind C3b and C4b, as has been found for factor H (Sim, R.B. and DiScipio, R.G., 1982, Biochem. J. 205:285; Alsenz, J. , et al., 1984, Biochem. J. 224:389). Activation of protein kinase C by phorbol esters induces phosphorylation of CRl in neutrophils, monocytes, and eosinophils (Changelian, P.S. and Fearon, D.T., 1986, J. Exp. Med. 163:101) and the CRl cytoplasmic domain of 43 amino acids has a sequence that is homologous to a site that is phosphorylated by protein kinase C in the epidermal * growth factor receptor (Hunger, T. , et al., 1984, Nature 311:480; Davis, R.J. and Czech, M.P., 1985, Proc. Natl. Acad. Sci. U.S.A. 82:1974). However, this cytoplasmic sequence, which was found in three independent clones of the 10 tonsillar library, is most likely that of B cell CRl, which is not phosphorylated after activation of protein kinase C (Changelian, P.S. and Fearon, D.T., 1986, J. Exp. Med. 163:101) . 15 7. EXAMPLE: CRl 5' CDNA SEQUENCES CONTAIN A FOURTH LONG HOMOLOGOUS REPEAT Analysis of a partial cDNA sequence of CRl revealed a strucure in which three LHRs, LHR-B, LHR-C, LHR- D, of 450 amino acids were each comprised of seven short 20 consensus repeats (SCR) of 65 amino acids characteristic of C3/C4 binding proteins (see Section 6, supra) . In the examples described herein, we describe the cloning and nucleotide sequence of a fourth amino-terminal LHR, LHR-A (Klickstein, L.B., et al., 1987, Complement 4:180) by the 25 sequencing of 5' cDNA clones. Analysis of LHR-A revealed that it is 99% homologous to LHR-B in the five 3' SCRs, but only 61% homologous in the two 5' SCRs. 7.1. MATERIALS AND METHODS 30 7.1.1. CONSTRUCTION OF A CDNA LIBRARY r A selectively primed cDNA library, λHH, was constructed from 3 μg of poly (A) RNA purified from DMS( induced cells as described (Chirgwin, J.M. et al., 1979, 35 Biochemistry 18:5290; Aviv, H. and Leder, P., 1972, Proc. Natl. Acad. Sci. U.S.A. 69:1408; Ausubel, F.M. , et al., 1987, Current Protocols in Molecular Biology, John Wiley & Sons, New York) with the following modifications. LK35.1, a 35-mer oligonucleotide, 5'-TGAAGTCATC ACAGGATTTC ACTTCACATG TGGGG-3', was used in place of oligo(dT) η . D and 40 μCi of 32 . ---3.B α P-dCTP were added during second strand synthesis. One third of the cDNA was cloned in λgtll and a cDNA library was constructed from human tonsilar poly(A) RNA as described in Section 6.1.2, supra. 750,000 independent recombinants were obtained. 7.1.2. ISOLATION OF CLONES, PROBES, AND DNA SEQUENCE ANALYSIS The probes used for screening cDNA libraries were CRl-1 (Wong, W.W. , et al., 1985, Proc. Natl. Acad. Sci. U.S.A. 82:7711) (ATCC accession no. 57331), CR-2 (Wong, W.W., et al., supra) , CR1-4 (Wong, W.W. et al., 1986, J. Exp. Med. 164:1531), and CR1-18, a 252 bp Sau3AI fragment from the 0.5 kb EcoRI fragment of cDNA clone λH3.1 corresponding to nucleotides 101-352 in Figure 1. Under conditions of high stringency, CR1-18 hybridizes only to cDNA clones encoding either the NH_-terminal SCR of LHR-A or the signal peptide. The inserts of the cDNA clones were sequenced by the dideoxynucleotide technique (Sanger, F., et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463) after subcloning fragments into M13mpl8 and M13mpl9 (Yanisch- Perron, C. et al., 1985, Gene 28:351). 7.2. RESULTS A specifically primed λgtll cDNA library, λHH, that contained 7.5 x 10 5 recombinants was prepared with cDNA synthesized from poly (A) RNA from DMSO induced HL-60 cells. These cells express only the F allotype of CRl (Lublin, D.M., et al., 1986, J. Biol. Chem. 261:5736) which is predicted to have four LHRs (Lapata, M.A. , et al. , 1984, Nucl. Acids Res. 12:5707). The primer, LK35.1, was an antisense 35-mer corresponding to nucleotides 896-930 of the partial cDNA sequence of CRl presented in Figure 3. This oligonucleotide was shown to hybridize to LHR-B, LHR-C and i 5 , , , LHR-D under the conditions of reverse transcription. Two t * hundred and fifty positive clones were identified in a plating of 3.8 x 10 5 unampli.fied recombinant phage screened with a mixture of the CRl cDNA probes, CRl-l and CR1-4. Thirty-eight positive clones were picked and plaque 10 purified. Southern blots of EcoRI-digested DNA from these clones were screened with the 23-mer oligonucleotide, KS23.1, 5'-CTGAGCGTAC CCAAAGGGAC AAG-3' , corresponding to nucleotides 763-785 of the partial CRl cDNA sequence of Figure 3. This probe hybridizes under conditions of high 15 stringency at a single site in the sequence encoding LHR-B but not to sequences encoding LHR-C or LHR-D. The insert of clone AH7.1 (Fig. 9) contained three EcoRI fragments of 1.0 kb, 0.9 kb and 0.4 kb and the two larger fragments hybridized to KS23.1, indicating that this clone contained 20 sequences coding for the 3' 5/7 of LHR-A and all of LHR-B. This finding confirmed that LHR-A is highly homologous to LHR-B. Clone λH3.1 (Fig. 9) contained a single KS23.1- positive EcoRI fragment of 1.0 kb and a 5', 0.5 kb fragment 25 that hybridized weakly with CR1-4 at high stringency. This clone was considered to contain the additional 5' sequence completing LHR-A, including SCRs -1 and -2 and 0.1 kb of upstream sequence. None of the remaining 36 clones, all of which hybridized with CRl-1, were detected with the probe, 30 CR1-18, a 252 bp Sau3AI fragment from the 0.5 kb EcoRI fragment of clone λH3.1 that does not hybridize to sequences encoding LHR-B, -C or -D. DNA sequence analysis of λH3.1 revealed that the open reading frame continued to the 5' end of the cDNA, 35 indicating that the clone did not extend to the translational start site. Therefore, the cDNA libraries, λHH and λS2T, were rescreened with the probe CR1-18 to identify one clone from each, AH10.3 and AT109.1, respectively. The EcoRI fragments of these clones that hybridized with CR1-18 were sequenced as were the inserts from the clones, AH3.1 and AH7.1. The composite sequence is presented in Figure 1 such that the nucleotide following number 1531 in Figure 1 is nucleotide #1 in Figure 3. The overlapping sequences of the cDNA clones from the HL-60 and tonsillar libraries are identical. Immediately upstream of LHR-A, clones AH10.3 and AT109.1 contain identical putative hydrophobic leader sequences (Von Heijne, G. , 1986, Nucl. Acids Res. 14:4683) encoding 41 amino acids, including an ATG matching the consensus NNA/GNNATGG proposed for eukaryotic translation initiation sites (Fig. 10) (Kozak, M. , 1986, Cell 44:283). A second ATG, located six codons upstream of the chosen ATG and just downstream of an in-frame stop codon, is a poor match for this consensus sequence. The first three amino acids of this leader sequence for CRl, MGA, are the same as those reported for CR2. The sequences of these two clones diverge upstream of the ATG and that from clone λlθ.3 is believed to represent a portion of an intervening sequence, as has been described for other CRl cDNA clones in Section 6, supra. The signal peptidase cleavage is predicted (Von Heijne, G. , 1986, Nucl. Acids Res. 14:4683) to occur between glycine-46 and glutamine-47, suggesting that the blocked NH_-terminus of CRl (Wong., W.W. , et al., 1985, J. Immunol. Methods 82:303; Holeis, V.M. , et al., 1986, Complement 3:63) may be due to the presence of a pyrrolidone amide. The first two SCRs of the NH -terminal LHR-A contained in these clones are only 61% identical to the corresponding region of LHR-B, whereas SCRs 3-7 of LHR-A are 99% identical to the corresponding SCRs of LHR-B (Fig. 10) . Comparison of LHR-A with LHR-C reveals that only the third and fourth SCRs of each are highly homologous (99% identical) . LHR-A and -D have only 68% overall identity, with maximal identity of 81 between the sixth SCR of each LHR. Thus, completion of the 5' cDNA sequence of CRl indicates that the F allotype is t 5 comprised of 2039 ammo acids including a 41 ammo acid * signal peptide, four LHRs of seven SCRs each, two additiona COOH-terminal SCRs, a 25 residue transmembrane region and a 43 amino acid cytoplasmic domain. There are 25 potential N-linked glycosylation sites. 7.3. DISCUSSION The primary structure of the NH -terminus and th signal peptide of the F allotype of CRl has been deduced by the isolation and sequencing of 5' cDNA clones. The highly 15 repetitive nature of the CRl sequence made critical the development of an appropriate strategy for the preparation and identification of cDNA clones encoding this region of the receptor. A cDNA library was prepared using as a prime a 35-mer oligonucleotide known to hybridize under the 20 conditions of reverse transcription to LHR-B, -C and -D; the possibility was considered that this primer might hybridize also to LHR-A that had been predicted to be highly homologous to LHR-B (see Section 6 supra) . Appropriate cDN clones were identified by the use of another 25 oligonucleotide, KS23.1, that hybridizes only to LHR-B under stringent conditions, thereby increasing the probability of finding 5' cDNA clones. Two clones were found that encompassed almost all of the residual sequence of CRl, and 30 a Sau3AI fragment of one of these, CR1-18, had sequence k sufficiently unique to permit its use in the identification ,. of the remaining 5' clones (Figs. 9, 10). , A 250 bp probe from the 5' region of LHR-A, CR1- * 18, hybridized not only to CRl transcripts of 7.9 and 9.2 35 kb, but also to a 2 kb transcript in human tonsillar RNA under stringent conditions. This cross-hybridizing mRNA was not observed with CRl cDNA probes from other LHRs or in northern blots of RNA from dimethyl sulfoxide-induced HL-60 cells and HSB-2 T lymphoblastoid cells. Thus, CRl contains sequences homologous to two additional B cell proteins, one that is encoded by this newly recognized mRNA, and CR2. 8. EXAMPLE: EXPRESSION OF RECOMBINANT HUMAN CRl As described supra, human CRl cDNA clones have been isolated that span 7.0 kb and contain an open reading frame encoding 2039 amino acids (Fig. 1) . The proposed precursor form of the receptor includes a 41 amino acid signal peptide, four long homologous repeats (LHRs) of 450 amino acids with each LHR comprised of 7 short consensus repeats (SCRs) , two COOH-terminal SCRs of 65 amino acids, a 25 amino acid transmembrane domain, and a 43 amino acid cytoplasmic region. Thus, the CRl F allotype contains 30 SCRs. The NH_-terminal LHR, LHR-A (see Section 7, supra) , is 61% identical to the corresponding region of LHR-B in the first two SCRs and 99% identical in the COOH-terminal five SCRs. Restriction fragments of eight CRl cDNA clones were spliced to form a full length construct of 6.9 kb and placed downstream of a mouse metallothionein promoter or a cytomegalovirus promoter, and transfected into L (mouse) cells or COS (monkey) cells. Recombinant cell surface CRl was detected by indirect radioimmunoassay and im unofluorescence. No antigen was detected on cells transfected with the parental vector (CRl ) only. Im unoprecipitation of transfected, surface 125I-labeled, COS (monkey) cells by anti-CRl monoclonal antibody, and analysis by non-reducing sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, yielded a 190,000 daltons molecular weight band which co-migrated w5 :h the F allotype from human erythrocytes. The expression of recombinant CRl antigen of the correct molecular weight (Klickstein, L.B., et al., 1988, FASEB J. 2:A1833) provides evidence that the cDNA contains the entire coding sequence of human CRl. 8.1. CONSTRUCTION OF PLASMID pBSABCD, CONTAINING THE ENTIRE CRl CODING SEQUENCE We describe herein the construction of plasmid pBSABCD, a vector encoding the full length (SCRs 1-30) CRl protein. The 2.3 kb insert from cDNA clone λT8.2 10 (Klickstein, L.B., et al., 1987, J. Exp. Med. 165:1095; see Section 6, supra) was subcloned into pUC18 as an EcoRI fragment, such that the 5' end was proximal to the Hindlll site in the plasmid polylinker. This plasmid was named pl88.2. pl88.2 was cut with Apal and Hindlll, and the large 15 4.7 kb fragment containing CRl sequence from SCR 26 through the 3' untranslated region plus vector sequences was gel- purified. The insert from cDNA clone AT50.1 (Klickstein, L.B., et al., 1987, J. Exp. Med. 165:1095; see Section 6, 20 supra) was subcloned as an EcoRI fragment into M13mpl8. This phage was called 18R50.1. DNA from the replicative form of this clone was cut with Hindlll and Apal, and the 1.45 kb fragment containing CRl SCRs 18-25 was isolated, ligated to the 4.7 kb fragment from pl88«2, and the ligation 25 transformed into E. coli DH5α. This plasmid was called p8.250.1. The 0.75 kb and the 0.93 kb EcoRI fragments from cDNA clone AT8.3 (Wong, W.W. , et al., 1985, Proc. Natl. Acad. Sci. U.S.A 22:7711) were subcloned into plasmid 30 pBR327. These subclones were called pCRl-1 and pCRl-2, * respectively, and contained SCRs 11-14 and SCRs 17-21, respectively. The EcoRI inserts were purified from each. The 0.75 kb pCRl-1 fragment was digested with Smal, and the digest was ligated to pUC18 DNA cut with EcoRI and Smal. A 35 subclone, pl81-1.1, with a 0.5 kb insert corresponding to SCRs 12-14, was isolated. The 0.93 kb fragment of pCRl-2 was digested with Hindlll, and ligated to pUC19 cut with EcoRI and Hindlll, and a subclone, pl91-2.1, was isolated that contained a 0.27 kb insert containing SCR 17. The cDNA clone AT6.1 (See Section 6, supra; Klickstein, L.B., et al., 1987, J. Exp. Med. 165:1095; Wong, W.W., et al., 1987, J. Exp. Med. 164:1531) was digested with EcoRI, and the 0.37 kb fragment corresponding to CRl SCRs 15 and 16 was subcloned into pBR322. This clone was called pCRl-4. Clone pl81-l.l was cut with EcoRI and Seal, and the 1.4 kb fragment was isolated. Clone pl91-2.1 (Klickstein, L.B., et al., 1987, J. Exp. Med. 165:1095; see Section 6, supra) was digested with EcoRI and Seal and the 2.0 kb fragment was isolated, ligated to the 1.4 kb fragment from pl81-l.l, and the mixture was transformed into E. coli DH5α. The resulting plasmid was called pl-11-2. Plasmid pl-11-2 was digested with EcoRI, and the 0.37 kb insert fragment from pCRl-4 was inserted by ligation. The resulting plasmid was used to transform E. coli DH5α. A subclone was chosen that contained a 0.39 kb BamHI-Hindlll fragment. This plasmid was called pl42 and contained CRl SCRs 12-17. The 3.5 kb EcoRI-Hindlll insert fragment from pδ.250.1 was transferred to pGEM3b. This plasmid was called pG8.250.1. The 1.2 Hindlll fragment from pl42 was purified and ligated to pG8.250.1 that had been cut with Hindlll. A subclone was chosen that contained a 2.4 kb Pstl-Apal insert, thus selecting the correct orientation. This plasmid was called pCD and contained CRl sequences from SCR 12 through the 3' end. The cDNA clone λ5'7.l (Klickstein, L.B., et al., Sept. 1987, Complement 4:180; see Section 7, supra) was cut with Pstl, and the 1.35 kb fragment Orresponding to SCRs 6-12 was isolated and ligated to Ε>_ x-cut pCD. The mixture was transformed, and a subclone was selected which contained 1.35 kb and 1.1 kb Hindlll fragments. This clone was called pBCD. The cDNA clone λ5'3.1 (Klickstein, L.B., et al., 1987, Complement 4:180; see Section 7, supra) was cut with 5 EcoRI, and the digest was ligated to EcoRI-cut pUC18. A f subclone, p3.11-l, was isolated, that contained a 1.0 kb insert corresponding to SCRs 3-7, which insert was gel- purified. The cDNA clone λS'10.3 (Klickstein, L.B., et al., 1987, Complement 4:180; see Section 7, supra) was cut with 10 EcoRI, and the 0.63 kb insert containing SCRs 1 and 2 was subcloned into pUC18. This clone was called plθ.3.5. Plasmid plθ.3.5 was partially digested with EcoRI, and a 3.4 kb fragment corresponding to linear plasmid was isolated and ligated with the 1 kb fragment from p3.11-l. A subclone, 15 pLA, was picked, which contained a 1.3 kb Pstl fragment, in the correct site of insertion and orientation. The cDNA clone AT109.4 (Klickstein, L.B., et al., 1987, Complement 4:180; see Section 7, supra) was digested 20 with EcoRI, and subcloned into pUC18. A subclone was chosen that contained a 0.55 kb EcoRI fragment corresponding to the 5' untranslated region through the leader sequence and SCRs 1 and 2. The plasmid pl09.4 was cut with Pstl and BspMII, and a 3.0 kb fragment containing the vector, leader 25 sequence, and SCR 1, was isolated. The fragment was ligated to a 0.81 kb Pstl-BspMII fragment from pLA that contained SCRs 2-5. This new plasmid was called pNLA. The plasmid pNLA was partially digested with EcoRI and completely digested with Pstl, and a 1.1 kb EcoRI-Pstl fragment 30 containing CRl sequence from the leader sequence through SCR 5 was isolated and ligated to pBluescript KS+ (Stratagene, San Diego, CA) to put an Xhol site on the 5' side of the cDNA. This plasmid was called pXLA. 35 The plasmid pBCD was cut with EcoRV and then partially digested with Pstl, and a 6.0 kb Pstl-EcoRV fragment containing CRl sequence from SCR 6 through the 3' untranslated region was isolated and ligated to Pstl + Smal-digested pXLA. The resulting bacterial expression . plasmid, which contains the entire CRl cDNA coding sequence, was called pBSABCD. 8.2. CONSTRUCTION AND ASSAY OF PLASMID piABCD, A MAMMALIAN EXPRESSION VECTOR CONTAINING THE ENTIRE CRl CODING SEQUENCE The pBSABCD plasmid was digested with Xhol and Notl, and the insert was ligated downstream from the CMV promotor in the 4.4 kb fragment of the expression vector, CDM8 (Seed, B. , 1987, Nature 329:840-842), which also had been cut with these restriction enzymes. The resulting construction was termed piABCD (Fig. 11) . Alternatively, the 6.9 kb Xhol-NotI fragment was ligated downstream from the metallothionein promoter in the expression vector, pMT.neol, which had also been cut with these restriction enzymes. The resulting construction was termed pMTABCD (Fig. 11) . Sheep erythrocytes sensitized with rabbit antibody (EA) and limited amounts of C4b [EAC4b(lim)] and 12,000 cpm 125I-C3b per cell [EAcC4b(lιm) ,3b] were prepared by sequential treatment of EAC4b(lim) (Diamedix) with Cl, C2 and 12.5I-C3 followed by incubation for 60 minutes at 37°C m gelatin veronal-buffered saline containing 40 mM EDTA. Alternatively, methylamine-treated C3 [C3(ma)] were covalently attached to sheep E (erythrocytes) treated with 3-(2-pyridyldithio) propionic acid N-hydroxysuccinimide ester (Sigma) (Lambris, J.D., et al., 1983, J. Immunol. Methods 65:277) . EAC4b were prepared with purified C4 (Hammer, CH. , et al., 1981, J. Biol. Chem. 256:3995). Both piABCD and pMTABCD were transfected by the DEAE (diethylaminoethyl)-dextran method into COS (monkey) cells. Recombinant CRl was detected on the surface of the transfected cells by immunofluorescence using the anti-CRl monoclonal antibody, YZ-1; and by immunoprecipitation of T 5 _ _ I-labeled cells followed by non-reducing SDS-PAGE, which * revealed a protein having a mobility identical to that of CRl immunoprecipitated from human erythrocytes of a donor homozygous for the F allotype (Wong, W.W. , et al., 1983, J. Clin. Invest. 72:685); and by formation of rosettes with 10 sheep erythrocytes coated with C3b (Fearon, D.T., 1980, J. Exp. Med. 152:20). The identical electrophoretic mobilities of the native and recombinant CRl proteins confirmed that the CRl F allotype contains SCRs 1-30. In addition, murine L cells were co-transfected 15 by the DEAE-dextran method (Ausubel, F.M., et al., 1987, Current Protocols in Molecular Biology, Seidman, J.G. and Struhl, K. , eds., John Wiley & Sons, New York; Seed, B. , 1987, Nature 329:840) in duplicate with 0, 2, or 4 μg of 20 either piABCD or pMTABCD and 2 μg of pXGH5, a reporter plasmid that directs the expression of growth hormone (Selden, R.F., et al., 1986, Mol. Cell. Biol. 6:3173). The cells were harvested after two days and assayed for expression of CRl by binding of YZ1 monoclonal anti-CRl 25 antibody. There was a dose response relationship between recombinant plasmid DNA and the expression of CRl antigen (Table II) . 30 » 35 TABLE II ' DOSE RESPONSE OF RECOMBINANT CRl AND HUMAN GROWTH HORMONE IN CO-TRANSFECTED L CELLS *For radioimmunoassay (RIA) , replicate samples of 3 x 10" transfected cells in 0.1 ml phosphate-buffered saline containing 1% bovine serum albumin and 0.02% sodium azide were incubated at 0°C for 60 minutes with 3 μg/ml YZ-1 IgGl anti-CRl (Changelian, P.S., et al., 1985, J. Immunol. 134:1851). The cells were washed ancLresuspended in 0.1 ml of buffer containing 1-2 μCi/ml of I-F(ab')_ goat-anti- mouse IgG or I-protein A. After 2 l-2 hours at 0°C, the cells were washed and assayed for I. The plasmid, piABCD, directed the expression of nearly three-fold more CRl antigen than did pMTABCD. The growth hormone concentration in the culture medium varied by less than two-fold with the exception of plate 5. Additional experiments revealed that piABCD directed the transient expression of three-fold more CRl antigen in COS cells than in L cells. CRl antigen was present in clusters on the surface of the transfected COS cells when assessed by indirect immunofluorescence of cells stained with YZ1 anti- CRl mAB (Fig. 12) . This distribution of recombinant CRl on COS cells resembles that of wild type CRl on human leukocytes (Fearon et al., 1981, J. Exp. Med. 153:1615). The molecular weight of the recombinant CRl was determined by surface iodination of COS cells transfected with piABCD, immunoprecipitation of cell lysates with Sepharose-YZl, SDS-PAGE and autoradiography. The recombinant CRl had a molecular weight of 190,000 unreduced 5 which is equivalent to that of the F allotype and less than t i that of the S allotype of erythrocyte CRl (Fig. 14) . The C3b-binding and C4b-binding function of recombinant CRl was assayed by the formation of rosettes between the transfected COS cells and EAC4b or 10 EAC4b(lim) ,3b. In 31 separate transfections, 5%-50% of COS cells transfected with the plasmid, piABCD, bound five or more EAC4b or EAC4b(lim) ,3b (Fig. 13). The COS cells expressing CRl did not form rosettes with EAC4b(lim) ,3bi, although this intermediate did form rosettes with Raji B 15 lymphoblastoid cells expressing CR2. 8.3. EXPRESSION OF CRl FRAGMENTS Expression vectors encoding part of the CRl coding sequence (deletion mutants) were constructed as 20 described infra, and found to express their respective CRl inserts when transformed into COS cells. The CRl fragments were expressed as cell-surface proteins. 25 8.3.1. CONSTRUCTION OF DELETION MUTANTS piBCD, piABD, piACD, piAD, piBD, piCD and piD The construction of these deletion mutants was performed by taking advantage of the presence of a single Bsml site in a homologous position near the amino-termirius of each of the four CRl long homologous repeats (LHRs) , and 30 the absence of Bsml sites elsewhere in the CRl cDNA and Bluescript vector (Stratagene, San Diego, CA) . Ten micrograms of the plasmid pBSABCD were partially digested with 50 units of the restriction enzyme Bsml for 45 minutes, and the digest was fractionated by 35 > agarose gel electrophoresis. DNA fragments of 8.55 kb, 7.20 kb and 5.85 kb were purified that corresponded to linear segments of the parent plasmid that lacked one, two or three LHRs, respectively. Each of the three fragments was ligated to itself and the ligations used separately to transform competent E. coli DH5α to ampicillin resistance. The 8.55 kb fragment was generated as the consequence of cleavage of pBSABCD at two adjacent Bsml sites, thus there are three possible product plasmids after ligation, pBCD, pACD or pABD, where the capital letters represent the LHRs that remain in the plasmid. These were distinguishable by restriction mapping with Smal. DNA was prepared from 12 colonies, digested with Smal, and separated by agarose gel electrophoresis. Five clones had two Smal fragments of 2.5 kb and 6.1 kb, corresponding to deletion of the coding sequence of LHR-A, thus representing pBCD. Three clones had a single linear fragment of 8.5 kb corresponding to pACD. Four clones had two Smal fragments of 1.2 kb and 7.4 kb, which was expected for the deletion of the coding sequence of LHR-C, producing pABD. The 5.6 kb insert of each of these three constructions was gel-purified after double digestion with Xhol and Notl, and ligated to the expression vector CDM8 that had been gel-purified after digestion with the same restriction enzymes. E. coli DK1/P3 was transformed with the ligation mixtures and DNA was prepared from five colonies of each. The presence of the deleted CRl cDNA insert in the expression vector was shown in each case by Sacl digestion, which revealed the expected two fragments of 4.20 kb and 5.75 kb. These plasmids were called piBCD, piACD and piABD. The 7.20 kb fragment from the partial digestion of pBSABCD was a consequence of Bsml digestion at three adjacent sites or, equivalently with respect to the large fragment, at two sites with a single uncut site between them, thus there were two possible products obtainable after transformation, pAD and pCD. These were distinguished by double digestion with Xhol and Pstl, which yielded two fragments of 1.0 kb and 6.2 kb in the case of pAD, and a linear fragment of 7.2 kb for pCD. The 4.2 kb insert from each of these plasmids was gel-purified after double digestion with Xhol and Notl, and subcloned into CDM8 as t « above. The presence of the deleted CRl cDNA in the expression vector was shown by double digestion with Pstl and Bglll. The clone piAD had fragments of 2.4 kb and 6.2 kb, while piCD had a single fragment of 8.6 kb. 10 The 5.85 kb fragment from the Bsml digestion of pBSABCD represents a product of complete digestion and a single clone, pD, was obtained after transformation of E. coli DH5α. This was confirmed by double digestion with Hindlll and Bglll which yielded the expected 3.7 kb and 2.2 15 kb fragments. The 2.9 kb insert of the clone was gel- purified after double digestion with Xhol and Notl and ligated to the expression vector as above. Hindlll digestion of the resulting piD clone yielded the expected 7.3 kb fragment, a Xhol + Bglll double digest gave 2.2 kb 20 and 5.1 kb fragments, and a Sacl digest resulted in the expected 1.5 kb and 5.8 kb fragments. The plasmid pBD was prepared by Bsml partial digestion of pBCD. The linear 7.2 kb fragment corresponding 25 to cleavage of two adjacent Bsml sites was gel-purified, self-ligated as above, and E. coli DH5α was transformed to ampicillin resistance. pBD was identified by the presence of 1.2 kb and 6.0 kb fragments upon Smal digestion. The 4.2 kb insert was purified after double digestion with Xhol and 30 Notl, and transferred to CDM8 as above. The clone piBD was confirmed by observation of the expected 0.8 kb and 7.8 kb fragments after Hindlll digestion. COS cells transiently expressing the piABCD, piBCD, piCD, and piD constructs, respectively, were 35 surface-labelled with 125I, and i.mmunopreci.pi.tated with anti-CRl antibody. On SDS-PAGE following reduction, the product of the piABCD construct comigrated with the F allotype of CRl, while the deletion mutants demonstrated stepwise decrements of approximately 45,000 daltons, indicative of the deletion of one, two and three LHRs, respectively (Fig. 17) . 8.3.2. CONSTRUCTION OF DELETION MUTANTS piPl, piEl, piE2, piE-2, piUl, piU-2 and piA/D The plasmid piABCD was completely digested with BstEII and the two fragments at 1.35 kb (a doublet) and 8.6 kb were gel-purified, mixed, and ligated, and E. coli DK1/P3 was transformed to ampicillin and tetracycline resistance. Colonies were screened by hybridization with the CRl cDNA probe CR1-4 (see Section 8.1, supra) , and strongly positive clones were picked and further screened by digestion with Smal. piEl was identified by the presence of two fragments at 2.7 kb and 7.3 kb, and piE2 was identified by a single 10.0 kb linear fragment. piE-2 was identified as a weakly CR1-4 positive clone that contained a single 8.6 kb Smal fragment. The plasmid piPl was obtained by complete digestion of piABCD with Pstl and gel-purification of the large, 10.0 kb fragment. This fragment was ligated and E. coli DK1/P3 was transformed with the mixture. The resulting plasmid, piPl, contained a single, 10.0 kb Smal fragment. The plasmids piUl and piU-2 were prepared by first transforming the dcm " strain GM271/P3 with the plasmid pXLA, and isolating DNA. This DNA was double digested with Stul and Notl, and the 3.3 kb fragment was gel-purified. The plasmid pBSABCD was partially digested with Nsil, and the resulting four base pair 3' overhangs were removed by treatment with the Klenow fragment of E. coli DNA polymerase I. The DNA was then digested to completion with Notl, and fragments of 5.4 kb and 4.0 kb were gel-purified. These were ligated to the 3.3 kb Stul-Notl fragment from pXLA, and the ligation mixture was used to transform E. coli DH5α to ampicillin resistance. Colonies were screened by hybridization to the CRl cDNA probe CR1-4, and positive i- 5 clones were further checked by restriction digestion with * Hindlll which yielded three fragments of 0.8 kb, 1.3 kb and 6.5 kb for pUl, and two fragments of 0.8 kb and 6.5 kb for pU-2. The Stul-blunted Nsil splice was confirmed to be in- frame by DNA sequencing of these plasmids. The inserts of 10 pUl and pU-2, 5.6 kb and 4.2 kb, respectively, were gel- purified after Xhol and Notl double digestion, and were ligated to the expression vector CDM8 as described supra. The structures of the clones, piUl and piU-2, were confirmed 15 by restriction digestion with Xhol + Pstl, yielding the expected two fragments of 1.2 kb and 8.8 kb for piUl and a linear 8.7 kb fragment for piU-2. The plasmid piA/D was prepared by first digesting piABCD with Pstl to completion. The Pstl digest was then partially digested with Apal, and the 3' overhangs were 20 removed with the Klenow fragment of E. coli DNA polymerase I. The DNA was then fractionated by agarose gel electrophoresis and the 7.5 kb fragment was isolated, ligated, and Used to transform E. coli DK1/P3 to ampicillin 25 and tetracycline resistance. The construction was confirmed by double digestion with Kpnl + Sad, which yielded the expected four fragments of 0.8 kb, 1.5 kb, 1.7 kb and 3.3 kb. 30 4 * 35 EXAMPLE: IDENTIFICATION OF C3b AND C4b BINDING DOMAINS 9.1. ASSAYS AND RESULTS Plasmids piABCD, piAD, piCD, and piD, containing the LHR(s) denoted by the capital letter(s) of their names, were transformed into COS cells, which were used in assays to assess the ability of their encoded CRl fragments to bind C3b or C4b. Binding assays were carried out by observation of erythrocyte rosetting resulting from the binding of C3b or C4b-coated red cells by COS cells expressing a full- length CRl molecule or a CRl deletion mutant on their cell surface (transient expression) . Transfected cells, 1-4 x 10 /ml, were incubated with C3- or C4-bearing erythrocytes, 2-6 x 10 /ml, in 0.02 ml for 60 minutes at 20°C. The percentage of transfected cells forming rosettes was evaluated microscopically with a transfected cell scored as a rosette if there were at least five adherent erythrocytes. The results are shown in Table III. TABLE III FORMATION OF ROSETTES BETWEEN COS CELL TRANSFECTANTS EXPRESSING RECOMBINANT FORMS OF CRl AND SHEEP ERYTHROCYTES BEARING C3(ma) OR C4(ma) % Transfectants Forming Rosettes % Transfectants Fluorescent with Anti-CRl COS Cell Transfectant 10 piABCD piAD piBD piCD piD piA/D piE-2 1 (1) 102 (1) 15 The numbers of C3(ma) per erythrocyte were 60,000, 350,000 and 900,000, respectively, in the three experiments using n this intermediate. ff The number of C4(ma) per erythrocyte were 160,000 and 140,000, respectively, in the two experiments using this intermediate. 20 π Number of experiments. In each of three separate experiments, the proportion of COS cells expressing the full length piABCD 25 construct that formed rosettes with the EC3(ma) was similar to the fraction having detectable recombinant receptor, as assessed by immunofluorescence using either YZ1 monoclonal anti-CRl antibody or rabbit anti-CRl antiserum (Table III) . In contrast, cells expressing piD did not form rosettes, 30 indicating that a C3-binding site(s) must reside in or 4 require the presence of LHR-A, -B or -C. A site was shown •» to be present in both LHR-B and -C by demonstrating that , cells expressing either the piBD or piCD constructs formed * rosettes with EC3(ma) . Cells expressing piAD, piA/D, or 35 piE-2 did not have equivalent C3-binding function. As the piE-2 construct differs from piCD only in having SCR-1 and -2 of LHR-A instead of the first two SCRs of LHR-C, the function of the C3-binding site in LHR-C must require these NH -terminal SCRS. The proportion of COS cells expressing the full length piABCD recombinant that formed rosettes with EC4(ma) was less than the fraction rosetting with EC3(ma) , perhaps reflecting fewer C4(ma) per erythrocyte (Table III) or fewer C4-binding sites per receptor. Deletion mutants having all or part of LHR-A, the piAD, piA/D and piE-2 constructs, bound EC4(ma) better than did the deletion mutants, piBD and piCD; piD lacked this function. Thus, the C4-binding site of CRl resides primarily in LHR-A, although secondary sites may be present in LHR-B and -C. The improved rosetting capability of the piE-2 construct relative to that of piCD suggests that SCR-1 and -2 of LHR-A are involved in the C4 binding site. Radioimmunoassay of the binding of YZl monoclonal anti-CRl antibody indicated significant uptake by COS cells expressing the piABCD, piAD, piBD, and piCD constructs (Table IV) . Cells transfected with piD or piA/D, which is comprised of the five NH,-terminal SCRs of LHR-A and the three COOH-terminal SCRs of LHR-D, did not bind YZl anti-CRl antibody, although the products of these constructs bound polyclonal anti-CRl antiserum (Table IV) . Thus, the YZl epitope is repeated in LHR-A, -B and -C, is not present in the NH_-terminal SCRs of LHR-A, and is not present or is inaccessible in LHR-D. TABLE IV BINDING OF MONOCLONAL AND POLYCLONAL ANTI-CRl ANTIBODY TO COS CELL TRANSFECTANTS EXPRESSING RECOMBINANT FORMS OF CRl Replicate samples of 3 x 10 transfected cells in 0.1 ml 15 phosphate-buffered saline containing 1% bovine serum albumin and 0.02% sodium azide were incubated at 0°C for 60 minutes with 3 μg/ml YZl IgGl anti-CRl mAb (Changelian, P.S., et al., 1985, J. Immunol. 134:1851) or with 90 μg/ml rabbit IgG anti-CRl antibody. The cells were washed an resuspended in 0.1 ml of buffer containing 1-2 μCi/ l of I-F(ab') goat-anti-mouse IgG or I-protein A. After.1-2 hours at 20 0°C, the cells were washed and assayed for I. Values shown are the mean of duplicate determinations, cpm per 3 x 10 COS cells. 9.2. DISCUSSION 25 The conserved Bsml site found midway through the coding sequence of the first SCR in each LHR permitted the construction of a series of deletion mutants that corresponded closely to the boundaries of the LHRs, and maintained the open reading frame and the appropriate 30 positions of the four cysteines necessary for the presumed disulfide bond formation (Fig. 16) . Comparison of the C3(ma)- and C4(ma)-binding functions of these deletion mutants distinguished not only the LHRs having these specificities, but also those SCRs critical for determining 35 the ligand specificity. Thus, the capacity of piAD, piA/D, and piE-2 forms of the receptor, but not the piD form, to mediate rosette formation between the transfected COS cells and EC4( a) indicated that the NH -terminal two SCRs of LHR-A contained a site for interaction with this complement protein (Table III) . This site was only relatively specific for C4(ma) because transfectants expressing piAD and piA/D also were capable of binding EC3(ma) (Table III). The C3(ma)-binding function of the receptors encoded by the piBD and piCD constructs, demonstrated by rosette assay and factor I-cofactor function for cleavage of C3(ma) (Table III; Fig. 18) , indicated the presence of sites specific for C3(ma) in the first two SCRs of these LHRs. These sites also were capable of interacting with C4(ma) (Table III). Thus, there are preferential, but overlapping, C4- and C3- binding activities in LHR-A, -B and -C. Alternatively, the capacity of the COS cells expressing the piBD and piCD constructs to bind EC4(ma) may have been caused by the transfer of nucleotides encoding the NH -terminal 36 amino acids from SCR-1 of LHR-A to LHR-B and -C through the ligation of the Bsml fragments. However, these 36 amino acids alone did not confer on the piD product C4-rosetting function. We cannot exclude a secondary function of LHR-D in these reactions because this LHR was present in all the constructs assayed for function. The finding of three distinct ligand recognition sites in CRl, two for C3b and one for C4b (Fig. 19) , indicates that each receptor molecule may be capable of effectively binding complexes bearing multiple C4b and C3b molecules despite having a relatively low affinity for monovalent ligands (Arnaout, M.A. , et al., 1983, Immunology 48:229). This finding also provides an explanation for the inability of soluble C4b to inhibit formation of rosettes between erythrocytes bearing C3b and a human B lymphoblastoid cell line (Gaither, T.A., et al., 1983, J. Immunol. 131:899). Possible ligands for which CRl would be especially adapted may be the molecular complexes, C4b/C3b and C3b/C3b, that are generated during activation of the classical and alternative pathways, respectively. Since there are distinct binding sites in three of the four LHRs, the CRl structural allotypes differing by their number of LHRs may * have significant functional differences caused by variation t in the number of ligand binding sites. Although m vitro studies have not reported differing binding activities of the F, S and F' (A, B and C, respectively) allotypes, the smaller F' allotype presumably having only three LHRs might 10 have an impaired capability to clear immune complexes. The F' allotype has been reported possibly to be associated with systemic lupus erythematosus (van Dyne, S., et al., 1987, Clin. Exp. Immunol. 68:570) . 15 10. EXAMPLE: DEMONSTRATION OF FACTOR I COFACTOR ACTIVITY The recombinant CRl protein, and specific fragments thereof, in both cell-surface and solubilized forms, were demonstrated to have C3b factor I cofactor activity. 20 Assays of factor I cofactor' activity were carried out by modifications of a published procedure (Fearon, D.T., 1979, Proc. Natl. Acad. Sci. U.S.A. 76:5867). For assay of factor I cofactor activity of 25 solubilized CRl and fragments, cell-surface CRl protein and fragments were solubilized with Nonidet P-40, and the lysate was immunoprecipitated with anti-CRl monoclonal antibody YZ-1 coupled to Sepharose beads. Detergent lysates of 1 x 10 transfected COS cells were immunoprecipitated 30 sequentially with Sepharose UPC10 anti-levan and Sepharose- 4 YZ-1. The immunoprecipitate was then assayed for factor I » cofactor activity by incubation of the washed beads for 60 minutes at 37°C with 0.5 μg of 125I-C3(ma) and 200 ng of * factor I in 0.05 ml PBS, 0.5% NP-40. After incubation, the 35 supernatant containing radiolabeled C3(ma) was analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography. Factor I cofactor activity was indicated by the appearance on the autoradiogram of lower molecular weight forms of the alpha chain of C3(ma) resulting from proteolytic cleavage by factor I. For assay of factor I cofactor activity of cell- surface CRl and fragments, transfected COS cells carrying a CRl expression vector (piABCD, piAD, piBD, piCD, or piD, described supra) were incubated with 0.5 μg 125I-C3(ma) and 0.2 μg factor I (Fearon, D.T., 1977, J. Immunol. 119:1248), and analyzed as described supra. The factor I-cofactor activity of cell-surface recombinant CRl is shown in Figure 15. Factor I cleaved the alpha chain of C3(ma) into fragments of molecular weights 76,000 and 46,000 only in the presence of immunoimmobilized, 5 recombinant CRl or factor H (Fig. 15) . The regions corresponding to bands from the autoradiogram were excised from the gel and assayed for 125I to determine the amount of alpha chain cleaved. In the presence of factor H, 91% of the alpha chain was cleaved while in the presence of 0 increasing amounts of recombinant CRl, 26%, 41%, and 55%, respectively, was cleaved. Although the COS cells transfected with the CDM8 vector alone contained some endogenous factor I-cofactor activity, an increase in this t . function was evident with COS cells transfected with piABCD, pi .BD and pi.CD (Fig. 18) . No enhanced cleavage of 125I- C3( a) was seen with COS cells transfected with piAD or piD. Thus, among these constructs, only the deletion mutants, piBD and piCD, that conferred on COS cells a capacity for 0 binding C3, also had factor I-cofactor activity for cleavage of C3. The results of the assays for factor I cofactor activity with both cell-surface and solubilized forms of CRl and fragments thereof are shown in Table V. 5 TABLE V FACTOR I COFACTOR ACTIVITY OF CELL-SURFACE AND SOLUBILIZED FORMS OF CRl and CRl FRAGMENTS Factor I Cofactor Activity Plasmid a Cell-Surface Solubilized piABCD + + piAD piBD + ND C piCD + + piD - ND d Encoding the assayed CRl protein or fragment, and transfected into COS cells for expression. (+) denotes an increase in cofactor activity above the endogenous level observed upon transfection with the CDM8 vector alone. Not determined. Not determined, due to the absence from LHR-D of the epitope recognized by anti-CRl monoclonal antibody YZ-1. As shown in Table V, expression of piABCD (encoding a full- length CRl protein) , piBD (encoding LHR-B and -D) or piCD (encoding LHR-C and -D) produced a CRl product with C3b factor I cofactor activity. The data of Table V thus provide evidence that the CRl protein or a fragment thereof can promote complement inactivation. 11. EXAMPLE: EXPRESSION OF RECOMBINANT SOLUBLE CRl The CRl cDNA was modified by recombinant DNA procedures so that a soluble form (sCRl) of CRl or CRl fragments was produced. The sCRl constructs were expressed in a mammalian system where the expressed protein was secreted from the cells. Large quantities of the soluble polypeptides were produced, which, in contrast to the membrane bound form of CRl proteins, did not have to be solubilized to obtain them in solution. 11.1. MATERIALS AND METHODS 11.1.1. ENZYME DIGESTIONS All restriction enzyme digestions, linker ligations, and T4 DNA ligase and E. coli DNA polymerase reactions were done according to the manufacturer's (New England Biolabs, Inc., Beverley, MA) recommendations. E. coli DH1 or DH5α were made competent by the procedure of Morrison, D.A., 1979, Meth. Enzymol 68:326-331. Competent bacterial cells were transformed with DNA according to Maniatis, T. , et al., 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. Plasmids were purified by alkaline lysis or by the boiling method (Maniatis, T., et al., supra) . 11.1.2. DNA FRAGMENT ISOLATIONS DNA fragments were purified from agarose (BioRad, Richmond, CA) gels as follows. The appropriate DNA band was excised from the gel using a blade, and the agarose slice was placed on a piece of parafilm, sliced into very small pieces, and transferred to a new piece of parafilm. The agarose pieces were crushed, and the agarose transferred to a 1.5 ml tube. An equal volume of phenol (Ultra pure, BRL, Gaithersburg, MD) was added, the mixture vortexed, then frozen at -70 "C for 10 minutes, and centrifuged for 10 minutes. The aqueous phase was further extracted twice with phenol/chloroform (1:1), and twice with chloroform. The DNA was then ethanol precipitated, the pellet washed, dried in vacuo, and resuspended in 10 mM Tris-HCl, pH 7.0, 1 mM EDTA. DNA fragments were isolated from low gelling temperature agarose (FMC, Corp., Rockland, ME) as follows. The appropriate DNA band was excised from the agarose gel, placed in a 1.5 ml tube, and melted a 65°C for 15 minutes. The liquified gel was extracted with phenol containing 0.1% 5 sodium dodecyl sulfate (SDS, ultra pure, BRL, Gaithersburg, MD) . The aqueous phase was further extracted once with phenol-SDS and twice with chloroform. The DNA was then ethanol precipitated in 2.0 M NH.Acetate, dried, and resuspended in water. 11.1.3. TRANSFECTION INTO MAMMALIAN CELLS Transfection of DNAs into mammalian cells was performed by the CaPO precipitation and glycerol shock procedure of Graham and van der Eb (1973, Virology 52:456- 15 467) . DUX Bll CHO cells, after being incubated with the DNA-calcium phosphate preparation for 4 to 6 hours, were subjected to glycerol shock by removing the growth medium by aspiration and adding 5 ml of 20% glycerol DMEM medium for 1 20 minute. Cells were then washed twice in complete alpha MEM and incubated in this medium for 48 hours. 11.1.4. CHO TRANSFECTANT CELL CULTURE DUX Bll CHO cell transfectants were grown in DHFR 25 (dihydrofolate reductase) selection medium consisting of alpha MEM medium (Gibco) without nucleosides, supplemented with 10% dialyzed fetal calf serum (Gibco) and 4 mM L- glutamine. Amplification was carried out by growing cells in increasing concentrations of methotrexate (Sigma, #A- 30 6770, Amethopterin) (Kaufman, R.J., et al., 1985, Molec. 4 Cell Biol. 5:1750-1759). * 35 11.1.5. ELISA FOR THE DETECTION OF SOLUBLE CRl LEVELS 11.1.5.1. CRl STANDARDS Detergent lysates of hemoglobin-free red blood cell (RBC) ghosts were used as a CRl standard in the ELISA (enzyme-linked immunosorbent assay) . The ghosts were prepared as previously described (Wong, W.W. and Fearon D.T., 1987, Meth. Enzymol 150:579-585). Briefly, expired whole blood was obtained from the Red Cross. The red cells were washed three times in PBS, then lysed in 6 volumes of hypotonic lysis buffer (10 mM Tris pH 8, 0.1 mM PMSF (phenyl methyl sulfonyl fluoride), 0.1 mM TPCK (tosylamide- phenylethyl chloromethyl ketone) , aprotonin, 2 mM EDTA) . The ghosts were washed several times in lysis buffer, counted in a hemocytometer, aliquoted and frozen at -70°C until needed. For the CRl ELISA, ghosts were diluted to 1.6 g x 10 ghosts/ml in solubilizing buffer (10 mM Tris pH 8, 50 mM KC1, 0.2% NP40, 0.3% DOC, 6.2 mM PMSF, 0.2 mM iodacetamide, aprotonin, 0.1 mM TPCK, 2 mM EDTA, 0.2% NaN3) and serially diluted to 2.5 x 10 ghosts/ml for use as standards in the ELISA. Absorbances at 490 nm were plotted and any unknown sample run was referred to the plot to obtain ghost equivalents/ml. 11.1.5.2. CRl ELISA Immulon-II plates were coated with 100 μl/well of a 0.4 μg/ml concentration of an anti-CRl monoclonal antibody (clone J3D3, AMAC IOT 17) (Cook, J. , et al., 1985, Molec. Immunol. 22:531-538) in PBS and incubated overnight at 4°C. The antibody solution was then discarded and the plates were blocked by the addition of blocking buffer (1.0% BSA in PBS) at 300 μl/well and incubation at 37"C for 2 hours. After blocking, plates were used immediately or stored at 4°C until needed. Plates were washed three times using PBS containing 0.05% Tween-20. Samples were added at 100 μl/well in duplicate and incubated 2 hours at 37°C. If necessary, samples were diluted in solubilizing buffer. Standard RBC ghosts were included on each plate. After sample incubation, plates were washed three times and a conjugate (Wilson, M.B. and NaKane, P.K., 1978, Immunofluorescence and Related Staining Techniques, North Holland Biomedical Press, pp. 215-224) of horseradish peroxidase (HRP) and the monoclonal antibody YZl 10 (Changelian, P.S., et al., 1985, J. Immunol 184:1851-1858) was diluted 1:8000 in 50% FCS, 50% blocking buffer and added at 100 μl/well. After incubating for two hours at 37°C, the plates were again washed three times with PBS containing 0.05% Tween-20. The substrate orthophenylenediamine (OPD) 15 was added at 0.2% concentration in substrate buffer (0.36% citric acid H 2 0, 1.74% Na_HP0 4 .7H 2 0, 0.1% thimerosal, 0.4% H-0 , pH 6.3) at 100 μl/well. The reaction was stopped after 20 minutes at room temperature using 50 μl/well of 2 N 2 _0 n H2-SO4.. Absorbances at 490 nm were read. 11.2. GENETIC MODIFICATIONS OF CRl CODING SEQUENCES CRl cDNA is composed of approximately 6,951 nucleotide base pairs (Fig. 1, Sections 6, 7, supra) . The 25 translational stop signal of the native cDNA is located at base pair 6145. The protein is a membrane-bound receptor molecule composed of four long homologous repeats (LHRs) which are exposed on the exterior surface of the cell membrane, plus a membrane-spanning domain of approximately 30 25 amino acids, followed by a carboxyl terminal region extending into the cytoplasm. This cytoplasmic domain consists of forty-three amino acids. The strategy we used to produce soluble CRl molecules (sCRl) was to remove the 35 transmembrane region that anchors a protein in the cell membrane and then to express the truncated constructs as secreted polypeptides. 11.2.1. CONSTRUCTION OF pBSCRlc . Plasmid pBSABCD (Example 8, supra) contains the CRl cDNA from nucleotides 1 to 6860 and lacks the untranslated sequences 3' to the EcoRV site at nucleotide 6860. CRl cDNA possesses a unique Ball restriction endonuclease recognition site at base pair 5914, twenty-nine base pairs away from the start of the transmembrane domain. pBSABCD was first digested with Ball to produce a linear molecule with flush ends and was then ligated using T4 DNA ligase to a synthetic oligonucleotide consisting of two 38 nucleotide complementary strands with the following sequence: 5': CCAAATGTACCTCTCGTGCACATGATGCTtaaCTCGAG 3': GGTTTACATGGAGAGCACGTGTACTACGAATTGAGCTC The resulting molecule had a restored Ball site and an altered sequence which reproduced the native CRl sequence up to and including the alanine residue at the start of the transmembrane domain. In addition, a translational stop signal (in lower case and underlined above) had been introduced immediately after the alanine, followed by an Xhol restriction site to faciliate subcloning the altered cDNA. Xhol digestion of this plasmid (designated pBSCRlc) excised the cDNA insert (designated sCRlc) by cutting at the oligonucleotide-added Xhol site in the cDNA and at the Xhol site in the pBSKS+ β multiple cloning site at the 5' end of the CRl cDNA. pBSCRlc contains the following C-terminal sequences: Base No . 5911 : CTGGCCAAATGTACCTCTCGTGCACATGATGCTTAACTCGAG Amino Acids : L A K C T S R A H D A END Xhol site 11.2.2. CONSTRUCTION OF pBSCRls Λ A second sCRl construct lacking a transmembrane * region was generated as follows. pBSABCD was digested with Sacl which cut at the unique Sacl site at nucleotide base pair 5485 in the CRl cDNA and at the Sacl site in the multiple cloning site of the host plasmid, located at the 3' 10 end of the CRl cDNA. This digestion resulted in the excision of 1375 nucleotides of DNA sequence from the 3' en of the cDNA. This fragment was then removed electrophoretically. The exposed ends of the resulting plasmid, containing the remaining sCRl cDNA, were made flush 15 using T4 DNA polymerase and a blunt-end ligation was performed. The Pharmacia univeral translation terminator (catalog #27-4890-01, Pharmacia, Inc., Piscataway, NJ) , a self-complementary oligomer which contains translational stop signals in all three reading frames, was also included 20 in the ligation. Upon ligation, the inserted oligomer provided a new translation stop signal for the sCRl cDNA. 11.2.3. CONSTRUCTION OF pBM-CRlC pBMT3X is a eukaryotic expression vector 25 (Krystal, M. , et al., 1986, Proc. Natl. Acad. Sci. USA 83:2709-2713) that contains the human metallothionein - 1A gene, which confers to cells resistance to increased levels of heavy metals such as cadmium. The vector also contains 30 the mouse metallothionein-1 gene that contains an engineered 4 Xhol site preceding the initiation codon for the Mt-1 protein. The Xhol site is used as the insertion site for expression of genes under the control of the mouse Mt-I * promoter. 35 sCRlc insert (approximately 5.9 kb) was excised from pBSCRlc using Xhol and then ligated to the unique Xhol site of vector pBMT3X. The correct orientation of the sCRlc insert in pBMT3X was determined by restriction digestion (Maniatis, T. , et al., 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) . The resulting plasmid was named pBM-CRlc. 11.2.4. CONSTRUCTION OF DELETION MUTANTS pT-CRlCl, pT-CRlc2, pT-CRlc3 pT-CRlc4, and pT-CRlc5 Various deletion mutants were also constructed that specifically deleted portions of the sCRl cDNA (Fig. 20) . Each deletion mutant lacked the transmembrane region of the full length cDNA so that expression of the mutants would yield soluble polypeptides. 11.2.4.1. pT-CRlcl pBSCRlc was digested with Smal, resulting in two fragments of size 2.56 kb and 7.3 kb. These fragments were separated by agarose gel electrophoresis, and the 7.3 kb fragment was purified and religated to itself. E. coli DH5α cells were made competent (Morrison, D.A. , 1979, Meth. Enzymol. 68:326-331) and then transformed with the ligation mix. The resulting plasmid was named pBL-CRlcl. This construct removed 38% of LHR-B, 100% of LHR-C, and 51% of LHR-D of the CRlc Asert. In addition, it regenerated the Smal site at junction 2335/4894 bp and maintained the correct translational frame. pBL-CRlcl was digested with Xhol and the CRl insert was separated from the pBluescript ® vector. The isolated CRl fragment was then inserted into the unique Xhol site of expression vector pTCSgpt to produce plasmid pT-CRlcl. 11.2.4.2. pT-CRlc2 pBSCRlc was digested with Clal and Ball, resulting in two fragments of size 3.96 kb and 5.9 kb. These fragments were purified from an agarose .gel. Plasmid pBR322 was digested with Clal and Ball and the 2.9 kb pBR322 * fragment was purified and ligated to the 5.9 kb fragment t from pBSCRlc. E. coli DH5α cells were transformed with the ligation mix and the resulting plasmid was termed pBR8.8. This plasmid was digested with Xbal, generating two fragments of size 7.45 kb and 1.35 kb. The 7.45 kb fragment 10 was purified from an agarose gel and religated to itself. The resulting plasmid, pBR7.45, was digested with Clal and Ball, and the isolated 4.5 kb fragment containing the sCRl cDNA was ligated to the 3.96 kb fragment from pBSCRlc, resulting in plsmid pBL-CRlc2. This construct removed 90% 15 of LHR-B in the sCRl insert, regenerated the Xbal site at junction 1637/2987 bp, and maintained the correct reading frame. pBL-CRlc2 was digested with Xhol,.,and the sCRl insert was separated from the pBluescript ® vector. The isolated sCRl fragment was then inserted into the unique 20 Xhol site of expression vector pTCSgpt to produce plasmid pT-CRlc2. 11.2.4.3. pT-CRlc3 25 pBSCRlc was digested with Nsil resulting in three fragments of sizes 1.09 kb, 1.35 kb, and 7.46 kb. The 7.46 kb fragment was purified from an agarose gel and religated to itself, thus generating plasmid pBL-CRlc3. This construction removed 77% of LHR-A and 100% of LHR-B in the 30 sCRl insert. The Nsil site was regenerated at junction 463/2907 bp while maintaining the correct translation frame. pBL-CRlc3 was digested with Xhol and the sCRl insert separated from the pBluescript ® vector. The isolated sCRl fragment was then inserted into the unique Xhol site of 35 expression vector pTCSgpt to produce plasmid pT-CRlc3. 11.2.4.4. pT-CRlc4 pBSCRlc digested with Pstl. The Pstl site in the polylinker region of pBluescript ® had been removed during ligation of the CRl cDNA to this vector (Example 8.1, supra) . The resulting fragments of size 1.35 kb and 8.5 kb were separated by gel electrophoresis, and the 8.5 kb fragment was purified and religated to itself, generating plasmid pBL-CRlc4. This construction removed 31% of LHR-A and 69% of LHR-B of the sCRl insert. The Pstl site was regenerated at junction 1074/2424 bp, thus maintaining the correct reading frame. pBL-CRlc4 was digested with Xhol and the sCRl insert separated from the pBluescript ® vector. The isolated sCRl fragment was then inserted into the unique Xhol site of expression vector pTCSgpt to produce plasmid pT-CRlc4. 11.2.4.5. pT-CRlc5 pBL-CRlcl was digested with Smal, thus linearizing the plasmid at the unique Smal site. The plasmid was dephosphorylated, and ligated to phosphorylated Nhel linker containing a Nonsense codon (New England Biolabs, Beverley, MA) . This type of linker contains a translational stop codon in all three possible reading frames, and it also contains an Nhel restriction site, which faciliates confirming the presence of the nonsense linker i the sCRl cDNA. The resulting plasmid was named pBL-CRlc5, and it retained LHR-A and 62% of LHR-B of the sCRl cDNA. pBL-CRlc5 was digested with Xhol, and the sCRl insert was separated from the pBluescript ® vector. The isolated sCRl fragment was then inserted into the unique Xhol site of expression vector pTCSgpt to produce plasmid pT-CRlc5. 11.3. EXPRESSION OF SOLUBLE CRl As demonstrated herein, the expression of a soluble form of CRl that can be secreted from cells in high yield is (i) not limited to one exact site in the CRl cDNA to be used for deletion or truncation, and (ii) is also not 5 limited to the use of a particular expression vector (see t * infra) . The ability to produce secreted sCRl was demonstrated in two different expression systems. 11.3.1. CONSTRUCTION OF pTCS SERIES 10 OF EXPRESSION VECTORS The pTCS series of expression vectors which were used consists of three plasmids, each with a unique Xhol cloning site for insertion of cDNAs (Fig. 21) . Transcription of the inserted cDNA is driven by a set of 15 tandem promotors. The SV40 early promoter which is located upstream of the adenovirus 2 major late promotor (AD2 MLP) . Between the beginning of the cDNA and the AD2 MLP is the adenovirus tripartite leader. Transcribed mRNAs are terminated at a polyadenylation signal provided by the 20 murine immunoglobulin kappa (Igc) sequences located downstream of the Xhol cDNA cloning site. Selectable markers xanthine-guanine phosphoribosyltransferase (gpt) , dihydrofolate reductase (dhfr) , or neomycin resistance (neo r ) were provided by the insertion of the corresponding 25 markers from pSV2gpt, pSV2dhfr, or pSV2neo, respectively. These plasmids were also the source of the bacterial origin of replication and beta-lactamase gene for ampicillin resistance. In general, the choice of which of these vectors to use depends upon which selectable marker or 30 combination of markers is preferred for selection of the recombinants. The complete DNA sequences are known for adenovirus 2 (Ad2) , SV40, pSV2cat (Gorman, C. , 1985, DNA Cloning, Volume II, A Practical Approach, ed. D.M. Glover, 35 IRL Press, pp. 143-190),and murine immunoglobulin kappa. Sequences are located in the GenBaήk ® database and the National Biomedical Research annotation and references. Any of these sequences could also serve as a source for the appropriate segments of the pTCS vectors. The vectors pTCSgpt, pTCSneo, and pTCS dhfr were constructed from the intermediate plasmids pEAXgpt and pMLEgpt as follows: 11.3.1.1. CONSTRUCTION OF pEAXgpt Step 1. The Ad2 MLP DNA fragment was derived from M13 mp9/MLP (Concino, M.F., et al., 1983, J. Biol. Chem. 258:8493-8496). This plasmid contains adenovirus 2 sequences of nucleotides 5778 (Xhol site) to 6231 (Hindlll site) including the PvuII restriction site at nucleotide 6069 and the SacII site at nucleotide 5791 (see NBRF Nucleic database, accession #Gdad2) . The Xhol to Hindlll fragment had been cloned into the Hindlll and Sail sites of M13 mp9 to generate plasmid M13 mp9/MLP. Plasmid M13 mp9/MLP was digested with EcoRI and Hindlll and the smaller MLP containing fragment isolated. A pUC plasmid (Pharmacia, Inc. , Piscataway, NJ) was also digested with EcoRI and Hindlll and the larger fragment from this plasmid was then ligated to the EcoRI to Hindlll MLP fragment. This resulted in a new MLP-containing plasmid with the plasmid backbone of pUC. This plasmid was digested with Smal, ligated to Sail linkers, and recircularized. This new plasmid was then digested with PvuII which cleaved the plasmid at the PvuII site located at position #6069 within the adenovirus 2 insert sequences. The resulting linear fragment was ligated to Xhol linkers and recircularized. This plasmid was then digested with Xhol and Sail and the smaller fragment containing MLP DNA was isolated (fragment #1) . Step 2. Plasmid, pSV2gpt (American Type Culture Collection (ATCC) Accession No. 37145) , was digested with PvuII, ligated to Sail linkers, and digested with Sail. The final product was a linear pSV2gpt fragment that served as the source of the gpt gene (fragment #2) . 5 Step 3. A murine immunoglobulin Igκ fragment t * (Hieter, P.A. , et al., 1980, Cell 22:197-207) was digested with Haelll and Avail and the fragment containing the polyadenylation sequences isolated. In the murine Ig kappa sequence available in the NBRF Nucleic database (accession 10 #Kcms) , the Ig stop codon is at position 1296, followed by the Avail site at 1306, the AATAAA polyadenylation site at 1484, and the Haelll site at 1714. The overhanging ends of this fragment were filled in with E. coli DNA polymerase, and the fragment was then ligated to Xhol linkers, and 15 digested with Xhol. This fragment (fragment #3) served as the source of the polyadenylation site. Step 4. Fragments 1, 2, and 3 were ligated together with T4 DNA ligase to produce a circular plasmid. The correct orientation of the fragments in this plasmid was 20 confirmed by restriction enzyme analysis. Downstream of the Xhol cDNA cloning site was the murine kappa polyadenylation site, and further downstream from this site was the SV40 promoter and gpt gene. Upstream of the Xhol site was the 25 MLP promoter and further upstream from this promoter was the bacterial origin of replication and ampicillin gene. This plasmid was then digested with Sail and the overhanging ends filled in with E. coli DNA polymerase. The resulting blunt end fragment was ligated to EcoRI linkers and recircularized 30 with T4 DNA ligase. This final plasmid was designated pEAXgpt. 35 11.3.1.2. CONSTRUCTION OF pMLEqpt Step 1. Plasmid pMLP CAT (Lee, R.F., et al., 1988, Virology, 165:51-56) is an expression plasmid with a pML vector backbone and contains the adenovirus 2 MLP and tripartite leader sequences 5' to the CAT gene. pMLP CAT was digested with Xhol and SacII; the Xhol cut at a site between the CAT gene and the L3 region of the tripartite leader, and SacII cut at position #5791 within the adenovirus DNA but 5' of the MLP. The AD2 MLP and tripartite leader were thus located on this small Xhol to SacII fragment (fragment #4) . Step 2. Plasmid pEAXgpt was digested with Xhol and SacII, and the smaller MLP containing fragment was discarded. The larger fragment (fragment #5) was isolated. Fragments 4 and 5, both with SacII and Xhol ends, were ligated to produce plasmid pMLEgpt. 11.3.1.3. CONSTRUCTION OF pTCSgpt Step 1. pMLEgpt was digested with SacII and the ends filled in with T4 DNA polymerase to yield a blunt end fragment (fragment #6) . This SacII site is located at nucleotide 5791 in the Adenovirus 2 sequence, 5' of MLP- tripartite leader. Step 2. pSV2dhfr (ATCC Accession No. 37146) was digested with Hindlll and PvuII. The smaller 342 nucleotide fragment containing the SV40 early promoter was blunt ended using the Klenow fragment of E. coli DNA polymerase (fragment #7) . Fragments 6 and 7 were ligated with T4 DNA ligase. Restriction enzyme analysis confirmed that the fragments were correctly oriented to give two, tandem promoters upstream of the Xhol cDNA cloning site, each promoter able to prime RNA synthesis in the same direction. This plasmid was named pTCSgpt (Fig. 22) . 11.3.1.4. CONSTRUCTION OF pTCSdhfr Step l. pSV2dhfr was digested with Hindlll and PvuII, and the larger fragment was then purified from an agarose gel (fragment #8) . The smaller SV40 early promoter containing fragment was discarded. 5 1 Step 2. pTCSgpt was digested with EcoRI and then * filled in with the Klenow fragment of E. coli DNA polymerase to generate blunt ends. This linear fragment was then digested with Hindlll, and the fragment (about 1600 nucleotides) containing the pTCS transcription unit of SV40 10 promoter, MLP, tripartite leader, Xhol cDNA cloning site, murine Igλ sequences, and second SV40 promoter was isolated (fragment #9) . This fragment had one flush end and one Hindlll overhanging end. Ligation of fragments 8 and 9 . ID_ generated plasmid pTCSdhfr. 11.3.1.5. CONSTRUCTION OF pTCSneo Step 1. pSV2neo (ATCC No. 37149) was digested with Hindlll and BamHI, and the larger fragment (fragment #10) was isolated. This fragment contained the plasmid 20 backbone and neo gene. Step 2. pTCSdhfr was digested with Hindlll and BamHI, and the pTCS transcription unit (fragment #11) was isolated from an agarose gel after electrophoresis of the 25 digestion products. Ligation of fragments 10 and 11 generated plasmid pTCSneo. 11.3.2. EXPRESSION AND ASSAY OF PLASMIDS pBSCRlc, pBSCRls AND pBM-CRlc, MAMMALIAN EXPRESSION VECTORS CONTAINING SOLUBLE CRl CODING 30 SEQUENCES 4 * 35 11.3.2.1. EXPRESSION OF CRl CONSTRUCTS TRUNCATED AT DIFFERENT POSITIONS .WITHIN THE CRl cDNA Plasmids pBSCRlc and pBSCRls were constructed (Section 11.1, supra) such that most of the cDNA coding regions, except the transmembrane and cytoplasmic regions were preserved (Fig. 20) . pBSCRls is shorter than pBSCRlc since it is also missing a portion of LHR-D and SCRs 29 and 30 that are present in pBSCRlc. The sCRl portions of these plasmids were inserted into pTCSgpt, followed by transfection and expression as described infra. pBSCRlc/pTCSgpt construction: pBSCRlc was digested with Xhol to yield the 5.9 kb insert, sCRlc. sCRlc was inserted into the Xhol cDNA cloning site of pTCSgpt to produce pBSCRlc/pTCSgpt. pBSCRls/pTCSgpt construction: pBSCRls was digested with Xhol and Pvul to release the sCRls insert. The ends of the insert were made blunt with T4 DNA polymerase. This insert was purified from an agarose gel. Vector pTCSgpt was digested with Xhol, and the overhanging Xhol ends were filled in with E. coli DNA polymerase I. Next, the sCRls insert was ligated to the blunt end vector to produce pBSCRls/pTCSgpt. Plasmids pBSCRlc/pTCSgpt and pBSCRls/pTCSgpt were digested with Fspl, and the resultant linear DNA's were transfected into Chinese Hamster Ovary cells that were mutant in the dhfr gene (CHO DUX Bll cells) via calcium phosphate coprecipitation with plasmid pSV2dhfr. Transfectants were selected by their ability to grow in DHFR selection medium. Culture supernatants of transfectant clones were assayed for secreted sCRl by ELISA. Culture supernatants from fifty pBSCRlc/pTCSgpt recombinants were assayed and the positive recombinants were taken through the amplification process by culturing them in increasing concentrations of methotrexate. In addition, pools of transfectants were prepared by co-culturing eight pBSCRlc/pTCSgpt transfectants together per pool and carrying them through the same amplification process. Results of the amplification are presented in Table VI. c 10 15 20 25 30 35 TABLE VI EXPRESSION OF pBSCRlc/pTCSgpt * clones 2 and 35 were chosen for large scale production of sCRl. t Clone 35 was subcloned by limiting dilution, and the production of soluble CRl was determined for each subclone. pBSCRlc/pTCSgpt-clone 35.6 was the highest producer, showing 17.7 g/ml sCRl. MTX: methotrexate Twelve recombinants from pBSCRls/pTCSgpt were assayed for production of soluble CRl by ELISA. All twelve candidates showed detectable levels of secreted sCRl. The best producers gave levels of sCRl which were comparable to those produced by the best pBSCRlc/pTCSgpt transfectants. pBSCRlc/pTCSgpt and pBSCRls/pTCSgpt recombinants produced soluble CRl with similar levels of production. This indicated that the ability to produce a soluble CRl polypeptide was not dependent upon an exact truncation point within the CRl cDNA. Initial attempts to amplify the cell line, clone 35.6 beyond 500 nm methotrexate were not successful. For this reason, alternative cell lines were sought from the panel shown in Table VI. Candidates were chosen on the basis of expression comparable to clone 35. At methotrexate levels in which the expression was beginning to plateau, lines were subcloned and screened for sCRl concentrations in the supernatants. Cell line 15, resistant to 50 nm methotrexate, was chosen on this basis. It was subcloned, creating cell line 15.19, increasing the expression to the 35.6 level. Next, 15.19 was cultured in media containing various concentrations of methotrexate. Only 2500 nm methotrexate produced an elevated sCRl expression level, increasing the secretion by 63% above 35.6. This cell line, designated 15.192500, was then subcloned by limited dilution, creating cell lines 15.192500.07, 15.192500.10 and 15.192500.65. These cell lines produced 143, 119, and 103 percent more sCRl per ml respectively than 35.6. 11.3.2.2. EXPRESSION OF sCRlc IN TWO DIFFERENT EXPRESSION SYSTEMS The truncated CRl cDNA insert, sCRlc, was inserted into the expression vector pTCSgpt and expressed as described above. It was also inserted into the expression vector pBMT3X as described supra in Section 11.2.3, to yield pBM-CRlc. Both these expression vectors have very strong promoters. Expression of soluble CRl was tested in both systems to determine whether one system would produce better yields of secreted polypeptide. C127I mouse cells (ATCC Accession No. CRL 1616, Rockville, Maryland) were transfected with pBM-CRlc using the calcium phosphate method (Graham, F.L. and van der Eb, A.J. , 1973, Virology 52:456-467). After glycerol shock, the cells were refed with D-MEM medium containing 10% fetal bovine serum and 2 mM L-glutamine, and incubated at 37°C for 48 hours. Thereafter, the cells were trypsinized, and split at 1:5 and 1:10 ratios into complete D-MEM medium plus 10 μM cadmium chloride. Cadmium-resistant colonies appeared within 10 days. Ten colonies were removed with the use of cloning cylinders. Each colony was transferred to a 60 mm petri dish containing complete D-MEM medium, and incubated at 37°C, 5% CO- until the cells reached confluency. Thereafter, for each dish, the cells were trypsinized and divided into three 60 mm dishes to be used for preparation of frozen cell stocks, RNA extraction, and ELISA test of the cell medium for the presence of secreted sCRlc. When cell medium from each confluent petri dish was removed and subjected to ELISA analysis, all pBM-CRlc clones tested were positive for soluble CRl production. The levels of secreted sCRl from the pBM-CRlc recombinants were comparable to those from the pBSCRlc/pTCSgpt recombinants. This indicated that the ability to produce high levels of secreted sCRl polypeptide was not dependent upon the use of only certain promoters or expression systems. 11.3.3. EXPRESSION AND ASSAY OF PLASMIDS pT-CRlcl, pT-CRlc2, pT-CRlc3, pT-CRlc4, and pT-CRlc5, MAMMALIAN EXPRESSION VECTORS CONTAINING SOLUBLE CRl CODING SEQUENCES The pT-CRlc series of deletion mutants were missing the transmembrane and cytoplasmic domains, as were the constructs, pBSCRlc and pBSCRls. In addition, the deletion mutants also contained fairly large deletions of various LHR regions of the CRl cDNA (see Fig. 20) . The deletion mutants were expressed in CHO DUX Bll cells and the levels of soluble CRl polypeptide produced were measured. For each deletion construct, forty different pools of clones were selected for ELISA analysis to determine whether soluble CRl polypeptides were being produced. Four of five pT-CRlc constructs were found to be secreting sCRl into the cell culture medium, as determined either by ELISA or by the presence of functional activity in the cell culture media. Supernatants from cells transfected with three of the five pT-CRlc constructs were producing sCRl that was functional as determined by a hemolytic assay (see Table VII and Section 13.2, infra). TABLE VII PRODUCTION OF FUNCTIONAL sCRl FRAGMENTS* Construct ELISA Hemolytic Assay pT-CRlcl - + pT-CRlc2 + + pT-CRlc3 pT-CRlc4 + Not determined pT-CRlc5 - + Supernatants tested for ELISA or hemolytic assays were obtained either from cultures growing in T75 flasks or in 24 well dishes. Since various amounts of soluble CRl could have accumulated in the culture supernatants under these conditions, the results shown are qualitative. (+) indicates the production of functional sCRl as detected by the indicated assay. The fact that the deletion mutants were also able to produce soluble CRl, further demonstrated that the ability to express sCRl was not dependent upon one exact genetic modification of the CRl cDNA. As long as the transmembrane regions were deleted, all constructs were able to produce a soluble polypeptide. 12. EXAMPLE: PRODUCTION AND PURIFICATION OF SOLUBLE CRl Large quantities of sCRl were produced in a hollow fiber bioreactor system. The quantities of sCRl obtained were proportional to the relative yield of the inoculated recombinant clones. For optimal purification results, a serum-free medium was chosen that resulted in high production levels of sCRl in the absence of large quantities of exogenously added fetal calf serum polypeptides. 12.1. LARGE SCALE PRODUCTION OF SOLUBLE CRl A Cell-Pharm™ Cell Culture System I (CD Medical, Inc., Miami Lakes, FL) , equipped with a model IV-L hollow fiber bioreactor (30 kD molecular weight cutoff) , was assembled under sterile conditions. Two clones (clone 2 and clone 35 of pBSCRlc/pTCSgpt) were expanded into eight T-225 flasks. At confluency, the cells were trypsinized, washed, pelleted, and resuspended in culture media. Approximately 5 x 10 8 cells of clone 2 and 10 x 108 cells of clone 35 were inoculated into two separate hollow fiber bioreactors. A 20 liter feed reservoir of alpha-MEM plus 10% fetal calf serum, 8 mM L-glutamine, 100 μg/ml penicillin-streptomycin and the appropriate concentration of methotrexate (50 nM for clone 2; 500 nM for clone 35) was used. Premixed gas (5% C0 2 in air) was bubbled into the reservoir medium through the oxygenator to maintain pH. Media recirculation, replacement and gas flow rates were adjusted to yield maximum production. Samples were harvested through inoculating ports, centrifuged at 1000 rpm for 10 minutes, filtered through a 0.22 μM pore size filter, and kept at 4°C before purification. Harvest volume and frequency were increased gradually from 25 ml, three times per week at the beginning of the culture, to 40 ml, five times a week after 2-3 months. The production of sCRl was assayed by a CRl ELISA. The yields of clone 2 and clone 35 for the first month after inoculation were 66 μg/day and 1060 μg/day, respectively. These yields increased as the cultures became established. 12.1.1. PRODUCTION OF SCRl IN SERUM-FREE MEDIA Two commercially available serum-free media were tested for their ability to support cell growth and production of sCRl. A confluent T75 flask of pBSCRlc/pTCSgpt clone 35 was divided into two T75 flasks. One flask was cultured with alpha MEM, supplemented with 10% fetal calf serum, L-glutamine, antibiotics, and 500 nM methotrexate. The other flask was weaned stepwise from 5%, 1%, 0.5% and no fetal calf serum in alpha MEM plus L- glutamine, antibiotics, 500 nM methotrexate plus HB CHO growth supplement (Hana Biologies, Inc. , Ala eda, CA) . The cell growth and sCRl production levels of the two flasks were compared. The growth of the cells in the serum-free media never reached confluency. The levels of sCRl production are given in Table VIII. In each case, the level of sCRl production was best when cells were grown in 10% fetal calf serum. For comparison, the levels found at day 14 m serum-free media were 1.4 x 10 10 ghosts/ml as compared to 4.2 x 10 10 ghosts/ml for 10% fetal calf serum supplemented media. TABLE VIII PRODUCTION OF sCRl IN SERUM-FREE MEDIA SUPPLEMENTED WITH CHO GROWTH SUPPLEMENT VERSUS 10% FETAL CALF SERUM CONTAINING MEDIA Cell growth and sCRl production in recombinants were tested using a second source of serum-free media (CHO- 1, Ventrex Laboratories, Inc., Portland, ME). Since it was not necessary to wean serum-grown cells into this media, cells were thawed and cultured directly in the serum-free media. This media consists of a DME-F12 base and a growth additive. Equal numbers of cells were thawed and seeded into separate wells in a 24-well plate. After the cells had attached, the media was discarded, and either 10% fetal calf serum containing media or serum-free media was added to appropriate wells. Each condition was performed in duplicate. Unlike the previously tested serum-free media, the CHO-1, Ventrex Laboratories media yielded similar levels of cell growth as did the fetal calf serum containing media. 12.1.2. CONCLUSIONS The above-described results indicated that sCRl producing CHO cells could be maintained in a defined sόruni- free media. This resulted in a savings in the cost of culture media for large scale production runs. A further advantage was that purification of sCRl from the cell culture supernatants was simplified, since no fetal calf serum proteins had to be removed. 12.2. PURIFICATION OF SOLUBLE CRl With the advent of specific anti-CRl antibodies, it became possible to replace the many chromatographic steps needed to produce purified CRl with a simplified two step procedure. This increased the yields of CRl proteins that could be obtained to approximately 1-5 mg CRl per 5.9 x 10 13 erythrocytes (Wong, W.W. , et al., 1985, J. Immunol. Methods 82:303-313). However, since the reported purification was of membrane-bound forms of CRl, it was always necessary to solubilize the CRl containing material in detergents. Soluble CRl produced by recombinant transfectants does not have to be solubilized with detergents for purification; it is already soluble. Although soluble CRl can be purified by anti-CRl antibody chromatography (see below) , this procedure does not lend itself easily to large-scale production. The extent of scale-up is limited by the amount of anti-CRl antibody that can be obtained for preparing the antibody matrix of the antibody purification columns. In addition, the high binding affinity of an antibody such as YZ-1 for CRl means that rather harsh conditions, for example pH 12.2, have to be used to remove the bound sCRl product from the antibody matrix (Wong, W.W. , et al., 1985, J. Immunol. Methods 82:303-313). To have the capacity of purifying very large quantities of soluble CRl, purification procedures involving HPLC columns were developed. These HPLC columns can easily be scaled up to produce even larger quantities of purified soluble CRl. In addition, they do not require harsh conditions for the elution and recovery of sCRl. 12.2.1. ANTIBODY AFFINITY COLUMN PURIFICATION 12.2.1.1. METHODS For antibody affinity purification of sCRl, 100 mg of monoclonal antibody YZ-1 was covalently coupled to 7 mg of AffiGel-10 (BioRad, Richmond, CA) according to the manufacturer's instructions. CRl containing supernatant from cell cultures was incubated with the immobilized YZ-1 in a flask rocking at 4°C overnight. The material was poured into a glass column and washed extensively with 10 mM Hepes, 0.1 M NaCl, pH 7. The sCRl was eluted using 20 mM sodium phosphate, 0.7 M NaCl, pH 12 (Yoon, S.H. and Fearon, D.T., 1985, J. Immunol. 134:3332-3338). Eluted fractions were tested for the presence of protein using the Biorad Protein Assay (BioRad, Richmond, CA) . Samples containing protein were immediately pooled and dialyzed in 0.1 M Hepes pH 7 overnight (2 x 1 liters) at 4 β C. The sample was then dialyzed in PBS. Presence of sCRl was analyzed by CRl ELISA. 12.2.1.2. RESULTS Cell culture supernatant containing sCRl produced, by transfectant pBSCRlc/pTCSgpt clone 2 was loaded onto the anti-CRl antibody affinity column and the peak sCRl fractions pooled. An aliquot of this purified material was run on a 4-20% SDS-PAGE "^.l (DAIICHI; Inc., polyacrylamide gels; modified procedure of Laemmli, U.K., 1970, Nature 227:680-685). Under reducing conditions, the apparent molecular weight of soluble CRl was about 224,000 daltons (Fig. 24) . This purified CRl was also shown to be active by its ability to inhibit complement-mediated hemolysis as well as C5a and C3a production (Section 13, infra). » « 5 12.2.2. CRl PURIFICATION BY HPLC < » 12.2.2.1. METHODS 12.2.2.1.1. STARTING MATERIAL When cultures were first established in the 10 bioreactors, the levels of sCRl production were lower than when the cultures had been growing for several months. Generally there was a period of several weeks before the cells in the bioreactor reached confluency and produced maximum levels of sCRl. Cell culture supernatants with low 15 levels of sCRl could be concentrated before purification by either ammonium sulfate precipitation or by ultrafiltration. Ammonium sulfate fractionation of supernatants over the range of 60 to 80% saturation precipitated sCRl in essentially equivalent yields. The precipitate was 20 dissolved in a minimum volume and dialysed into starting buffer for the cation exchange HPLC. Alternatively, the CHO cell culture supernatants could be concentrated by ultrafiltration and dialyzed into starting buffer for cation _ _ e Ό exchange chromatography. As the bioreactors produced higher concentrations, of soluble CRl, the CHO cell culture supernatants from these cultures could be dialyzed directly into starting buffer for cation exchange chromatography. 30 * 12.2.2.1.2. CATION EXCHANGE HPLC PROCEDURE * Samples were dialyzed into starting buffer (0.02 M sodium phosphate, 0.06 N sodium chloride, pH 7.0) and then filtered through a 0.2 μm filter to remove any particulate 35 material. The sample was then loaded onto a cation exchange high pressure liquid chromatography column (10 cm x 10 mm, Hydropore-SCX HPLC column from Rainin) . The column was washed and eluted with a sodium chloride gradient developed using 0.02 M phosphate, 0.5 N NaCl, pH 7.0. The sCRl eluted somewhere between 0.06 N and 0.25 N NaCl. Elution was monitored by absorbance at 280 nm and by ELISA. 12.2.2.1.3. ANION EXCHANGE HPLC PROCEDURE If desired, further purification of the cation HPLC purified sCRl could be obtained by anion HPLC. Peak fractions from the cation HPLC were dialyzed into the starting buffer for anion HPLC. Samples were loaded and the column (Hydropore-AX from Rainin) was washed in 0.01 M phosphate pH 7.5. The column was eluted with a series of steps and gradients developed using 0.01 M phosphate, 0.5 N NaCl, pH 7.5. The sCRl eluted somewhere between 0.0 N and 0.3 N NaCl. Elution was monitored as before for cation exchange HPLC. The concentrations and pH of the cation and anion HPLC column buffers are given as examples only. Other buffer concentrations, salt conditions, or pH conditions would also work. 12.2.2.1.4. WESTERN BLOT ANALYSIS Western blotting was performed using a modified procedure from Towbin, H. , et al., 1979, Proc. Natl. Acad. Sci. USA, 76:4350-4354. Briefly, purified sCRl was run on a 4-20% SDS-PAGE, transferred to nitrocellulose, specifically probed with anti-CRl (mouse mAb YZ-1 or J3D3) , and detected with goat anti-mouse antibody conjugated with alkaline phosphatase. 12.2.2.2. RESULTS For a typical run, 50-100 ml of supernatant from a bioreactor culture were dialyzed into starting buffer and loaded onto a lO cm x lO mm cation exchange HPLC. The peak -In¬ fractions were determined by ELISA and absorbance at 280 nm, and were pooled. The protein concentration of the pool was determined by absorbance at 280 nm (e(l%) at 280 nm = 10, as * estimated from the CRlc amino acid composition) . Several tens of milligrams were purified from 100 ml of amplified t culture supernatant. ♦ As an example, 100 ml of culture supernatant from transfectant pBSCRlc/pTCSgpt clone 2 produced 22 mg of purified sCRl, as determined by absorbance at 280 nm, when purified by cation HPLC (Fig. 24) . When monitored by CRl 10 ELISA, the yield was calculated to be 202% with another 13% in the flow-through or column wash fraction. The greater than 100% yield probably reflects matrix effects in the ELISA. Given the rates that culture supernatant can be 15 withdrawn from a bioreactor, it should be possible at this level of methotrexate amplification to produce about 100 mg of purified soluble CRl per week per bioreactor. Some ways in which this level of production can be scaled up, include amplifying the starting cultures to a maximum extent with 20 methotrexate prior to seeding the bioreactor, increasing the number of bioreactors in production at any one time, and using larger capacity HPLC columns. 25 12.2.2.3. CHARACTERIZATION OF PURIFIED SOLUBLE CRl The sCRl containing peak fraction from the cation HPLC (Fig. 24) was further purified on an anion HPLC. The purity of the sCRl material at the various steps was tested by SDS-PAGE (Fig. 25) . The smaller bands seen in these 30 heavily loaded gels represent fragments of sCRl as * determined by Western Blot analysis using anti-CRl * monoclonal antibodies, YZl or J3D3. The fragment sCRl bands were not seen in most preparations. 35 The functional activity of purified sCRl was tested by its ability to inhibit classical complement- mediated hemolysis by 50% at a purified sCRl concentration of 0.25 μg/ml. The purified soluble CRl was also able to inhibit classical complement C5a production by 50% at 5 μg/ml and C3a production by 50% at 13 μg/ml (see Section 13, infra) . 12.2.2.4. CONCLUSIONS As described supra, we developed an improved method for the purification of soluble CRl that can easily be scaled up to produce the quantities of sCRl needed for therapeutic applications. The basic elements of this procedure included a starting material that is already soluble, thus eliminating the requirement of solubilizing membrane bound CRl with detergents. The reduction of fetal calf serum concentrations in the bioreactor cultures and/or the use of alternative culture medias in these cultures eliminated the need to remove high concentrations of extraneous proteins from the sCRl-containing starting material during subsequent purification. Furthermore, the development of an HPLC procedure for purification provided a method for large-scale purification. Either cation HPLC or a combination of cation HPLC followed by anion exchange HPLC can be used for purification. Substantially pure soluble CRl in high yield can be achieved by this procedure in only 1 or 2 steps. 13. EXAMPLE: DEMONSTRATION OF IN VITRO ACTIVITY OF SOLUBLE CRl 13.1. INHIBITION OF THE NEUTROPHIL OXIDATIVE BURST In the reperfusion injury model of - ssue damage incurred during a myocardial infarction, activated complement components induce neutrophil adhesion and activation. The activated neutrophil undergoes an oxidative burst creating highly toxic oxygen radicals. These and other potential toxins are released during neutrophil degranulation, damaging the surrounding tissue. Soluble CRl may reduce the area of damaged tissue by preventing the 5 * generation of C3a and C5a, the complement components » involved in neutrophil activation. To monitor the ability of soluble CRl to block the generation of C5a during complement activation in vitro, a bioassay which can quantitate the generation of oxygen 10 radicals produced by neutrophils during a C5a induced oxygen burst was used (Bass, D.A. , et al., 1983, J. Immunol. 130:1910-1917). This assay employs dichlorofluorescin diacetate (DCFDA) , a lipid soluble molecule which can enter cells, become trapped, and turn highly fluorescent upon 15 oxidation. 13.1.1. MATERIALS AND METHODS 13.1.1.1. MATERIALS 20 Fresh whole blood, human complement sources (Beth Israel Hospital, Boston, MA) , dried Baker's yeast, PBS with 0.1% gelatin and 5 mM glucose, 100 mM EDTA, 10 mM DCFDA in HBSS (Kodak) , Red blood cell (RBC) lysing buffer (Ortho Diagnostics), purified C5a (Sigma Chemical Co., St. Louis, 25 MO) , and soluble CRl were used. 13.1.1.2. PREPARATION OF NEUTROPHILS Neutrophils were prepared as described by Bass 30 (1983, J. Immunol. 130:1910-1917). 2.0 ml of whole blood was washed 3 times in PBS-gelatin-glucose, resuspended in 5 ml of 10 μM DCFDA in HBSS plus 5 ml PBS-gelatin-glucose and * incubated for 15 minutes at 37 β C. Cells were then t centrifuged and resuspended in 2.0 ml PBS-gelatin-glucose 3 plus 5 mM EDTA. 13.1.1.3. PREPARATION OF YEAST PARTICLES Dried baker's yeast was resuspended in H 2 0, washed 2 times and boiled for 30 minutes. Particles were rewashed 2 times in H_0 and resuspended at 0.5 grams/ml in H,0 (Simpson, P.J., et al., supra) . ^ 13.1.1.4. ACTIVATION OF NEUTROPHILS BY PURIFIED C5a 100 μl of DCFDA-loaded cells were treated with RBC lysing buffer, washed one time in PBS-gelatin-glucose- EDTA and resuspended in 1.0 ml of PBS-gelatin-glucose. Fifty μl of purified C5a at 200 ng/ml or control was added to 0.5 ml of target cells at 37°C and analyzed on the flow cytometer at various time intervals. 13.1.1.5. ACTIVATION OF NEUTROPHILS BY PURIFIED C5a IN HUMAN SERUM OR PLASMA 100 μl of DCFDA-loaded cells were incubated with 50 μl of C5a diluted 1:1 in human serum or heparinized plasma (100 ng/ml) or control at 37°C for 30 minutes. The RBC's were lysed out, and the neutrophils were analyzed on a flow cytometer. 13.1.1.6. ACTIVATION OF NEUTROPHILS BY YEAST PARTICLE- ACTIVATED HUMAN SERUM OR PLASMA 425 μl of fresh frozen serum and plasma plus 50 μl of sCRl or control were incubated with 25 μl of yeast particles at 37 β C for 30 minutes. The complement-activated and control samples were then centrifuged to remove the yeast particles. Ten 2-fold dilutions of each of these samples were performed in PBS-gelatin-glucose-EDTA. 50 μl of each serial dilution of control and activated serum and plasma was added to 50 μl of DCFDA-loaded target cells and incubated at 37 β C for 30 minutes. The RBC's were then lysed out, and neutrophils were analyzed by flow cytometry. 13 . 1. 2 . RESULTS 13.1.2.1. C5a INDUCES AN OXYGEN BURST IN HUMAN NEUTROPHILS WHICH CAN BE MEASURED USING DCFDA 5 Figure 26 shows a rapid increase in fluorescence k intensity of the human neutrophils after stimulation with 9 purified C5a. Within four minutes after addition of C5a (20 ng/ml final concentration) , the neutrophils were 10-fold brighter than control DCFDA-loaded neutrophils. By 20 10 minutes, the neutrophils were 20-fold as bright as controls. This assay seems to be a sensitive indicator of C5a. 13.1.2.2. HUMAN SERUM BLOCKS THE OXYGEN BURST EFFECTS OF PURIFIED C5a ON NEUTROPHILS No increase in fluorescent intensity was observed 15 in neutrophils loaded with DCFDA and incubated with purified C5a diluted in human serum. This effect may be due to platelet derived growth factor (PDGF) released from platelets during clotting. It has been shown that low levels of PDGF can inhibit C5a-induced neutrophil activation 20 (Wilson, E., et al., 1987, Proc. Natl. Acad. Sci. USA 84:2213-2217) . 13.1.2.3. HEPARINIZED PLASMA DOES NOT BLOCK THE EFFECTS OF C5a ON NEUTROPHILS 25 C5a diluted 1:1 in heparinized plasma induced an oxygen burst in DCFDA loaded neutrophils. Although not as dramatic as C5a in buffer, there was a ten-fold increase in fluorescent intensity after a 30 minute incubation with the neutrophils. The decreased signal may be caused by PDGF 30 release during phlebotomy or plasma isolation. More gentle and rapid isolation of the plasma from the cellular components of blood may minimize the release of PDGF and allow for better C5a function. 35 13.1.2.4. SCRl PRESENT DURING COMPLEMENT ACTIVATION BLOCKS C5a GENERATION Zymosan induced activation of human complement in the presence of soluble CRl showed reduced C5a activity as measured with the DCFDA assay. As can be seen in Fig. 27, the 1:16 dilution of human plasma activated in the presence of sCRl generated 70% less fluorescence intensity increase in the neutrophils as the 1:16 diluted plasma activated without sCRl present. This implies inhibition of C5a generation by sCRl. Further optimization of the DCFDA assay and plasma collection should result in a more dynamic and sensitive assay of soluble CRl activity. 13.2. INHIBITION OF COMPLEMENT MEDIATED HEMOLYSIS 13.2.1. METHODS The ability to inhibit complement was tested by assaying for inhibition of complement-mediated red cell lysis (hemolysis) . The inhibition of hemolysis was determined as a function of soluble CRl concentration. The sCRl samples to be tested were diluted in 0.1 M Hepes buffer (0.15 N NaCl, pH 7.4), and 50 μl were added to each well of a V-bottom microtiter plate typically in triplicate. Human serum, used as the complement source, was diluted 1 to 125 in Hepes buffer, and 50 μl were added to each well. Next, commercially available sheep erythrocytes with anti-sheep antibody (Diamedix Cat. No. 789-002) were used as received and added 100 μl/well to initiate the complement pathway leading to hemolysis. The plate was incubated for 60 minutes at 37°C and then centrifuged at 500 x g for 10 minutes. The supernatants were removed and placed in a flat-bottom microtiter plate. The extent of hemolysis was measured as a function of the sample absorbance at 410 nm. The maximal absorbance (corresponding to maximal hemolysis) , Amax , was obtained from the absorbance of an erythrocyte sample containing only human serum A„, minus the absorbance of a sample containing only the red cells, A_. Thus, A = A_ - A n . The difference between the absorbance of an erythrocyte sample containing both human serum and sCRl, and the absorbance of a cell sample containing sCRl only, was 5 defined as A samt e - The inhibition, IH, was expressed as •» the fraction (A maχ -A sample /A maχ ) , and IH 5Q was defined as the concentration of sCRl required to produce a value of IH = 1/2. To monitor chromatography fractions, the serum-free controls were not included and anti-complement activity was 10 monitored qualitatively as a decrease in the absorbance at 410 nm of the sample. The hemolytic assay described above was also \ised to assess the capability of human recombinant sCRl to inhibit sheep red cell lysis by complement from other 15 species, such as guinea pig and rat. For each species, fresh-frozen serum or freshly lyophilized serum or plasma was used as a complement source. In some cases sera were obtained commercially (Sigma Chemical Company, St. Louis, MO) . 20 The serum was first titered for its capacity to lyse activated red cells. The greatest dilution which yielded at least 80% maximal red cell lysis was chosen to assess the effects of added human sCRl. The assay was then performed as described above, substituting animal for human 25 serum at the preferred dilution. 13.2.2. RESULTS As indicated in Figure 28, purified sCRl 30 inhibited classical complement-mediated lysis by 50% at a sCRl concentration of 0.12 μg/ml. The ability of antibody affinity purified sCRl to inhibit the hemolytic assay was compared to that of unpurified material (sCRl containing cell culture supernatant) . The purified sCRl had activity 35 comparable to that of the unpurified sCRl, with both g producing 50% inhibition in the hemolytic assay at 1.6 x 10 ghosts/ml. This indicated that the purification procedure was not substantially diminishing the functional activity of the final sCRl product. To determine if purified sCRl could be stored frozen, an aliquot was stored at -70°C for one week. The concentration of the frozen sCRl was the same as the nonfrozen sCRl, as determined by absorbance at 280 nm and CRl ELISA. The frozen sCRl also had the same activity as the nonfrozen sCRl as determined by inhibition of hemolysis. The ability of human recombinant sCRl to inhibit hemolysis mediated by complement from several species is summarized in Table IX. TABLE IX HEMOLYSIS OF SENSITIZED SHEEP RBC USING COMPLEMENT FROM VARIOUS ANIMAL SERA * * Inhibition * Inhibition (IH)** by sCRl (ghost/ml) (gh IH os 5 t0/*m*l) Yes 66%(2.6x10 ) l.OxlO 9 10 Yes 94%(2.5xl0 ) 2.0X10 Yes 94%(1.2X10 9 ) 1.0x10 Yes 85%(2.6X10 9 ) 2.4x10 8 Yes 77%(3.8xl0 ) l.OxlO- 15 No No No 20 * lyophilized sera obtained commercially (Sigma Chemical Co. , St. Louis, Mo. ** as defined in text (Section 13.2) 25 Both guinea pig and rat complement appeared to be inhibited by human sCRl. The lack of clear inhibition for other species may reflect (a) the mappropriateness of using rabbit antibodies and sheep erythrocytes in the assay system, or (b) the high concentration of serum required for 30 hemolysis in this system. 35 13.3. INHIBITION OF C3a AND C5a PRODUCTION 13.3.1. METHODS The ability to inhibit complement was also tested by assaying for specific inhibition of C3a and C5a D production. For all experiments, a single human serum pool, to be used as a source of complement, was aliquoted and stored frozen at -70°C. Human IgG was heat-aggregated, aliquoted, and stored frozen at -70°C. For each experiment, serum aliquots were equilibrated at 37°C with varying 0 concentrations of sCRl to be tested. The complement pathway was initiated by the addition of aggregated human IgG. Control samples containing no IgG were always included. After a fixed reaction time of 15 minutes (determined in an earlier time-course study to provide a convenient time 5 interval during which the production of C5a or C3a is nearly complete, i.e. , greater than 90%) , the levels of the released complement peptides (C5a or C3a) were determined by radioimmunoassay using commercially available 0 radioimmunoassay (RIA) kits (C5a RIA, Amersham Cat No. RPA.520; C3a RIA, Amersham Cat. No. RPA.518) in modified procedures. Since a competitive immunoassay was used, complement peptide (C5a and C3a) concentrations varied 5 inversely with the counts. The counts bound (CB) for a sample were defined as the total counts (in counts per minute, cp ) measured in the pellet. The y-axis in Figure 29 represents the fraction inhibition. The fraction inhibition is equal to the counts 0 bound (CB) for a "sample", less the CB in the "sample with no sCRl", divided by the CB for the "no IgG control" less the CB in the "sample with no sCRl." 35 INHIBITION = [ (CB sample) - (CB no sCRl) 1 [(CB no IgG) - (CB no sCRl) ] 13.3.2. RESULTS The activity of purified sCRl was assayed by testing its ability to inhibit C5a and C3a production in an activated human serum sample. As indicated by Figure 29, under the conditions tested, purified sCRl was able to maximally inhibit C5a production by 100% and C3a by 60%. Inhibition of 50% was observed at sCRl concentrations of 5 μg/ml for C5a production and 15-20 μg/ml for C3a production. The data suggest that recombinant sCRl inhibits the C5 convertase more efficiently than the C3 convertase. 14. EXAMPLE: DEMONSTRATION OF FUNCTIONAL IN VIVO THERAPEUTIC ACTIVITY OF SOLUBLE CRl 14.1. SOLUBLE CRl DEMONSTRATES IN VIVO FUNCTION IN A REVERSED PASSIVE ARTHUS REACTION The Arthus reaction is a classic immunologically induced inflammatory response caused by injecting antigen locally that then reacts with antibodies in circulation. The major biological response is characterized by immune complex deposition, complement fixation, polymorphonuclear (PMN) leukocyte infiltration, release of lysosomal enzymes, vasoactive amine, and local tissue damage (Uriuhura, T. and Movat, H.Z., 1966, Exp. Mol. Pathol. 5:539-558; Cochrane, C.G., 1968, Adv. Immunol. 9:97-162). A modification of the direct Arthus reaction, the reversed passive Arthus reaction (RPAR) , has been used as a model for identifying anti- inflammatory agents (Pflum, L.R. and Graeme, M.L., 1979, Agents and Actions 9:184-189). In a RPAR, antibody is injected locally and antigen is present in the circulation. When tested in a rat RPAR model, soluble CRls were able to block the local inflammatory reaction. The mechanism of the action of this soluble CRl function . in vivo may be mediated through the inhibition of complement pathway enzymes. 14.1.1. MATERIALS AND METHODS Female five week old Sprague Dawley rats (CD strain) weighing about 100-125 grams (Charles River Laboratories, Wilmington, MA) were anesthesized with an intraperitoneal injection of 0.1 to 0.3 ml Avertin solution. This solution was a 1:2 dilution of a stock solution made with 1 g tribromoethanol in 15 ml Amel ethanol. The fur on the backs of the animals was shaved. Next, the tail was warmed, first with warm water and then with a heat lamp. Using a 1 ml syringe, 0.35 ml of ovalbumin (Calbiochem Corp., San Diego, CA) at 5 mg/ml in 0.15 M phosphate buffered saline (PBS) was injected intravenously into the tail vein, about 1-2 inches from the tip of the tail. Five minutes later, the rats were injected intradermally with 0.08 ml of 20 mg/ml rabbit Ig fraction of anti-ovalbumin antibody having an antibody titer of 4 mg/ml (Organon Teknika Corp. , Cappel Division, West Chester, PA) or with 0.08 ml of 20 mg/ml rabbit IgG (Sigma Chemical Co., St. Louis, MO) , or with PBS. Each injection was performed in duplicate and the areas around the injection were circled with a marker pen. The rats were then monitored at 1, 4, and 18 hours. After 24 hours, the rats were killed by submerging them in dry ice for 3 minutes. Skin samples were dissected from the injected sites. One of the duplicate samples was fixed in 10% formalin for paraffin embedding and the other frozen for cryostat sections. Tissue sections were prepared and stained with hematoxylin and eosin. 14 . 1. 2 . RESULTS A weak RPAR reaction (e.g., edema and erythema) began to be visible after 3 to 5 hours following intradermal injection of anti-ovalbumin antibody. The intensity of the reaction gradually increased until the size of the reaction " 5 4 reached 3-5 mm in diameter after 24 hours (Fig. 30b) . No * reactions were observed in the rat skin where only non- immune rabbit IgG or PBS was injected. Under microscopic examination of the tissue sections prepared from the site of the lesion, many acute 10 inflammatory cells were visible in the dermis, particularly around the blood vessels (Fig. 31b) . This is typically recognized as vasculitis and perivasculitis. The tissue indicated a typical inflammatory condition with extensive 15 infiltration of PMN outside of the blood vessels, the presence of erythrocytes in the connective tissue, and the loosening of collagen fibers. 14.1.3. EFFECT OF INTRADERMAL ADMINISTRATION OF SOLUBLE CRl A mixture of purified sCRl was prepared by 20 combining 40 μl of 0.75 mg/ml sCRl with an equal volume of anti-ovalbumin or normal rabbit IgG or PBS. Either the sCRl:anti-ovalbumin mixture or the sCRl:rabbit IgG mixture, or the sCRl: PBS mixture was injected intrader ally into 25 intravenously ovalbumin primed rats. Barely visible lesions developed in the injection sites that received sCRl plus anti-ovalbumin antibody (Fig. 30a) . As expected, no lesions developed in the injection sites that received sCRl: rabbit IgG or sCRl:PBS. When sections of tissue surrounding the 30 sCRl: nti-ovalbumin injection sites were examined micro¬ scopically, clusters of PMN and mononuclear cells could be found surrounding the venules, but there was no extensive infiltration of PMN or extravasation of erythrocytes (Fig. 35 31a) . These data indicate that soluble CRl administration caused an inhibition of damage to the endothelial cells and an inhibition of the inflammatory reaction. In order to determine the minimum effective dosage of sCRl that is required to block a RPAR in the above ovalbumin rat model, ten-fold serial dilutions (neat, 1/10, 1/100, 1/1,000 and 1/10,000) of the 0.75 mg/ml sCRl stock were tested. Each sCRl dilution was mixed with an equal volume of neat or one-half dilution of anti-ovalbumin antibody. Each site was injected with a total of 80 μl. The ability of sCRl to inhibit RPAR was dose dependent, with effective reduction of edema observed at 300 ng per site (Table X) . TABLE X EFFECT OF DOSAGE ON THE INHIBITION OF RPAR BY sCRl determined as follows. Rats of similar age (6 wee^s) and body weight (110-125 g) were injected intravenousl y ith 250 μg of sCRl in 0.35 ml. At 2 minutes, 5 minutes, 10 minutes, 60 minutes, and 24 hours post-injection, the rats were sacrificed and blood was obtained from vena σava puncture. 1-2 ml of sera from each rat was obtained by centrifugation at 1800 rpm for 10 minutes, and the amount of sCRl in each sample was determined by CRl ELISA. Two-fold dilutions of 1 ^g/ml of purified sCRl spiked into control ψ 4. rat serum or detergent lysates of hemoglobin-free red blood Q cell ghosts (1.6 x 10 ghosts/ml) were used as CRl standards. The results are shown in Table XI. 10 TABLE XI PHARMOCOKINETIC DATA ON SERUM CONCENTRATIONS OF INJECTED SCRl WITH TIME Time After Intravenous 15 Injection Control 2 min 5 min 20 10 min 60 min 24 hrs 25 These data indicate that sCRl can be detected 24 hours following intravenous injection. At 24 hours, the level of sCRl in the serum was 50% of the peak level that was observed 10 minutes post-injection. 30 Additional studies in Sprague Dawley rats and cynomolgus monkeys (Table XII) were performed to further characterize the pharmacokinetics of in vivo administered sCRl. Each animal received a single intravenous injection of either 125I-labelled sCRl alone (14-28 million cpm for 35 rat, 126-153 million cpm for monkey) or a mixture of unlabelled (about 1 mg/kg) and 125I • -labelled sCRl. In study 2-431, dose of 1 mg/kg or 10 mg/kg of unlabelled sCRl were also tested in monkeys. Blood was collected from each animal at several time points within the sampling time indicated in Table XII. The clearance of sCRl from the blood followed a biphasic pattern in rats and monkeys. The first phase (β) had a short half-life measured in minutes. This half-life was dose dependent as shown in monkey study 2-431 where a 1 mg/kg dose gave t . of 9.13 min and a 10 mg/kg dose gave t. /2 of 29 min. The second phase (β) showed a much longer half-life measured in hours (see Table XII and figure 32) . The results of the monkey studies indicated that there were no clinical signs of toxicity observed in monkeys associated with the administration of a single intravenous injection at doses of 1.0 and 10 mg/kg. TABLE XII PHARMACOKΪNETIC STUDIES OF TP10-HD** 2-378 2-592 2-709 2-403 2-431 The half-lives were determined by y = mx + b, where y = value at i v m ~ slope, x = t^, b = extrapolated t * ' ^tel:hods used for determin.ing b3.ood levels of sCRl included measuring total radioactive coun'cs ( study 2-378) , measuring TCA precipi table counts (studies 2-592, 2-709, 2 403) and reactivity in a CR1 ELISA as described i .section 11 .15 supra (studies 2-592, 2-709, 2-403 and 2-431 ) . 14.3. SCRl REDUCES INFARCT SIZE IN RATS WITH REPERFUSED INFARCTED MYOCARDIUM As described herein, sCRl which was able to inhibit the activity of the complement pathway C3/C5 convertase in vitro was also able to reduce the extent of reperfusion injury in an in vivo rat myocardial infarct model. Myocardial infarction can be induced in a rat by coronary ligation. If established within the first few hours after myocardial infarction, reperfusion has been shown to reduce the infarct size, to improve the left ventricular function, and to reduce mortality (Braunwald, E. and Kloner, R.A. , 1985, J. Clin. Invest. 76:1713-1719). However, reperfusion to a myocardium that is severely ischemic but not irreversibly injured, can itself produce and extend injury. The mechanisms responsible for the reperfusion-induced injury may include injury mediated by oxygen free radicals and cellular calcium overload. Leukocytes acting either alone or in concert with microvascular endothelial cells may contribute to this injury. Complement activation may be involved in this process (Rossen, R.D., et al., 1985, Cir. Res. 57:119-130; Crawford, M.H. , et al., 1988, Circulation 78:1449-1458). 14.3.1. SUPPRESSION BY SCRl OF COMPLEMENT ACTIVATION AND MYOCARDIAL REPERFUSION INJURY IN RATS We administered sCRl to rats subjected to transient myocardial ischemia with subsequent reperfusion. The mechanism of injury to ischemic, but not irreversibly damaged, reperfused myocardium involves a leukocyte- dependent inflammatory reaction (Romson et al., 1983, Circulation 67:1016; Martin et al., 1988, Circ. Res. 63:483; Kraemer & Mullane, 1989, J. Pharmacol. Exp. Therap. 251:620; Litt et al., 1989, Circulation 80:1816; Ambrosio et al., 1989, Circulation 80:1846) that may require complement activation (Maroko et al., 1978, J. Clin. Invest. 61:661; Crawford et al., 1988, Circulation 78:1449). Animals were divided into groups at random and were given bolus intravenous injections of phosphate-buffered saline, alone * 5 (n = 29) or containing 1 mg of sCRl (n = 31) immediately * » before occlusion of the left coronary artery by suture ligation. After 35 minutes, the sutures were released, the thorax closed, and the animals were returned to their cages for 7 days, when they were killed and the myocardial infarct 10 was measured (Weisman et al., 1988, Circulation 78:186); the 7-day interval provided a reliable assessment of infarct size and permitted analysis of possible adverse effects of sCRl on infarct healing. The aortas of hearts that had been excised from rats under methoxyflurane anesthesia were 15 cannulated, and the coronary arteries were perfused first with Krebs Henseleit solution and then with 30 mM KC1 for diastolic arrest. After fixation by intracoronary perfusion and immersion in 10 percent buffered formalin, 2 mm transverse sections of the hearts were histologically 20 analyzed by digitizing the areas of the normal, total infarcted and trasmurally infarcted left ventricular myocardium. The summed values of the fractional areas of all slices were used to calculate myocardial infarct size and the ratio of transmural necrosis to total necrosis. All 25 procedures and care of the animals were in accordance with institutional guidelines. Survival rates in the group given buffer alone (24 of 29) and the sCRl-treated group (25 of 31) were similar, with deaths occurring immediately after 30 coronary artery ligation in all but one of the control rats. Ligation 'of the coronary artery was judged to be successful in 22 animals in each group that met all of the following criteria: immediate electrocardiographic changes compatible with ischemia; cyanosis of the anterior left ventricular 35 wall; and histologic evidence of myocardial necrosis post mortem. The structure was released successfully in all rats except two of the sCRl treated animals. Analysis of all survivors, including the two rats in whom reperfusion was not achieved, demonstrated that treatment with sCRl reduced the size of myocardial infarction from a mean of 16+ 2 percent of the left ventricular mass in the control rats to 9+ 2 percent in the sCRl group (P<0.01). The frequency of transmural infarction also was lower in the sCRl-treated (6 of 25) than in the control rats (12 of 24) (P<0.04). The infarct segment thickness summed over four sections of hearts from all rats treated with sCRl was 7.8 + 0.4 mm, which was not significantly different from that of all untreated animals 7.3 + 0.4 mm, but slightly less than that of the remote, uninfarcted interventricular septum from the hearts of these two groups of rats (sCRl rats, 9.3 + 0.2 mm; untreated rats, 9.4 + 0.2 mm). There was also no difference in the intraventricular cavity size of these two 3 groups (sCRl rats, 64.9 + 3.6 mm ; untreated rats, 68.9 + 2.6 mm 3) . Therefore, sCRl suppresses myocardial infarct size but does not interfere with healing in a manner that causes ventricular dilation and left ventricular wall thinning, as judged from observation of hearts one week after infarction. To determine whether suppression of tissue damage by sCRl was associated with inhibition of complement activation by ischemic myocardium, another group of buffer- treated (n = 7) and sCRl-treated rats (n = 8) was subjected to the same ischemia-reperfusion protocol, and the animals were killed 3 hours after reperfusion. The hearts were assessed by nitroblue tetrazolium (NBT) staining (Lillie, R.D., 1965, Histopathologic Technic and Practical Histochemistry, McGraw-Hill, New York ed:3:378) to delineate regions of irreversible injury from viable myocardium, and by immunoperoxidase staining (DeLellis, ±n Basic Techniques of Immunohistochemistry, DeLellis, Ed., Masson, New \ rk, 1981) with a mouse monoclonal antibody to the rat C5b-9 membrane attack complex (Schulze et al., 1989, Kidney Int. 35:60). A mouse peroxidase-antiperoxidase (PAP) system was used for the immunostaining as described. All steps of the procedure were preceded by three 10-minute washings in 0.05 M Tris-buffered saline. The sections were fixed in acetone and treated with 0.5 percent H O -methanol solution for 5 minutes, 4 percent heat-inactivated goat serum for 1 hour; and they were then sequentially incubated at room temperature with the primary, mouse monoclonal antibodies at 2 μg/ml for 18 hours, with affinity-purified F(ab') goat antiserum to mouse antibody (Organon-Tecknika, West Chester, PA) for 60 minutes, and with mouse PAP for 60 minutes. The slides were developed with 3,3'-diaminobenzidine tetrahydrochloride and counterstained with Gill's hematoxylin 3. In the NBT-negative, infarcted areas of the control rats (n - 7) , the C5b-9 complex was present primarily along the endothelium of capillaries and venules, but not in the myocardial fibers. In contrast, in rats that had received sCRl (n = 8) , the NBT-negative areas were consistently reduced in size, and little or no C5b-9 complex was detectable in these regions, as exemplified by the representative sections shown. Quantitation of leukocytes (Ambrosio et al., 1989, Circulation 80:1846) in these serial sections revealed that within infarct zones of control rats there were 195 + 28 leukocytes per square millimeter (150 high-power fields; n = 3) , which were almost exclusively within capillaries and venules. Coresponding sections from the hears of rats that had received sCRl had only 83 + 3 leukocytes per square millimeter (n = 4; P = 0.006), indicating that suppression of complement activation was associated with decreased accumulation of this inflammatory cell type. The localization of C5b-9 complexes along endothelial surfaces suggests that these cells may be the primary site of complement activation in the pathogenesis of reflow injury to ischemic myocardium, and contrasts with the more diffuse distribution of complement proteins throughout infarcted myocardium 24 hours following coronary artery occlusion (McManus et al., 1983, Lab. Invest. 48:436). While the latter may simply reflect the capacity of necrotic tissue to activate complement, the former may indicate that ischemically stressed endothelium acquires a complement- activating function. Complement activation by endothelial cells would be an especially potent stimulus for the early localization of neutrophils to ischemic myocardium, with C5a activating intravascular leukocytes and causing their rapid upreg lation of cellular receptors, including CRl and CR3 (Fearon & Collins, 1983, J. Immunol. 130:370; Arnaout et al., 1984, J. Clin. Invest. 74:1291). The latter receptor has been shown to promote the attachment of neutrophils to complement-activating endothelial cells bearing the ligand for CR3, iC3b (Marks et al., 1989, Nature 339:314). Therefore, suppression of complement activation by sCRl may account for the decreased numbers of neutrophils apparently adherent to endothelial cells. Reperfusion of ischemic myocardium by thrombolytic agents reduces infarct size, improves left ventricular function, and reduces mortality if established within a few hours of coronary artery occlusion (Guerci et al., 1987, N. Engl. J. Med. 317:1613; ISIS-2 Collaborative Group, 1988, Lancet ii:49; Van de Werf & Arnold, 1988, Br. Med. J. 279:1374). However, the potential benefits of reperfusion may not be fully achieved because reflow into myocardium that is severely ischemic, but not irreversibly injured, may induce necrosis (Becker & Ambrosio, 1987, Prog. Cardiovasc. Dis. 30:23; Braunwald & Kloner, 1985, J. Clin. Invest. 76:713). Two events thought to be causally related to necrosis are intravascular accumulation of neutrophils and microvascular endothelial cell injury (VanBenthuysen et al., 1987, J. Clin. Invest. 79:265), both of which may be a consequence of complement activation. The present finding * of a myocardial protective effect of sCRl supports the 5 possibility of a central role for complement, extending earlier studies in which complement was depleted with cobra venom factor, and offers a means by which the tissue-sparin potential of thrombolytic therapy may be enhanced. 10 14.3.2. CONCLUSIONS The results indicate that sCRl treatment is effective in reducing reperfusion injury _in vivo and in ameliorating the effects of myocardial infarction. To the extent that reperfusion injury can be ameliorated, the 15 absolute amount of salvaged myocardium can be increased and the time window for which reperfusion is clinically useful can be extended. Treatment with sCRl should be a useful concomitant therapy with thrombolytics as described in the next section or balloon coronary angioplasty during acute 20 infarction. 15. EXAMPLE: CO-FORMULATION OF SOLUBLE COMPLEMENT RECEPTOR 1 (SCR-1) WITH p-.ANISOYLATED HUMAN PLASMINOGEN-STREPTOKINASE-ACTIVATOR COMPLEX (APSAC) 25 Purified sCR-1 prepared as described in section 12.2 [0.93 mg in sterile Dulbecco's phosphate-buffered saline, 1.0 ml], was added to a vial of APSAC which had been reconstituted in sterile water (4.0 ml). The APSAC preparation contained the following: 30 APSAC: 30 units » D-Mannitol 100 mg * Human Serum Albumin E.P. 30 mg ♦ p-Amidinophenyl p'-anisate.HCl 0.15 mg * L-Lysine.HCl 35 mg 35 6-Aminohexanoic acid 1.4 mg (all figures are subject to normal analytical variances) The solutions were mixed well and the vial frozen at -78"C using solid CO.. The product was lyophilised at 2-3 mbar/-60°C (condenser temp) for 24 hours and the vial restoppered and stored at -70°C. On reconstitution, the vial was dissolved in 0.1 M Hepes, 0.15 M NaCl pH 7.4 (1.0 ml) and held on ice. Assays dilutions were made into this Hepes buffer. As controls, a vial of APSAC alone (same batch) was reconstituted in the same way and a freshly thawed sample of sCR-1 (same batch) was also tested. The samples were assayed for inhibition of complement-mediated hemolysis according to the method described in section 13.2.1 with the results given in the Table XIII below. ♦Figures in brackets are standard errors from quadruplicate determinations. 20 Curve fitting of the data in Table XII gave values for the concentration of sCR-1 which inhibited hemolysis by 50% of 15.7 + 3.0 mg/ml and 16.0 + 2.9 ng/ml for sCR-1/APSAC and SCR-1 alone. These figures are not different and the results indicate that the activity of 25 sCR-1 is unaffected by co-formulation with an APSAC pharmaceutical dosage form. 16, EXAMPLE: MOLECULAR DEFINITION OF THE F' ALLOTYPE OF HUMAN CRl: LOSS OF A C3b BINDING SITE IS ASSOCIATED WITH ALTERED FUNCTION 30 Human CRl is composed of tandem long homologous repeating (LHR) segments that encode separate binding sites for C3b or C4b. Homologous recombination with unequal crossover has been proposed as the genetic mechanism that gave rise to the CRl alleles that differ in their total 35 numbers of LHR. The F allotype has four LHR, maned LHR-A, -B, -C, -D, 5' to 3A The site in LHR-A preferentially binds C4b, and those in LHR-B and -C prefer C3b. A previous study revealed the presence of a fifth LHR with sequences similar to LHR-B and a third C3b binding site in the S allotype of higher molecular weight. In the present study, an 18 kb EcoRV fragment that was associated with the expression of the lower molecular weight F' allotype hybridized with a unique pattern of cDNA and intron probes specific for LHR-C. Deletion of LHR-B and one C3b binding site was proposed as the mechanism for the appearance of this F'-specific fragment. The molecular mechanism for the association of the F' allotype with SLE was explored by functional comparisons of soluble sCRl having one, two or three C3b binding sites. While these three variants did not exhibit any significant differences in their capacities to act as cofactors for the cleavage of monomeric C3b, their relative binding of dimeric ligand varied over 100 fold. Furthermore, the variant with only one C3b binding site was at least 10 fold less effective in the inhibition of the alternative pathway C3 and C5 convertases. These observations suggest that the F' allotype may be impaired in its capacity to bind opsonized immune complexes, to inhibit the formation of the alternative pathway C3 and C5 convertase, and perhaps to mediate other CRl-dependent cellular responses. They also demonstrate that certain functions of a CRl molecule may be enhanced by increasing the valency of the C3b binding sites. 16.1. INTRODUCTION Four allotypic forms of CRl that differ in size by 30 to 50 kD increments have been described. The transcripts that are associated with each allotype also differ in increments of -1.4 kb, indicating that their primary sequences vary in the number of LHR (Wong et al., 1983, J. Clin. Invest. 72:685; Dykman et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:1698; Dykman et al., 1984, J. Exp. Med. 159:691; Dykman et al., 1985, J. Immunol. 134:1787; Wong et al., 1986, J. Exp. Med. 164:1531; Holers et al., 1987, Proc. Natl. Acad. Sci. U.S.A. 84:2459). There 5 are four LHR in the F (or A) allotype of -250 kD, termed LHR-A, -B, -C, and -D, respectively, 5' to 3' (Examples 6 and 7, supra; Wong et al., 1989, J. Exp. Med. 169:847). While the first two SCR in LHR-A determine its ability to bind C4b, the corresponding units in LHR-B and -C determine 10 their higher affinities for C3b (Example 9, supra) . Analysis of the gene encoding the larger S (or B) allotype of ~290 kd by restriction mapping of genomic phage clones revealed a fifth LHR that is a chimera of the 5' half of 15 LHR-B and the 3' half of LHR-A and is predicted to contain a third C3b binding site (Wong et al., 1989, J. Exp. Med. 169:847). The smallest F' (or C) allotype of CRl of -210 kD, found in increased incidence in patients with SLE and* associated with patients in multiple lupus families (Dykman 20 et al., 1984, J. Exp. Med. 159:691; Van Dyne et al., 1987, Clin. Exp. Immunol. 68:570), may have resulted from the deletion of one LHR and may be impaired in its capacity to bind efficiently to immune complexes coated with complement fragments. The data presented infra define the molecular 25 basis of the F' allele by using intron probes specific for each LHR to analyze an EcoRV restriction fragment length polymorphism (RFLP) of the CRl that is present in individuals who express this allotype. To provide an explanation for the apparent association of the F' allotype 30 with SLE, soluble sCRl variants having one, two or three C3b I recognition sites and corresponding to the predicted • structures of the FA F, S allotypes, respectively, were , compared for their abilities to bind dimeric ligand, to act ♦ as cofactor for the cleavage of C3b, and to inhibit the 35 alternative and classical pathway C3 and C5 convertases. 16.2. MATERIALS AND METHODS Analysis of DNA. Genomic DNA was prepared from peripheral blood leukocytes, digested with EcoRV, electrophoresed and analysed by Southern blotting as previously described (Wong et al., 1986, J. Exp. Med. 164:1531). The CRl cDNA probe 1-1 hybridizes to SCR-4 to -7 of all the LHR while the probe 1-4 specifically hybridizes to SCR-1 and -2 of LHR-B and -C (Klickstein et al., 1987, J. Exp. Med. 165:1095; Klickstein et al., 1988, J. Exp. Med. 168:1699; Wong et al., 1989, J. Exp. Med. 169:847). The noncoding probe PE hybridizes to the intron between the two exons that encode SCR-2 in LHR-B and -C. PX hybridizes to the intron between the two exons that encode SCR-6 in LHR-A and -B, and HE hybridizes to the intron 5' of SCR-7 in LHR-A and -B (Wong et al., 1989, J. Exp. Med. 169:847) (Fig. 34). A genomic library derived from the DNA of an individual homozygous for the F allele was screened for CRl clones by hybridization to cDNA probes that span the entire coding sequence. Restriction mapping of the overlapping phage clones that span the F allele was performed as previously described (Wong et al., 1989, J. Exp. Med. 169:847). Construction of the expression plasmids and purification of soluble sCRl. A Pst I fragment which extends from SCR-5 in LHR-A to a corresponding position in LHR-B was isolated from 5 the plasmid pBSABCD that contains the complete coding sequence of the F allotype of CRl (Example 8.1, supra) . This was inserted into piABCD (Example 8.2, supra) which had been linearized by partial digestion with Pst I, resulting in the creation of a fifth LHR with coding sequences Q identical to that of LHR-B. A clone named piABBCD with an in-frame insertion was selected by restriction mapping, and the segment encoding the entire extracellular domain was excised by digestion with Xho I and Apa LI and treated with the Klenow DNA polymerase. The blunt ended fragment was 5 ligated to the linkers, 5'-TGAGCTAGCTCA-3 ' , digested with Nhe I, and inserted into the Xba I site of the expression vector Ap r M8, a derivative of CDM8 (Seed, 1987, Nature 329:840). This plasmid, named pasecABBCD, has a stop codon inserted after the thirty-seventh SCR and lacks the * sequences encoding the transmembrane and cytoplasmic 5 * domains. The plasmid, pasecABCD, was made by the transfer of the four LHR of the F allotype from pBSABCD into Ap r M8 using a similar strategy. A third plasmid, containing only three LHR and named pasecACD, was made by an in-frame deletion of the Pst I fragment extending from SCR-5 in LHR-A 10 to a corresponding position in LHR-B. Thirty to sixty μg of 7 each of the above plasmids were used to transfect 2 x 10 COS-1 cells (American Type Culture Collection, Rockville, MD) in the presence of 400 μg/ml DEAE-dextran, and 100 μM chloroquine for 4 hours at 37 β C in Dulbecco's modified Eagle 15 medium with high glucose (DMEM) (Hazelton, Lenexa, KS) and 10% Nuserum (Collaborative Research, Bedford, MA) . The cells were shocked for 3 minutes at room temperature with 10% DMSO in HBSS without divalent cations after removal of the transfection medium (Ausubel et al., 1987, iji Current 20 Protocols in Molecular Biology, John Wiley & Sons and Greene Assoc, New York), washed and cultured in DMEM and 10% FCS. The culture supernatants were collected every 48 hours for 10 days, clarified of cell debris by centrifugation, and 25 frozen at -70 β C. On thawing of the supernatants, PMSF and sodium azide were added to final concentrations of 5 mM and 0.2%, respectively, and sCRl was purified by affinity chromatography on mAb YZ-1-Sepharose as described except that detergents were omitted from the eluting buffer (Wong 30 et al., 1985, J. Immunol. Meth. 82:303; Example 12.2.1, supra) . The purified proteins were dialyzed twice against 1,000 volumes of PBS and frozen in small aliquots at -70°C. This procedure routinely yielded 150-200 μg of sCRl as 35 determined by the Micro BCA kit (Pierce, Rockford, IL) using BSA as a standard. The protein was analyzed by SDS-PAGE on a gel containing a linear gradient of 5% to 15% acrylamide. Cofactor activity of sCRl. Purified human C3 (Tack & Prahl, 1976, Biochemistry 15:4512) was treated with 0.5% TPCK-trypsin (Sigma, St. Louis, MO) for 5 minutes at 37"C and the reaction was stopped by the addition of a four fold molar excess of soy bean trypsin inhibitor. The C3b was labeled with 125I to a speci.fi.c acti.vi.ty of 5 x 105 cpm/μg using Iodogen (Pierce, Rockford, IL) . Cofactor activity of sCRl was assessed by incubation of 200 ng of C3b, 100 ng of factor I (Fearon, 1977, J. Immunol. 119:1248) with varying amounts of sCRl in 20 μl PBS for 1 hour at 37°C (Wong et al., 1985, J. Immunol. Meth. 82:303; Example 11, supra) . The reactions were stopped by boiling the samples in an equal volume of SDS-PAGE sample buffer containing 0.1 M dithiothreitol. After electophoresis and autoradiography, the areas of the dried gel corresponding to the position of the a' chains were excised and the amount of radioactivity measured in a Beckman gamma counter (Wong et al., 1985, J. Immunol. Meth. 82:303) . The counts associated with the ' chain in the absence of CRl were taken as the 100% control. Capacity of sCRl to bind dimeric C3b. C3b was cross-linked by dimethyl suberimidate (Sigma, St. Louis, MO) 5 (Wilson et al., 1982, New Engl. J. Med. 307:981) or 1,6- bismaleimidohexane (Pierce, Rockford, IL) (Weisman et al., 1990, Science 249:146), and dimers were selected by sedimentation on a linear gradient of 4.5% to 30% sucrose in PBS (Wilson et al., 1982, New Engl. J. Med. 307:981). Q Either method yielded dimers that bound to erythrocyte CRl with association constants (K ) that ranged from 1 to 3 x 10 8 M -1 . Three hundred ng of 125 I-C3b dimers (4 x lθ 6 Q cpm/μg) were incubated with 2 x 10 erythrocytes in 200 μl HBSS with 0.1% BSA in the absence or presence of incremental 5 amounts of unlabeled monomeric or dimeric C3b, or the different soluble forms of sCRl (Weisman et al., 1990, 249:146). After one hour on ice, cell-bound ligand was separated from unbound material by centrifugation of the erythrocytes through dibutylphthalate (Wilson et al., 1982, New Engl. J. Med. 307:981). The amount of dimeric C3b bound f in the presence of excess rabbit IgG anti-CRl was taken as * the nonspecific background, and specific counts bound in the absence of any inhibitor were used as the 100% control. For all these binding studies, erythrocytes from one normal individual were utilized. These cells were homozygous for 10 the F allotype and had relatively high amount of CR-1 (~800 YZ-1 mAb binding sites) . Inhibition of the alternative and classical pathway convertases. For assessment of the activation of the alternative pathway, 25% human serum was incubated with 15 5 x 10 zymosan particles (gift of Dr. Joyce Czop, Harvard Medical School, Boston, MA) in Veronal-buffered saline with 2 mM MgCl and 8 mM EGTA in the absence or presence of incremental amounts of sCRl. For assessment of the 20 activation of the classical pathway, 60 μg/ml of heat aggregated rabbit IgG was substituted for zymosan, and the reactions were performed in Veronal-buffered saline with 0.5 mM MgCl, and 0.15 mM CaCl_ (Weisman et al., 1990, Science 249:146). After incubation for 40 minutes at 37 β C, the 25 reactions were stopped by addition of 10 mM EDTA and assayed for the amounts of C3a and C5a cleavage using radioimmunoassay kits (Amersham, Chicago, IL) . 16.3. RESULTS 30 Structure of the F' allele of CRl. We have previously reported that when the DNA of individuals who expressed the -210 kD F' allotype of CRl was digested with EcoRV, an additional fragment of 18 kb was observed on probing the Southern blots with the CRl cDNA probe 1-1 (Wong 35 et al., 1986, J. Exp. Med. 164:1531) (Fig. 33). This probe was originally derived from SCR-3 to SCR-7 in LHR-B but its sequences were sufficiently homologous to allow hybridization to the fourth through the seventh SCR of other LHR (Examples 6 & 7, • supra; Klickstein et al., 1987, J. Exp. Med. 165:1095; Klickstein et al., 1988, J. Exp. Med. 168:1699; Wong et al., 1989, J. Exp. Med. 169:847). In order to assign each fragment to an LHR, the overlapping genomic clones that spanned the entire F allele were mapped by EcoRV (Fig. 34). Fragments of 9.4 kb and 22 kB corresponded to those expected from LHR-A and -D, respectively. This was confirmed by the hybridization of the 9.4 kb but not the 22 kb fragment to the intron probes PX and HE (Fig. 33) . Since there were no EcoRV sites in LHR-B, the largest fragment at the top of the blot that hybridized to all the probes represented the -32 kb fragment that spanned LHR-B and most of LHR-C (Figs. 33 & 34) . Restriction mapping of genomic clones that spanned the previously reported CRl-like pseudogene (Wong et al., 1989, J. Exp. Med. 169:847) indicates that the fragments of 20 kb and 15 kb are derived from this region (Fig. 33) . The 18 kb EcoRV fragment that was associated with the expression of the F' allotype hybridized to the cDNA probe 1-4 and the intron probe PE, indicating that it contained the 5' half of LHR-B or -C. This fragment did not hybridize to the intron probes PX and HE, indicating that it lacked the 3' half of LHR-B (Fig. 33). Deletion of LHR-B or another fragment of similar length from the -32 kb EcoRV fragment would yield a fragment of 18 kb which extended from the 3' most EcoRV site of UR-A to the 5' most EcoRV site of LHR-C (Fig. 34) . Such a fragment would be expected to hybridize only with the probes 1-4, PE, and 1-1, consistent with the findings in Figure 33. Since any -15 kb deletion including the PX and HE sites of L. -B necessarily includes at least one of the exons that contain the C3b binding site in either LHR-B or -C, the resulting allele of three LHR would encode only one C3b binding site. Plasmid construction and purification of soluble sCRl. There are no direct comparisons of the affinities of the CRl allotypes for opsonized immune complexes or multimeric ligands because individuals homozygous for the F' allotype have not been identified. The availability of complete CRl cDNA sequences and the results of the genomic analyses enabled us to produce sCRl with structures predicted for the different polymorphic variants. To assess the capacity of individual CRl molecules of each allotype for bivalent interactions with C3b dimers, cDNA constructs for soluble CRl were made by the insertion of a stop codon between the end of the 3' most SCR and the beginning of the transmembrane domain. This approach eliminates the potential for interactions between the dimeric C3b and separate, adjacent molecules of membrane-bound CRl. In addition, the use of soluble CRl avoids possible interference with enzymatic assays from the detergents required to maintain the solubility of membrane-derived preparations. The strategy employed for the insertion or deletion of an LHR utilized the conserved restriction sites to preserve the reading frame. The Pst I fragment that was inserted or deleted encoded SCR-5, -6, -7 of LHR-A and SCR- 1, -2, -3 and -4 of LHR-B (Fig. 35). Since the amino acid sequences of the third to the seventh SCR are identical in LHR-A and -B (Fig. 35) (Examples 6 & 7, supra) , these procedures would result in the insertion or deletion of sequences equivalent to an LHR-B. The plasmids pasecACD, pasecABCD, and pasecABBCD (Fig. 35) would therefore encode proteins that have one, two or three C3b binding sites, respectively. Soluble recombinant CRl was isolated by chromatography on YZ-1-Sepharose from the culture supernatants of COS cells that had been transfected with the CRl plasmids. Each sCRl protein was greater than 95% pure and the three forms exhibited incremental M differences of -30 kd under nonreducing conditions on SDS-PAGE, similar to those observed for the naturally occurring allotypes (Fig. 36) . Biosynthetic labeling with 35S-cysteme of the COS cells transfected with the vector Ap M8 alone showed no absorption of CRl-like proteins to the YZ-1 Sepharose. Furthermore, the soluble sCRl had M that were similar to the CRl isolated from 125I-labeled erythrocytes, consistent with deletion of only 70 amino acids from each molecule. In the lanes that contained sCRl isolated from pasecABBCD- or pasecABCD-transfected cells, small amounts of protein with M similar to the smaller forms were observed (Fig. 36, lanes 2 and 3) . These may represent the products of homologous recombination that were spontaneously generated within the transfected COS cells. Cofactor activity of sCRl. The functional integrity of the different forms of sCRl was measured in a cofactor assay in which radiolabeled C3b was converted to the iC3b and C3dg fragments. The amounts of sCRl that were required for 50% factor-I-mediated cleavage of the α' chain of C3b ranged from 3.5 nM for the pasecABBCD-derived protein to 8 nM for the pasecACD-derived protein, and differed only slightly for the three forms (Fig. 37) . Furthermore, conversion of C3b to C3dg was seen with the addition of 10 nM to 20 nM of all forms of sCRl. Thus soluble recombinant CRl, irrespective of the number of C3b binding sites, retained the capacity of the native molecule to bind C3b and served as a cofactor for the factor-I cleavage. Capacity of sCRl to bind dimeric C3b. In order to assess the effect of having different numbers of LHR-B on the binding of C3b-coated targets, the sCRl variants were used to inhi.bi.t the uptake of 125I-C3b dimer by erythrocyte CRl. The concentrations required for 50% inhibition reflected the relative binding of either the ligand or the cell bound receptor. In the experiment shown in Figure 38, « 10 nM of unlabeled C3b dimer was required for 50% inhibition 5 1 2 5 * of the interaction between I-C3b dimer and erythrocyte *■ CRl. The interaction of the receptor with monomeric C3b was much weaker, requiring 1 μM, or 100 fold more of this ligand to achieve similar inhibition (Fig. 38) . The low binding of this monomeric interaction suggests that cross-linking of 10 two discrete molecules of soluble CRl by the dimeric C3b ligand would not be favored under these conditions and that occupancy of two intramolecular binding sites is necessary for effective competition. This divalent interaction was ascertained by the requirement of 10 nM and 100 nM of the 15 pasecABCD- and the pasecACD-derived sCRl, respectively, for 50% inhibition. Interestingly, only 1 nM of the pasecABBCD-derived sCRl having three C3b binding sites was needed for a similar effect (Fig. 38) . Thus the soluble CRl forms with one, two or three C3b binding sites differed in 20 their binding of dimeric C3b but not for the monomeric form of this ligand that had been used as substrate for factor I cleavage (Fig. 37) . Inhibition of the alternative and classical pathway convertases. The capacities of the soluble CRl 25 variants to block the alternative and classical pathway convertases were compared by measurement of the C3a and C5a released on incubation of human serum with zymosan or aggregated IgG. while only 1 to 2 nM of the pasecABBCD or 30 the pasecABCD-derived sCRl were necessary to achieve 50% t, inhibition of both the alternative pathway C3 and C5 » convertases, 30 fold more of the pasecACD sCRl was required t for similar effects (Figs. 39A and 40A) . This is consistent » with the above predictions that the sCRl variants would bind 35 differently the C3b homodimers in the C5 convertases (Kinoshita et al., 1988, J. Immunol. 141:3895). That the same effect was seen with the C3 convertase indicated the presence of multiple molecules of C3b in association with the properdin-stabilized C3bBb complex. In contrast, large differences were not observed among the sCRl variants in their capacities to inhibit the classical pathway C3 and C5 convertase (Figs. 39B and 40B) , indicating that they bound similarly the C4b molecules within the C4bC2a complex or the C4b/C3b heterodimers of the C5 convertases (Takata et al., 1987, J. Exp. Med. 165:1494). Furthermore, except for the pasecACD-derived molecule, 2 to 10 fold more recombinant CRl was necessary to inhibit the enzymes of the classical relative to the alternative pathway, perhaps reflecting lower binding of sCRl for the C4b-containing convertases. 16.4. DISCUSSION That each polymorphic variant of human CRl is encoded by a different number of LHR is predicted by the -1.3 kb differences in the transcripts associated with each allotype (lWong et al., 1986, J. Exp. Med. 164:1531; Holers et al., 1987, Proc. Natl. Acad. Sci. USA 84:2459). The parallels between the homologies in the coding regions and the homologies in the corresponding noncoding regions of the different LHR of the CRl gene enabled us to predict the coding sequences based on a restriction map of the genomic clones. Thus the fith LHR in the S allele with a 5' half that resembled LHR-B and a 3' half that resembled LHR-A was expected to encode a third binding site for C3b in the S allotype (Wong et al., 1989, J. Exp. Med. 169:847). Since EcoRV was the only restriction enzyme among nineteen others that revealed a RFLP associated with the F' allotype (Wong et al., 1986, J. Exp. Med. 164:1531), a deletion in this allele apparently involved a highly homologous region. In this study, the 18 kb EcoRV fragment associated with individuals who expressed the F' allotype (Wong et al., 1986, J. Exp. Med. 164:1531) hybridized with a combination of exon-and intron-derived probes that was specific for LHR-C (Figs. 33 and 34) . This pattern was consistent only with the deletion of LHR-B or an equivalent region resulting in the loss of one C3b binding site. We could not confirm 5 that the appearance of the 18 kb fragment was accompanied by * the disappearance on Southern blots of a -30 kb fragment derived from LHR-B and -C because no individual homozygous for the F' allele was available for comparison. Although the smaller transcripts for this allotype might have arisen 10 through alternative splicing (Wong et al., 1986, J. Exp. Med. 164:1531; Holers et al., 1987, Proc. Natl. Acad. Sci. USA 84:2459), these mechanisms cannot account for the observed EcoRV RFLP. The association of the F' allotype with SLE is 15 consistent with the suggestion that this variant may have diminished capacity to bind opsonized immune complexes (Dykman et al., 1984, J. Exp. Med. 159:691; Van Dyne et al., 1987, Clin. Exp. Immunol. 68:570). We compared the functional capabilities of sCRl that differ in numbers of 20 LHR-B. The effective competition of C3b dimer uptake by soluble CRl in a recent study indicated that occupancy of tandem binding sites could occur (Weisman et al., 1990, Science 249:146), thus permitting a direct assessment of the binding of each receptor molecule for this bivalent ligand. 25 Our strategy differed both in the site of the inserted stop codon and in the use of soluble CRl purified from the culture supernatants of COS cells transiently transfected with plasmids that encode CRl molecules with two, one or no 30 LHR-B (Fig. 35) . The amounts of monomeric or dimeric C3b and pasecABCD-derived recombinant CRl necessary for 50% inhibition of binding of radiolabeled dimeric C3b to erythrocytes were very similar to those in an earlier report • (Weisman et al., 1990, Science 249:146). Moreover, the 35 binding of the purified sCRl for dimeric C3b increased 10 fold with the addition of each C3b binding site, resulting in a 100 fold difference between sCRl molecules derived from pasecACD or pasecABBCD (Fig. 38) . Consistent with the previous observation that the C4b binding site in LHR-A retains low affinity for C3b (Klickstein et al., 1988, J. Exp. Med. 168:1699), the pasecACD-derived sCRl with only LHR-A and -C was more effective than the C3b monomers in blocking the uptake of radiolabeled dimer (Fig. 38) . The higher binding observed for the pasecABBCD-derived sCRl relative to the pasecABCD-derived molecule similarly suggested engagement of two pairs of binding sites (Fig. 38) , and confirmed the previous hypothesis that multivalent interaction was favored by such a tandem array of LHR (Klickstein et al., 1988, J. Exp. Med. 168:1699; Wong et al., 1989, J. Exp. Med. 169:847). Since the binding of CRl for monomeric C3b is relatively low (Fig. 38) , the lack of gross differences in the cofactor capacities of the different sCRl for as in this (Fig. 37) and other studies (Seya et al., 1985, J. Immunol. 135:2661) indicated that the conditions used did not favor simultaneous occupancy of more than one active site by monomeric ligands. Differences in the effectiveness of the soluble CRl variants to block the alternative pathway C3 and C5 convertases is consistent with their differential affinities 5 for the C3b homodimers (Kinoshita et al., 1988, J. Immunol. 141:3895). Indeed, in this assay, the sCRl variants having two or more C3b binding sites were at least 30 fold more efficient than that which had only one site (Figs. 39A and 40A) . However, the pasecABBCD-derived sCRl is not more Q effective than that derived from pasecABCD (Figs. 39A and 40A) although its binding is much higher in a fluid phase assay (Fig. 38) . Thus, its full capacity in this assay may be restricted by the topographical distribution of the convertase sites on the activating surface. Since all three 5 variants studied retained one site for C4b and at least one adjacent site for C3b, their structure is consistent with their comparable capacities to inhibit the classical pathwa convertases (Figs. 39B and 40B) (Takata et al., 1987, J. * Exp. Med. 165:1494). The differences between our findings * and those of another study may be explained by the previous 5 * use of less stable fluid phase convertases and a mixture of * the F (or A) and F' (or C) allotypes instead of purified forms (Seya et al., 1985, J. Immunol. 135:2661). An alternative explanation was that the F' variant used in tha study had a different composition of LHR. 10 Although the efficiency of uptake of immune complexes by CRl is enhanced by the clustering of this receptor on erythrocytes (Paccaud et al., 1988, J. Immunol. 141:3889; Chevalier & Kazatchkine, 1989, J. Immunol. 15 142:2031), individuals with low CRl numbers may have fewer clusters of this receptor as well as fewer receptor molecules per cluster (Paccaud et al., 1988, J. Immunol. 141:3889). Thus the presence of the F' allotype and low amounts of CRl in SLE patients may result in fewer total C3b and C4b binding sites and a decreased efficiency in the 20 clearance of immune complexes from the circulation (Dykman et al., 1984, J. Exp. Med. 159:691; Van Dyne et al., 1987, Clin. Exp. Immunol. 68:570; Wilson et al., 1987, Immunol. Res. 6:192; Miyakawa et al., 1981, Lancet ii:493; Schifferli 25 et al., 1988, J. Immunol. 140:899). The lower affinities of sCRl observed for the classical pathway convertases (Figs. 39 and 40) indicate that the relative amounts of C4b and C3b deposited on soluble immune complexes may be critical to the CRl-dependent uptake and processing. The absence of 30 preclustered CRl in neutrophils under some conditions •V (Paccaud et al., 1990, Eur. J. Immunol. 20:283) suggests T that mechanisms that induce receptor aggregation may be » essential for the triggering of biologic reactions in ♦ nucleated cells (Daha et al., 1984, J. Immunol. 132:1197; 35 Bade et al., 1990, J. Immunol. 144:147). A shorter CRl allotype may further decrease the efficiencies of such interactions and lead to impairment of receptor-mediated cellular responses at tissue inflammatory sites. 17. DEPOSIT OF MICROORGANISMS E. coli strain DK1/P3 carrying plasmid piABCD (designated pCRl-piABCD) , encoding the full-length CRl protein, was deposited with the Agricultural Research Culture Collection (NRRL) , Peoria, Illinois, on March 31, 1988 and was assigned accession number B-18355. Chinese hamster ovary cell line DUX Bll carrying plasmid pBSCRlc/pTCSgpt clone 35.6, encoding a soluble CRl molecule, was deposited with the American Type Culture Collection (ATCC), Rockville, Maryland, on March 23, 1989 and was assigned accession number CRL 10052. The present invention is not to be limited in scope by the microorganisms deposited since the deposited embodiments are intended as single illustration of one aspect of the invention and any microorganisms which are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims. It is also understood that all base pair sizes given for nucleotides are approximate and are used for the purpose of description. Various references are cited herein, the disclosures of which are incorporated by reference in their entirety. International Application No; PCT/ MICROORGANISMS Optional Sh.il In eonnaetlon with Iha mlcroorganlem ralerred to on page ___- , llna__-.-ky.5~.-L'?.. ol Iha description > * A. IDINTIFICATION OP OIPOBIT ' Further dapoalla art Idanllflad on an additional lhaal |γj* * Nam. ol dapoaltary Inalltutlon * Agricultural Research Culture Collection Λ.dreee ol dapoaltary Inalllutton (Including poatal coda and country) ' Peoria, Illinois US DaW ol dapoalt * Aec««»ton Number * March 31 , 1988 B-18355 ADDITIONAL INDICATION* < (laava blank II not appllcabla). Thla Information la eonllnuad on a aaparala attaehad eheel Q C. DEBIONATtD BTATK* FOR WHICH INDICATIONS AM MAD! > (II Iha Indication* ara not lor all daalgnalad Stalaa) D. BtPAHATI FURNIBHINO OF INDICATION* • (laava blank II not appllcabla) Tlia Indlcallona llalad balow will ba aubmlttad lo Iha International Bufaau later • (Speclly Iha ganaral natura ol Iha Indication* e.g., " Ac ' ceielon Number ol Depotll ") (Authorliad OfHe-tr) [ " ] Th« data of racalpl (Irom Ih* applicant) by Iha Intarnatlonat Bureau '• (Authorliad Offlcir) Form PCT/RO/134 (January till) American Type Culture Collection Rockville, Maryland US Deposited on March 23, 1989 Accession NO. CEL-10052

Claims: WHAT IS CLAIMED IS: 1. A nucleic acid sequence comprising a sequence encoding a full-length CRl protein substantially as depicted in Figure 1 from nucleotide numbers 28 through 6147. * * 5 2. The sequence of claim 1 which comprises a DNA A sequence. 3. The sequence of claim 1 which comprises an RNA sequence. 10 4. A recombinant nucleic acid vector comprising the sequence of claim 1. 5. A recombinant nucleic acid vector comprising 15 the sequence of claim 2. 6. A recombinant DNA vector comprising pABCD. 7. A recombinant DNA vector comprising piABCD, 20 as deposited with the NRRL and assigned accession number B-18355. 8. A recombinant expression vector comprising the sequence of claim 1. 25 9. The expression vector of claim 8 which is capable of expressing the sequence in a bacterium. 10. The expression vector of claim 8 which is 30 capable of expressing the sequence in a mammalian cell. 11. The expression vector of claim 10 comprising piABCD, as deposited with the NRRL and assigned accession number B-18355. 35 12. A recombinant cell comprising the sequence of claim 1. 13. A recombinant cell comprising a cell containing the nucleic acid vector of claim 4. 14. A recombinant cell comprising a cell containing the nucleic acid vector of claim 5. 15. A recombinant cell comprising a cell containing the nucleic acid vector of claim 8. 16. A recombinant cell comprising a cell containing the nucleic acid vector of claim 10. 17. The recombinant cell of claim 12, 13 or 14 5 comprising a bacterium. 18. An Escherichia coli, as deposited with the NRRL and assigned accession number B-18355. o 19. A nucleic acid sequence comprising the sequence substantially as depicted in Figure 1 from nucleotide numbers 28 through 1533. 20. The nucleic acid sequence of claim 19 which 5 encodes a protein substantially lacking a transmembrane region. 21. The nucleic acid sequence of claim 20 in which the protein is secreted by a cell in which it is 0 expressed. 5 22. The nucleic acid sequence of claim 21 in which the protein is functional as detected by the ability in vitro to inhibit neutrophil oxidative burst, complement- mediated hemolysis, or C3a and C5a production. » 23. The nucleic acid sequence of claim 19, 20 or "J f . 21 which comprises a DNA sequence. * 24. The nucleic acid sequence of claim 19, 20 or 21 which comprises an RNA sequence. _ 25. A recombinant nucleic acid vector comprising the sequence of claim 19 or 20. 26. A recombinant nucleic acid vector comprising the sequence of claim 21 or 22. 15 27. A recombinant expression vector comprising the sequence of claim 19. 28. A recombinant expression vector comprising 20 the sequence of claim 20. 29. A recombinant expression vector comprising the sequence of claim 21. 25 30. The recombinant expression vector of claim 28 which is selected from the group consisting of pBSCRlc, pBSCRls, pBM-CRlc, pBSCRlc/pTCSgpt, and pBSCRls/pTCSgpt. 31. The recombinant expression vector of claim 30 28 which is selected from the group consisting of pT-CRlcl, pT-CRlc2, pT-CRlc3, pT-CRlc4, and pT-CRlc5. f i •» 35 32. A recombinant DNA vector comprising plasmid pBSCRlc/pTCSgpt, as deposited with the ATCC and assigned accession number CRL 10052. 33. A recombinant cell comprising the sequence of claim 19, 20 or 21. 34. The recombinant cell of claim 33 comprising a bacterium. 35. A recombinant cell comprising a cell containing the vector of claim 25. 36. A recombinant cell comprising a cell containing the vector of claim 26. 37. A recombinant cell comprising a cell containing the vector of claim 27. 38. A recombinant cell comprising a cell containing the vector of claim 28. 39. A recombinant cell comprising a cell containing the vector of claim 29. 40. A Chinese hamster ovary cell DUX Bll carrying plasmid pBSCRlc/pTCSgpt, as deposited with the ATCC and assigned accession number CRL 10052. 41. A protein comprising the amino acid sequence substantially as depicted in Figure 1. 42. A fragment of the protein of claim 41 which is characterized by the ability to bind C3b. 43. A fragment of the protein of claim 41 which is characterized by the ability to bind C4b. 44. A fragment of the protein of claim 41 which is characterized by the abilities to bind C3b and to bind • C4b. * 5 * 45. A fragment of the protein of claim 41 which * has factor I cofactor activity. 46. A fragment of the protein of claim 41 which 10 can inhibit C3 convertase activity. 47. A fragment of the protein of claim 41 which can inhibit C5 convertase activity. 15 48. The protein of claim 41 or a fragment thereof comprising 24 amino acids which is glycosylated. 49. The protein of claim 41 which is unglycosylated. 20 50. The protein of claim 41 which is expressed as a cell-surface protein. 51'. A protein comprising the amino acid sequence 25 substantially as encoded by the nucleotides depicted in Figure 1 from numbers 28 through 1533. 52. A nucleic acid sequence which encodes the protein of claim 51. 30 53. The protein of claim 51 which substantially lacks a transmembrane region. 35 54. The protein of claim 53 which is secreted by a cell in which it is expressed. 55. A CRl molecule substantially lacking a transmembrane region. 56. The CRl molecule of claim 55 which is 5 secreted by a cell in which it is expressed. 57. The CRl molecule of claim 55 which is unglycosylated. 0 58. The CRl molecule of claim 55 which is glycosylated. 59. The CRl molecule of claim 55 which is ,_ functional as detected by the ability in vitro to inhibit neutrophil oxidative burst, complement-mediated hemolysis, or C3a and C5a production. 60. The CRl molecule of claim 55 which is 50 encoded by a nucleic acid vector selected from the group consisting of pBSCRlc, pBSCRls, pBM-CRlc, pBSCRlc/pTCSgpt, and pBSCRls/pTCSgpt. 61. The CRl molecule of claim 55 which is 2 5 encoded by a nucleic acid vector selected from the group consisting of pT-CRlcl, pT-CRlc2, pT-CRlc3, pT-CRlc4, and pT-CRlc5. 62. The CRl molecule of claim 55 which is 30 expressed by a Chinese hamster ovary cell DUX Bll carrying plasmid pBSCRlc/pTCSgpt, as deposited with the ATCC and assigned accession number CRL 10052. 35 63. A recombinant cell expressing the protein of claim 41 on its surface. 64. A recombinant cell expressing the protein of claim 42, 43 or 45. 65. A recombinant cell expressing the protein of claim 51. 66. A recombinant cell expressing the protein of claim 55. 67. A recombinant cell expressing the protein of claim 56. 68. A recombinant cell expressing a fragment of the protein of claim 36 comprising 24 amino acids, which fragment is secreted by the cell. 69. A method for purifying a CRl protein or fragment thereof comprising: (a) obtaining a sample containing the CRl protein or fragment; (b) subjecting the sample to cation exchange high pressure liquid chromatography; and (c) eluting the protein or fragment from the high pressure liquid chromatography column. 70. The method according to claim 69 which further comprises after step (c) : (d) subjecting the protein or fragment to anion-exchange high pressure liquid chromatography; and (e) eluting the protein or fragment from the high pressure liquid chromatography column of step (d) . 71. The method according to claim 69 or 70 in which the CRl protein or fragment substantially lacks a transmembrane domain. b 72. A method for purifying a CRl molecule comprising: (a) expressing a CRl molecule substantially lacking a transmembrane domain in a cell in 0 culture such that the CRl molecule is secreted; (b) obtaining a sample of the cell culture fluid comprising the CRl molecule; 5 (c) subjecting the sample to cation exchange high pressure liquid chromatography; and (d) eluting the CRl molecule from the high pressure liquid chromatography column. 0 73. The method according to claim 72 which further comprises after step (c) : (d) subjecting the molecule to anion-exchange high pressure liquid chromatography; and (e) eluting the molecule from the high pressure 5 liquid chromatography column of step (d) . 74. A method for producing a CRl molecule comprising growing the cell of claim 12. 0 75. A method for producing a CRl molecule comprising growing the cell of claim 13. 76. A method for producing ϊ CRl molecule comprising growing the cell of claim 14. 5 77. A method for producing a CRl molecule comprising growing the cell of claim 15. 78. A method for producing a CRl molecule comprising growing the cell of claim 33. 79. A method for producing a CRl molecule comprising growing the cell of claim 34. 80. A method for producing a CRl molecule comprising growing the cell of claim 35. 81. A method for producing a CRl molecule comprising growing the cell of claim 36. 82. A method for producing a CRl molecule comprising growing the cell of claim 37. 83. A method for producing a CRl molecule comprising growing the cell of claim 38. 84. A method for producing a CRl molecule comprising growing the cell of claim 39. 85. A method for producing a CRl molecule comprising growing the cell of claim 40. 86. A method of treating a patient with an immune disorder or a disorder which involves undesirable or inappropriate complement activity comprising administering the protein of claim 41 or a fragment thereof comprising 24 amino acids to the patient. 87. A method of treating a patient with an immune disorder or a disorder which involves undesirable or inappropriate complement activity comprising administering the fragment of claim 42 or 43 to the patient. 88. A method of treating a patient with an immune disorder or a disorder which involves undesirable or inappropriate complement activity comprising administering the fragment of claim 45 to the patient. 89. A method of treating a patient with an immune disorder or a disorder which involves undesirable or inappropriate complement activity comprising administering the fragment of claim 51, 53 or 54. 90. A method of treating a patient with an immune disorder or a disorder which involves undesirable or inappropriate complement activity comprising administering the molecule of claim 55 to the patient. 91. A method of treating a patient with an immune disorder or a disorder which involves undesirable or inappropriate complement activity comprising administering the molecule of claim 56 to the patient. 92: A method of treating a patient with an immune disorder or a disorder which involves undesirable or inappropriate complement activity comprising administering the molecule of claim 59 to the patient. 93. A method of treating a patient with an immune disorder or a disorder which involves undesirable or inappropriate complement activity comprising administering the molecule of claim 62 to the patient. 94. A method of treating or preventing damage in a patient caused by a myocardial infarct comprising administering the protein of claim 41 or a fragment thereof comprising 24 amino acids to the patient. 95. A method of treating or preventing damage in a patient caused by a myocardial infarct comprising administering the molecule of claim 55 to the patient. 96. A method of treating or preventing damage in a patient caused by a myocardial infarct comprising administering the molecule of claim 56 to the patient. 97. A method of treating or preventing damage in a patient caused by a myocardial infarct comprising administering the molecule of claim 59 to the patient. 98. A method of treating or preventing damage in a patient caused by a myocardial infarct comprising administering the molecule of claim 60 or 61 to the patient. 99. A method of treating or preventing damage in a patient caused by a myocardial infarct comprising administering the molecule of claim 62 to the patient. 100. A method of treating or preventing damage in a patient caused by inflammation comprising administering the protein of claim 41 or a fragment thereof comprising 24 amino acids to the patient. 101. A method of treating or preventing damage in a patient caused by inflammation comprising administering the molecule of claim 55 to the patient. 102. A method of treating or preventing damage in a patient caused by inflammation comprising administering the molecule of claim 56 to the patient. 103. A method of treating or preventing damage in a patient caused by inflammation comprising administering 5 the molecule of claim 59 to the patient. 104. A method of treating or preventing damage in a patient caused by inflammation comprising administering the molecule of claim 60 or 61 to the patient. 0 105. A method of treating or preventing damage in a patient caused by inflammation comprising administering the molecule of claim 62 to the patient. Ig 106. A molecule comprising the fragment of claim 42, 43 or 44. 107. A molecule comprising the fragment of claim 45, 46 or 47. 20 108. A molecule comprising the fragment of claim 55, 56 or 59. 109. A molecule comprising the fragment of claim 25 60, 61 or 62. 110. A pharmaceutical composition comprising an effective amount of the protein or fragment of claim 42, 43 or 45, and a pharmaceutically acceptable carrier. 30 111. A pharmaceutical composition comprising an effective amount of the protein or fra g ment of claim 55, 56 or 59, and a pharmaceutically acceptal e carrier. 35 112. A pharmaceutical composition comprising an effective amount of the protein or fragment of claim 60, 61 or 62, and a pharmaceutically acceptable carrier. 113. A method of treating thrombotiG conditions in humans and animals, which method comprises administering to a human or animal in need thereof an effective amount of a soluble CRl protein and an effective amount of a thrombolytic agent. 114. The method according to claim 113, wherein the soluble CRl protein and thrombolytic agent are administered simultaneously. 115. The method according to claim 113, wherein the CRl protein is encoded by a nucleic acid vector selected from the group consisting of pBSCRlc, pBSCRls, pBM-CRlc, pBSCRlc/pTCSgpt, and pBSCRls/pTCSgpt. 116. The method according to claim 113 in which the thrombolytic agent is a plasminogen activator. 117. The method according to claim 113, in which the thrombolytic agent is selected from the group consisting of tissue plasminogen activator or a mutein thereof, single-chain urokinase, two-chain urokinase, streptokinase, and a fibrinolytically active hybrid protein which comprises one chain of a 2-chain protease linked to a chain of a different two chain protease, at least one of the chains in the hybrid protein being derived from a fibrinolytically active protease, such that the hybrid protein has a catalytic site essential for fibrinolytic activity which is optionally blocked by a removable blocking group. 118. The method according to claim 113 in which the thrombolytic agent is a reversibly blocked in vivo fibrinolytic enzyme wherein the catalytic site, essential for fibrinolytic activity is blocked by a group which is removable by hydrolysis at a rate such that the pseudo first order rate constant for hydrolysis is in the range 10 sec to 10 -3sec-1 m. l.sotoni.c aqueous media at pH 7.4 at 37°C. 119. The method according to claim 113 in which the thrombolytic agent is anisoylated streptokinase- plasminogen-activator complex (APSAC) . 120. A pharmaceutical composition comprising a soluble CRl protein and a thrombolytic agent together with a pharmaceutically acceptable carrier or excipient. 121. The pharmaceutical composition according to claim 120 in which the thrombolytic agent is anisoylated streptokinase-plasminogen activator complex (APSAC) . 122. The pharmaceutical composition according to claim 120 in which the soluble CRl protein is expressed by a Chinese hamster ovary cell DUX Bll carrying plasmid pBSCRlc/pTCSgpt as deposited with the ATCC and assigned accession number CRL 10052. 123. A molecule comprising a portion of the amino acid sequence substantially as depicted in Figure 1, which portion is characterized by the ability to bind C3b, and which molecule comprises at least two copies of the LHR-B sequence. 124. The method according to claim 86 in which the patient is a non-human animal. 125. The method according to claim 90 in which the patient is a non-human animal. 126. The method according to claim 94 in which the patient is a non-human animal. 127. The method according to claim 95 in which the patient is a non-human animal. 128. The method according to claim 100 in which the patient is a non-human animal. 129. The method according to claim 101 in which the patient is a non-human animal.

Inventors: CARSON GERALD R, CONCINO MICHAEL F, FEARON DOUGLAS T, IP STEPHEN H, KLICKSTEIN LLOYD B, MAKRIDES SAVVAS C, MARSH HENRY C JR, WONG WINNIE W, CARSON, GERALD, R., CONCINO, MICHAEL, F., FEARON, DOUGLAS, T., IP, STEPHEN, H., KLICKSTEIN, LLOYD, B., MAKRIDES, SAVVAS, C., MARSH, HENRY, C., JR., WONG, WINNIE, W.
Applicants: BRIGHAM & WOMENS HOSPITAL, T CELL SCIENCES INC, UNIV JOHNS HOPKINS, T CELL SCIENCES, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, THE JOHNS HOPKINS UNIVERSITY
Application year: 1990
Main classification: C12N15
IPC codes: A61K38, A61P7, A61P9, A61P29, A61P37, C07K1, C07K14, C07K16, C12N1, C12N5, C12N9, C12N15, C12P19, C12P21, C12R1